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Abstract
This thesis explored knowledge management effectiveness in the pharmaceutical sector
and included an examination of the critical relationship between knowledge
management (KM) and quality risk management (QRM) as the dual enablers of an
effective pharmaceutical quality system. The primary research objectives were to
improve understanding and effectiveness of the interdependency between KM and
QRM and to improve knowledge management across the pharmaceutical product
lifecycle, starting with a focus on knowledge transfer during technology transfer. The
thesis explored how improved KM across the product lifecycle coupled with thoughtful
and intentional connectivity between KM and QRM as defined by this study could lead
to more informed risk-based decision making and ultimately help benefit patients.
This research study employed a variety of methods, including literature review, expert
interviews, philosophical dialogue, focus groups, and case studies as a means to include
a large number of stakeholders across the pharmaceutical sector. The study progress
was disseminated through a variety of methods and channels including several peerreviewed papers and conference presentations as a means to solicit input and feedback.
The research findings verify that while KM and QRM are considered highly
interdependent in theory, in practice they are – at best – partially integrated. This
suggests the industry is not leveraging the best knowledge available to inform QRM,
leading to sub-optimal risk-based decision making. Furthermore, knowledge created
during QRM activities may not be effectively managed.
When considering technology transfer, the study found that while knowledge transfer
is considered critically important, knowledge transfer is only marginally effective for
explicit knowledge and somewhat ineffective for tacit knowledge. This lack of effective
knowledge transfer poses a risk to successful technology transfer and the goals of ICH
Q10.
In response to these findings, the research generated a variety of outputs, many of
which have already demonstrated outcomes and impacts on the sector and have the
potential for seminal importance. These outputs include a Knowledge Management
Process Model to define the process of knowledge management, the Risk-Knowledge
Infinity Cycle (RKI Cycle) as a framework to unite KM and QRM, a framework for
knowledge transfer enhancement (KTE Framework) during technology transfer, and a
variety of case studies to demonstrate the impact of these outputs and their
applicability across the product lifecycle.
These outputs can be immediately applied to the benefit of the pharmaceutical sector.
Areas of future study include additional assets such as training and application materials
to accelerate application of these outputs. Additional opportunity also exists to better
define knowledge transfer toolkits, create knowledge management frameworks for
other phases of the product lifecycle, and to better define the relationship between
data analytics, knowledge management and risk management.
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Glossary of Terms and Abbreviations
Term

Definition

AMT

Analytical Method Transfer

API

Active Pharmaceutical Ingredient

APQC

American Productivity & Quality Center, a member-based knowledge
management organisation

APR

Annual Product Review

ATMP

Advanced Therapy Medicinal Products

CAGR

Compound Annual Growth Rate

CAPA

Corrective Action Preventative Action

CMC

Chemistry, Manufacturing & Controls

CMO

Contract Manufacturing Organisation

CoE

Centre of Excellence

Cpk

Process Capability

CQA

Critical Quality Attribute

CRADA

Cooperative Research and Development Agreement

CTQ

Critical to Quality

DCOM

Direction, Competency, Opportunity, Motivation

DMADV

Define-Measure-Analyse-Design-Verify

DMAIC

Define-Measure-Analyse-Improve-Control

E2E

End-to-end

EU

European Union

FDA

United States Food and Drug Administration (US regulatory agency)

FMEA

Failure Mode Effects Analysis

GMP

Good Manufacturing Practice

GxP

‘Good Practice’ quality guidelines and regulations (where ‘x’ is a variable
(e.g., ‘M’ = ‘Good Manufacturing Practices’, L = Laboratory, D =
Documentation, C = Clinical)

HOKE

House of Knowledge Excellence

HPRA

Health Products Regulatory Authority (Ireland regulatory agency)
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Term

Definition

ICH

International Conference for Harmonisation of Technical Requirements for
Pharmaceuticals for Human Use

ICH Q8

ICH Guideline on Pharmaceutical Development

ICH Q9

ICH Guideline on Quality Risk Management

ICH Q10

ICH Guideline on Pharmaceutical Quality System

ICH Q11

ICH Guideline on Development and Manufacture of Drug Substances

ICH Q12

ICH Guideline on Technical and Regulatory Considerations for
Pharmaceutical Product Lifecycle Management

ICH Q14

ICH Guideline on Analytical Procedure Development
(guideline in development)

IEC

International Electrotechnical Commission (an international standards
organisation that prepares and publishes international standards for all
electrical, electronic, and related technologies)

ISO

International Organisation for Standardisation

ISPE

International Society for Pharmaceutical Engineering

KM

Knowledge Management
These terms will be used interchangeably throughout this thesis based on
context

KPI

Key Performance Indicator

KT

Knowledge Transfer

KTE

Knowledge Transfer Enhancement

MHRA

U.K. Medicines and Healthcare products Regulatory Agency

MSD

Merck Sharp & Dohme

NASA

National Aeronautics and Space Administration (US Space Agency)

NPI

New Product introduction

ONA

Organisational Network Analysis

PAC

Post-Approval Change

PDA

Parenteral Drug Association

PDCA

Plan-Do-Check-Act

PIC/S

Pharmaceutical Inspection Co-operation Scheme

PMTC

Pharmaceutical Manufacturing Technology Centre

PPKL

Pharmaceutical Product Knowledge Lifecycle
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Term

Definition

PPQ

Process Performance Qualification

PQR

Product Quality Review

PQS

Pharmaceutical Quality System

PRST

Pharmaceutical Regulatory Science Team (a research body at Technological
University Dublin)

Q&A

Questions & Answers

QbD

Quality by Design

QRM

Quality Risk Management
These terms will be used interchangeably throughout this thesis based on
context

RAQAB

Regulatory Affairs and Quality Advisory Board of PDA

RM

Risk Management

SIPOC

Supplier-Input-Process-Output-Customer

SME

Subject Matter Expert

TT

Technology Transfer

TU Dublin

Technological University Dublin

WHO

World Health Association
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Thesis Overview
This thesis has been organised into four parts across 12 chapters as a means to
summarise the important contributions of the associated research study as outlined
below. Significant findings from the research were disseminated through a series of
peer-reviewed papers in a variety of journals which enabled socialisation and feedback
on research progress during the study. These papers are referenced appropriately
throughout this thesis.
Part One lays the foundation for this research study, including relevant background and
context. A literature review examines expectations for managing knowledge and risk,
the interdependency of Knowledge Management (KM) and Quality Risk Management
(QRM), and reviews recent developments in KM. It further explores relevant regulatory
and industry guidance on technology transfer and knowledge management and profiles
related research by the Pharmaceutical Regulatory Science Team (PRST) at the
Technological University Dublin (TU Dublin).
Part Two examines the relationship between knowledge and risk. It explores the
opportunity to better integrate KM and QRM. In response to the findings of this
examination, potential solutions are provided through a proposed Knowledge
Management Process Model, the Risk-Knowledge Infinity Cycle (RKI Cycle) Framework
to integrate KM and QRM, and the KTE Framework as a means to enhance knowledge
transfer during technology transfer.
Part Three demonstrates how the RKI Cycle can be applied across the product
lifecycle, including three examples with a focus on each KM across the product lifecycle,
change management during commercial manufacturing, and the link between QRM, KM
and data analytics. This part also explores the concept of knowledge culture, including
a review of current cultural issues which are barriers to knowledge management in the
pharmaceutical industry, existing definitions of knowledge culture outside of the

1

pharmaceutical industry, and benchmarking the corollary of quality culture. This section
concludes with proposing a preliminary ‘ideal knowledge culture.’
Part Four brings the research study to a close with a review of the outputs, outcomes,
and impact of this research study, followed by conclusions and opportunities for future
research.
The following table (Thesis Overview) provides a chapter-level summary of the four
parts of this thesis.
Thesis Overview
Part
Part One: Research Study
Foundations

Part Two: Advancing KM
and Developing QRM-KM
Connectivity

Part Three: The RKI Cycle
Across the Product Lifecycle
and Knowledge Culture as a
Catalyst
Part Four: Outcomes and
Impact, Conclusions and
Opportunities for Future
Research

Chapters
• Chapter 1: Study Introduction and Context
• Chapter 2: Literature Review
• Chapter 3: Research Design, Methodology, and
Methods
• Chapter 4: A Process Model for Knowledge
Management
• Chapter 5: Re-Imagining the QRM-KM Interdependency
• Chapter 6: The Opportunity to Improve Knowledge
Transfer During Technology Transfer
• Chapter 7: A Proposed Framework and Toolkit to
Enhance Knowledge Transfer During Technology
Transfer
• Chapter 8: Demonstrating How the RKI Cycle can be
Applied Across the Product Lifecycle
• Chapter 9: Knowledge Culture as a Catalyst to
Accelerate RKI Cycle Adoption and Impact
• Chapter 10: Outputs, Outcomes, and Impacts of this
Research Study
• Chapter 11: Conclusions to this Research Study
• Chapter 12: Opportunities for Future Research
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Part One: Research Study Foundations
Part One lays the foundation for this research study, including:
•

Study introduction and context (Chapter 1)

•

A literature review of a variety of relevant topics (Chapter 2), setting the stage
for the managing of knowledge and risk to inform risk-based decision making
and ultimately benefit patients

•

An overview of the research methodology (Chapter 3)

3

Chapter 1: Study Introduction and Context
This thesis outlines a research study into Knowledge Management (KM) and Quality Risk
Management (QRM) in the pharmaceutical sector1,2. This study explored the current
state of KM and QRM as dual enablers of an effective Pharmaceutical Quality System
(PQS) and presented a framework for integrating them. It further examined the state
of knowledge management across the product lifecycle3, with specific focus on
technology transfer and the challenges associated with the identification and transfer
of tacit knowledge.
The purpose of this opening chapter is to outline the intent and scope of the overall
research study, define KM and its relevance within the pharmaceutical sector, preview
the anticipated impact of this study, and introduce the researcher.

1.1 Purpose of the research and the problem addressed
The overarching goal at the commencement of this research study was to advance the
understanding of KM within the pharmaceutical sector and encourage ways for it to be
adopted more widely.

There are many benefits associated with KM including

operational effectiveness and employee engagement (Yegneswaran, Thien and Lipa,
2017), and the outputs of this thesis will further advance these impacts.
However, the ultimate goal of this research was to provide tangible benefit to the
patient by improving PQS effectiveness through meaningful advancement of KM as a
PQS enabler. As will be discussed later in this chapter and reinforced throughout this
thesis, KM effectiveness in the pharmaceutical industry is lacking and the interrelationship between KM and QRM is not well established. Yet, when organisations can
apply their best knowledge, know-how, expertise, and experience – across boundaries

1

The term “pharmaceutical sector” for the purpose of this thesis refers to the collective organisations
involved in the product life cycle of a medicinal product (both chemical and biological entities) from
discovery to patient, including industry, regulators, academia and related associations.
2
For the purposes of this thesis, ‘biopharmaceutical’ and ‘pharmaceutical’ are considered synonymous,
both terms are used interchangeably based on the source.
3
The product lifecycle is defined in ICH Q10, section 1.2 and includes the stages of pharmaceutical
development, technology transfer, commercial manufacturing, and product discontinuation (ICH, 2008).
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including organisational structures, geographies, and time – to support risk-based
decision making, acceleration of product development through the use of prior
knowledge, more robust processes, solving problems at root cause, and right-first time
and on-time technology transfers – the patient stands to benefit. These patient benefits
will include increased product quality (e.g., through reduced variability), accelerated
availability of new therapies, the potential to reduce drug shortages, and more. Figure
1-1 illustrates this connection between the patient, the pharmaceutical regulations, the

Research Study Context

PQS as defined by ICH Q10 (ICH, 2008), and KM as an enabler to an effective PQS.

Patient

Regulations with associated
guidance and enforcement
ensure safe and efficacious
products for patients
(ICH, et al)

ICH Q10: PQS

TU Dublin PRST develops patient-focused strategies
to enable those involved in the manufacture of drug
products to meet the evolving international
regulatory expectations ensuring the availability of
high-quality medicinal products

Pharmaceutical regulations play a crucial in ensuring
the safety, efficacy and quality control of
pharmaceutical products

ICH Q10 a harmonised global standard for a modern,
Pharmaceutical Quality System, establishes Quality
Risk Management and Knowledge Management
as enablers to an effective PQS, applicable to all stages
of the product lifecycle

Figure 1-1 – The link between the patient, the regulations, the PQS, and KM as a PQS enabler

The researcher, as a member of the TU Dublin Pharmaceutical Regulatory Science Team
(PRST), sought to improve KM competency and utilisation across the industry as a
means to advance KM as an equally indispensable enabler to an effective PQS as QRM
and unlock the aforementioned benefits.

5

1.2 Background on Knowledge Management and Quality Risk Management
In 2008, the International Council for Harmonisation (ICH)4 published the guideline
Pharmaceutical Quality System ICH Q10 (ICH, 2008), which described a model for an
effective quality management system for the pharmaceutical industry, referred to as
the Pharmaceutical Quality System, or PQS. In ICH Q10, knowledge management as a
concept was cast into the mainstream of the pharmaceutical sector as it was positioned
as a key enabler of an effective PQS, as depicted in Figure 1-2.

Figure 1-2 – The pharmaceutical quality system per ICH Q10 (ICH, 2008)

ICH Q10 defined KM as a ‘Systematic approach to acquiring, analysing, storing, and
disseminating information related to products, manufacturing processes and
components’ (ICH, 2008). Additional definitions of KM are explored in Chapter 2
(section 2.1).
With KM and QRM positioned as key enablers for an effective PQS, the research study
began with a literature review, evaluating the relationship between risk and knowledge.
A key insight emerged from this review: risk varies inversely with knowledge applied.

4

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for
Human Use (ICH) is unique in bringing together the regulatory authorities and pharmaceutical industry
to discuss scientific and technical aspects of drug registration. ICH's mission is to achieve greater
harmonisation worldwide to ensure that safe, effective, and high-quality medicines are developed and
registered in the most resource-efficient manner.
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Therefore, a seemingly logical goal would be to maximise knowledge in order to
minimise risk. Figure 1-3 created by the researcher attempts to convey the relationship
between knowledge and risk, and the corresponding disciplines of knowledge
management and risk management, in a simple manner.

Figure 1-3 – Relating knowledge, knowledge management, risk & risk management

It is acknowledged by the researcher that there are limitations to this ideal state, such
as:
•

Risk cannot be completely eliminated in most situations, even with a high degree
of knowledge.

•

There are economic and other considerations for how much time and expense
is invested to maximise knowledge (i.e., at some point, risk will become
acceptable even if it could be further reduced).

•

There are scientific limitations to an organisation’s knowledge and
understanding.

Arguably one factor within the control of organisations is their ability to effectively apply
what is known (i.e., the ‘known-knowns’). This knowledge should be inclusive of
knowledge internal and external to the company and should include both explicit5 and

5

Explicit knowledge refers to documents, pictures, videos, and other codified knowledge.
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tacit6 knowledge. An organisation applying the best of their knowledge should be a
fundamental tenant of how risk management (RM) can leverage knowledge
management to maximise understanding and minimise risk.
However, as detailed in Chapter 2 of this thesis (Literature Review), there is strong
evidence that the pharmaceutical industry’s adoption of KM and competency in KM has
significantly lagged relative to the adjacent enabler of QRM as shown in the ICH Q10
PQS diagram (Figure 1-2). In fact, KM has been labelled an ‘orphan enabler’ (Calnan,
Greene and Kane, 2018). One must ponder why is it that QRM has progressed in the
industry and KM has been left behind?
The most common explanation is that QRM has benefited from having its own
regulatory guidance, namely Quality Risk Management, ICH Q9 (ICH, 2005), while KM
has no equivalent. Yet this leaves one wondering why did that happen? Why was no
guidance provided for KM? While this may itself warrant its own research study, the
researcher offers the following insights to address these questions based on his
experiences, observations, and review of the literature.
•

Quality risk management is embedded in a PQS based on Good Manufacturing
Practices (GMPs), while knowledge management is not.
QRM and KM are both acknowledged in a PQS based on ICH Q10 and on ISO
9001. But KM is not an identified requirement in a PQS based on GMPs. (ISPE,
2012)

•

Risk management has a head start: risk management has been studied for
about 70 years, while knowledge management only for about 30 years.

6

Tacit knowledge refers to knowledge that resides in the minds of individuals and is surfaced in
response to a situation or action (APQC, 2019). Common examples of tacit knowledge include decision
rationale, knowledge gained through experience, and mental models. Tacit knowledge is often referred
to as ‘know-how’, ‘know-why’, or ‘know-who’.
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RM as an area of study is associated with the insurance industry dating back to
about 1950 (Dionne, 2013). KM has only been recognised as a discipline since
1991. (Nonaka, 2007).
•

There is an existing body of literature, including many standards, on risk
management and related topics.
One need only look at the references section of ICH Q9 (ICH, 2005) to see there
are 17 references, including ten (10) cited ISO and/or IEC standards and three
(3) cited books on FMEA, in addition to two (2) other regulatory guidance
documents and two (2) other references. Many other standards exist, including
from the Project Management Institute (Project Management Institute, 2019),
the National Institute of Standards and Technology (NIST, 2016), and elsewhere.
Considering KM, given there is no equivalent to ICH Q9, KM is introduced in ICH
Q10 (ICH, 2008). There are no references to explain KM, and the definition of
KM in ICH Q10 was derived specific to ICH Q10. An ISO standard was not
published on KM until 2018 (ISO, 2018) and ISPE industry guidance in 2021 (ISPE,
2021b).

•

Quality risk management is ‘on the radar’ of regulatory authorities and
industry groups alike.
A recent presentation by O’Donnell (O’Donnell, 2020) asked a similar question:
Why had QRM progressed relative to KM? In reviewing QRM guidance in the
GMPs and other official guidance, O’Donnell identified at least 18 sources of
QRM guidance since 2008. When asking the same question of KM, only four
instances were noted, and typically these were a single passing reference to KM
in the respective document. Similarly, a review of the PDA Technical Report
Bookstore (PDA, 2021) includes a series of six Technical Reports focused on
QRM, while there are none on KM.

•

Quality risk management is more discrete and better understood than
knowledge management.
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QRM implementation in the pharmaceutical industry has been the subject of
many studies by academia, industry, and regulators. While there still remain
many challenges7 with QRM implementation, the core concepts of what QRM is
in practice are generally well established. Figure 1 in ICH Q9 (ICH, 2005),
included as Figure 1-4 below, conveys the essence of the RM process and several
potential tools in the appendix to Q9 support the ‘how.’ Conversely, there is no
equivalent figure to convey a generic KM process nor potential tools.

Figure 1-4 – Overview of a typical quality risk management process (Figure 1, ICH Q9) (ICH,
2005)

KM is further complicated as it can overlap with many different disciplines,
including Information Technology, Learning & Development, Operational
Excellence, Human Resources, and others, thus bringing much diversity of
opinion to what KM is and how to do it. A recent survey from Knoco highlights
the diversity of organisational alignment for KM functions in companies (Knoco,
2017, 2020). Furthermore, there is a broad diversity of issues for KM to address,
which typically require very different approaches to manage both explicit and
tacit knowledge. According to Birkinshaw (Birkinshaw, 2001), KM is difficult

7

QRM continues to evolve as witnessed by ongoing revision to ICH Q9, continued research and industry
focus
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because the range of possible approaches and tools to manage knowledge are
more highly diverse and subjective and tend to be specific to organisational
challenges or business models.
Research presented by Kane in 2018 started to shine a light on this issue of lagging KM
adoption in the pharmaceutical industry. Kane emphasised the importance and benefit
of managing knowledge as an asset in the pharmaceutical industry, providing a vision
for end-to-end product knowledge accessibility and availability, as well as a blueprint
for knowledge management (Kane, 2018). The findings and relevance of Kane’s
research on this study will be explored further in Chapter 2.
Further to lagging KM adoption, another finding of concern to the researcher was the
discovery that while QRM and KM are considered highly interdependent, they are not
well integrated in practice today. This suggested to the researcher a potential critical
gap in the realisation of ICH Q10: that the industry is not ensuring it is applying the best
of what it knows to make optimal risk-based decisions. This influenced the direction of
the research study, through an effort to develop a mechanism to address this gap. The
next sections in this chapter further introduce this research journey.

1.3 Researcher introduction and research positionality
While this research study commenced formally in 2018, in reality it began a decade
earlier when the researcher was first introduced to the concept of KM as a member of
the MSD8 delegation to a US Food and Drug Administration (FDA) Cooperative Research
and Development Agreement (CRADA9) workshop series. This CRADA chartered a
cohort of pharmaceutical and biotech companies to explore the industry’s adoption of
the FDA’s new quality initiative for the 21st Century (US FDA, 2002; FDA, 2007; Shanley,
2007). A series of workshops, held in September 2007 and February 2008, explored the

8

MSD, or Merck Sharp & Dohme, an American-based pharmaceutical company known as Merck & Co.,
Inc., Kenilworth, NJ USA in the USA and Canada, and MSD outside of the USA and Canada. Any and all
references to ‘Merck’ throughout this confirmation and associated works are solely in reference to
“Merck & Co., Inc., Kenilworth, NJ USA” unless otherwise stated.
9
The CRADA is a research agreement between FDA and non-Federal parties to collaborate in
developing and moving new technologies to market (FDA, 2018)
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practical implementation of the FDA’s new quality paradigm which had been formalised
through a series of new guidance documents and included preliminary exploration of
the concept of knowledge management, which was very much in its infancy at the time.
This was the researcher’s first in-depth exposure to these regulatory guidelines, and
more specifically to the role of KM in enabling an effective PQS, which launched a
learning journey spanning nearly 15 years. Steps taken and perspectives gained in this
journey are explored throughout this thesis. Embarking upon this research study
presented the researcher with a unique and exciting opportunity to drive meaningful
improvement for the pharmaceutical industry and the patients it serves beyond the
organisational boundaries of his employer.
In addition to the CRADA workshop series, the researcher had been a student of KM,
business strategy, organisational change management, lean six sigma and related
methodologies for over half of his 27+ year professional career. The researcher had
been conducting informal research in KM through personal learning, benchmarking,
publishing, and speaking as a KM thought leader and subject matter expert within the
pharmaceutical industry and across industries since 2008.
A specific example of a significant KM project dating back to 2008 is the researcher
initiating a Lean Six Sigma Black Belt certification project to devise a KM strategy for the
small molecule commercialisation function at a major multinational pharmaceutical
company (MSD). The strategy recommended that a proper KM organisational unit
should be created, and the researcher was selected to lead that function. Since then,
the KM organisational unit has led a successful KM program for MSD. These activities
established a strong foundation for the researcher in theory and practice and have
uniquely positioned the researcher for this research study. A timeline summary of key
activities in the researcher’s KM learning and thought leadership prior to this research
study is included in Appendix 1.
Through this professional experience, the researcher has demonstrated a diverse,
lengthy, and persistent presence in KM with a variety of global audiences for over a
decade. These audiences included regulatory authorities, industry groups, academia,
12

and organisations outside of the pharmaceutical industry. The researcher has also been
active in KM through a variety of channels, including as a speaker, author, panellist,
industry SME, guest lecturer at Columbia University and conference planning
committee member.

These events and more presented opportunities for the

researcher to demonstrate thought leadership and influence on a broad scale while at
the same time embarking on a rewarding learning journey. These collective experiences
inherently formed the researcher’s thinking in undertaking this research study.

1.4 Focus of this research study
Initially, the researcher set out to explore two hypotheses focused primarily on
improving KM and in particular, KM involving tacit knowledge. These two hypotheses
are discussed in detail in Chapter 3 and the essence of which are presented here as
follows:
1. The pharmaceutical sector does not currently have a holistic end-to-end view
of what it knows about its products across the product lifecycle, nor how to
best enable knowledge ‘flow’ to ensure the best possible quality- and
operational-related outcomes.
2. Tacit knowledge is critical but is not effectively managed during key activities
across the pharmaceutical product lifecycle, such as technology transfer.
During the course of the study on end-to-end KM, the researcher was struck by the
pervasive gap in adoption between QRM and KM as highlighted in section 1.1 of this
Chapter. This motivated the researcher to accelerate examination of and reflection on
the dual ICH Q10 enablers of QRM and KM in an attempt to challenge the siloed thinking
evident in the pharmaceutical industry regarding these topics. This led to a third
hypothesis as follows:
3. Quality risk management and knowledge management are not adequately
integrated to ensure the best possible risk-based decisions. Strengthening the
relationship between QRM and KM has the opportunity to improve patientfocused outcomes across the product lifecycle through reduced risk to product
quality and availability.
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The research study explored each of these three hypotheses; and the journey taken is
described in the next chapters of the thesis, beginning with a literature review in
Chapter 2. Notably, the research activities for this study were in parallel and iterative,
and not necessarily in the order presented. While setting the context, the researcher
believed it to be useful to introduce some of the primary outputs of the study at this
stage.

1.5 Overall timeline and progression of the research
As noted previously, the research as described in the thesis was iterative in nature and
while the study initially embarked with a focus on improving knowledge management
for technology transfer (hypotheses 1 and 2), the emergence of the importance of the
QRM-KM interdependency (hypothesis 3) changed the course of the research. This is
reflected by the order in which this research is presented in this thesis. However, it is
useful to introduce an overall timeline and progression of the research. This timeline,
consisting of four phases, is shown in Figure 1-5. The numbered activities highlight
many of the outward-facing research activities (e.g., conference presentations, papers
published) and four primary outputs which are discussed in the next section.
Complete details of the key research activities as depicted in Figure 1-5 are provided in
Appendix 2.
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Research Phases
Phase 1: Problem Definition

Phase 2: KM Framework (KTE) & KTE Toolkit
Phase 3: QRM-KM Framework
Phase 4: Verification & Impact

Key Research Activities
1

2H
2018

3

5

1H
2019

7

2H
2019
2

4

9

11

1H
2020
6

13 15 17 19 21

10

12 14 16 18 20

KTE Framework
and KTE Toolkit

X

Conference /
Presentation

Paper /
Publication

X

Figure 1-5 – Timeline of research activities
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1H
2021

2H
2020
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23

22

Knowledge Management
Process Model
RKI Cycle

Primary
Output

2H
2021
24

26
RKI Cycle
across
product
lifecycle

1.6 Primary outputs of this study as relevant to the PQS
This research study resulted in many outputs, outcomes, and impacts as discussed in
detail in Chapter 10. Several of these outputs are expected in time to have a potentially
significant impact on at least four areas of the PQS. These four areas of the PQS are
identified in Figure 1-6.

Figure 1-6 – Anticipated impact of this study on the PQS

The following primary outputs which impact each of these PQS areas are as follows (the
output is noted in bold and the PQS area is underlined, and maps to Figure 1-6):
1. Development of a Knowledge Management Process Model to define a process
for KM as an enabler of the PQS.
2. Development of the Risk-Knowledge Infinity Cycle (RKI Cycle) framework to
define the relationship between QRM and KM as the dual enablers to the PQS.
3. Development of a Knowledge Transfer Enhancement Framework (KTE
Framework) to define a plan and toolkit for KM during the PQS lifecycle stage
of technology transfer.
4. Demonstration of RKI Cycle application and impact across the pharmaceutical
product lifecycle to illustrate the PQS dependency on effective KM and to
rapidly scale these new frameworks across the product lifecycle by maximising
knowledge to minimise risk.
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The following is an introductory explanation of each of these outputs.

1.6.1 Knowledge Management Process Model
A Knowledge Management Process Model (Figure 1-7), was strategically crafted similar
to the familiar (and perhaps iconic) QRM Process Model found in ICH Q9 (ICH, 2005).
The researcher believes that this model has the potential to enhance the understanding
of knowledge management as an equal party to QRM in enabling an effective PQS. This
model is fully introduced and discussed in Chapter 4 of this thesis.

Illustrative processes

Development
Studies

CPV
QRM

Change
Management

Technology
Transfer

…

Knowledge Creation
Newly acquired knowledge
(product, process & platform knowledge)

Basis for prior knowledge

Knowledge
Dissemination
Knowledge Storage & Visibility

Knowledge Availability

Growing and evolving knowledge

Knowledge Capture
Knowledge Identification,
Review & Analysis

Knowledge Management Practices
for both explicit and tacit knowledge

Knowledge communication,
exchange & sharing (via knowledge culture)

Knowledge Curation

(product, process & platform knowledge)

Knowledge Management

Knowledge Application, Growth & Transfer
QRM

Product
Filing

Technology
Transfer

Change
Management

CAPA
…
Illustrative processes

DECISION
© Lipa & O’Donnell 2020

Figure 1-7 – KM Process Model (preview)

1.6.2 Risk-Knowledge Infinity Cycle Framework
The development of the Risk-Knowledge Infinity Cycle (RKI Cycle) Framework (Figure
1-8) may well be the most exciting output of this research study. Based on its broad
appeal and the interest since its publication in October 2020 (Lipa, O’Donnell and
Greene, 2020a) and a subsequent survey assessing the utility of the RKI Cycle, the
framework is already attracting significant attention, even before this thesis was
written. This framework is fully introduced and discussed in Chapter 5 of this thesis.
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Figure 1-8 – The Risk-Knowledge Infinity Cycle (as applied to ICH Q10, preview)

1.6.3 Knowledge Transfer Enhancement (KTE) Framework
The development of a framework for Knowledge Transfer Enhancement (KTE
Framework) offers a pragmatic ‘how’ to guide KM and knowledge transfer (KT) during
the critical lifecycle stage of technology transfer. In addition, an accompanying KTE
Toolkit is proposed, along with case studies and demonstrated impact of tacit
knowledge transfer approaches. This framework and toolkit are fully introduced and
discussed in Chapter 7 of this thesis.

Figure 1-9 – KTE Framework (preview)

1.6.4 Demonstrating how the RKI Cycle can be applied across the product lifecycle
Finally, building on all of these outputs, a mapping of KM focus and associated KM
methods and tools was carried to demonstrate how the RKI Cycle can be applied across
the end-to-end product lifecycle. This mapping, along with two additional examples
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which illustrate application of the RKI Cycle to change management during commercial
manufacturing and to data analytics, illustrates the potential broad impact of the RKI
Cycle. These examples illustrating the RKI Cycle across the product lifecycle are fully
introduced and discussed in Chapter 8 of this thesis.

Figure 1-10 – The RKI Cycle applied across the product lifecycle – examples (preview)

In addition to each of these models and frameworks, the research study has fostered a
dialogue of learning and education in the exchange of ideas and socialisation of
concepts, touching several hundreds of people during the course of this study.
Furthermore, it is in the translation of theory to practice through these models,
frameworks, and maps that the researcher finds the greatest motivation and energy,
with the ambition of influencing a large industry and ultimately having a tangible impact
on the lives of patients served by this important industry.
This chapter has introduced the research study background and context. The next
chapter provides a review of the main literature sources considered as part of this
research study.
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Chapter 2: Literature Review
The purpose of this chapter is to provide a summary of the relevant literature
considered for this research study. The literature review focused on a variety of topics,
including the primary topics of knowledge management, risk management and
technology transfer, and did so both within and beyond the pharmaceutical sector.
Importantly, the literature review also examined a variety of intersections between
topics to better discern relationships and adjacencies. Figure 2-1 was designed to
convey the scope of the literature review and also how the various topics relate. The
three large circles represent the main areas of focus, while the smaller (purple) circles
represent related topics reviewed. Figure 2-1 also provides a mapping of where the
various topics are covered in this thesis.

Technology Transfer
• Regulatory Guidance
• Industry Guidance
• ex-pharma sector

Chapter 2.3

Knowledge
Transfer
Chapter 2.3

Knowledge
Management

Risk Management
• Regulatory Guidance
• Risk & Knowledge
(ex-pharma sector)

• Regulatory Guidance
• Industry Guidance &
Developments
• PRST Research

Chapters 1 & 2.2

Chapters 1 & 2.1
Quality
Culture
Chapter 9

Domains of
Knowledge
Chapter 2.4

Knowledge
Culture
Chapter 9

Figure 2-1 – Scope of literature review

The review of each topic within this chapter will typically follow a progression from
more general (e.g., managing knowledge across the product lifecycle) to more specific
(e.g., managing knowledge specifically for technology transfer as a stage in the product
lifecycle). Where applicable, for a given topic this review will first address regulatory
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guidance, followed by industry guidance, and finally other academic or research-related
literature.
It is useful to provide a brief explanation of pharmaceutical sector context as there a
variety of different organisations cited during the course of this study, with different
and sometimes overlapping missions. This research study will reference a sector
comprised of three primary cohorts: industry (for-profit organisations which provide a
pharmaceutical product or associated service); regulatory agencies (authorities which
have legal authority to regulate the pharmaceutical industry in their respective
countries); and academia. In addition, there are a variety of associations which
comprise of a mix of these cohorts.
•

Most notably referenced in this study ICH, the International Council for
Harmonisation. For the context of this study, ICH has authored a variety of
guidelines which are widely adopted by worldwide regulatory authorities.
Successful implementation of ICH guidelines forms a core focus of this research
study, given their importance, relevance, and global reach.

•

Also of significance to this study are the professional associations of ISPE
(International Society for Pharmaceutical Engineering) and PDA (Parenteral Drug
Association), which each provide a venue for cross-stakeholder dialogue and
exchange of ideas to advance the industry. One feature of these associations is
the creation of ‘best practices’, authored by industry subject matter experts, to
support the industry in technical and regulatory success.

•

Another industry association referenced within this research study is
BioPhorum, although this association is primarily comprised of industry and
focused on connecting leaders and experts across industry members to share
best practices and align on industry positions.

These stakeholders and associations will be referenced regularly through this research
study. The following diagram (Figure 2-2) is intended to help the reader understand
these various entities and serve as a helpful ‘quick reference guide’ throughout this
document.
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Pharmaceu)cal Sector Landscape
as relevant to this research study

Regulatory authori.es (na.onal level)

Regulators

(illustra)ve subset)

Illustra(ve
subset of
health authori(es

Industry

Swiss-based associa2on, primarily of regulatory authori2es and
industry associa2ons, seeking harmonisa2on of regulatory
guidance worldwide
The Interna3onal Council for Harmonisa3on of Technical
Requirements for Pharmaceu3cals for Human Use (ICH) is unique in
bringing together the regulatory authori3es and pharmaceu3cal
industry to discuss scien3ﬁc and technical aspects of drug
registra3on. ICH's mission is to achieve greater harmonisa3on
worldwide to ensure that safe, eﬀec3ve, and high-quality medicines
are developed and registered in the most resource-eﬃcient manner.
Harmonisa3on is achieved through the development of ICH
Guidelines via a process of scien3ﬁc consensus with regulatory and
industry experts working side-by-side.

Academia
Other regulatory
en((es

Addi2onal regulatory en22es
whom engage in regulatory guidance
and/or harmonisa3on involving
pharmaceu3cal GMP-related topics
Member-based industry organisa2on,
crea2ng industry best-prac2ces and
aligning industry posi2on

Industry organisa2on connec2ng
stakeholders to advance the industry,
implement regulatory guidelines & develop
good prac2ces

Industry organisa2on connec2ng across
stakeholders to advance the industry,
implement regulatory guidelines & provide
industry guidance

Create an environment where the
global biopharmaceu3cal industry can
collaborate and accelerate their rate of
progress, for the beneﬁt of all…by
bringing leaders together; mobilising
communi3es; crea3ng partnerships and
replacing isola3on.

ISPE provides a neutral environment where
our individual Members and experts
belonging to Regulatory Authori3es can
engage in open dialogue on issues that will
ul3mately beneﬁt pa3ents around the world.

PDA creates awareness and understanding of
important issues facing the pharmaceu3cal and
biopharmaceu3cal community and delivers highquality, relevant educa3on to the industry…to
assist the advancement of pharmaceu3cal
science and technology in the interest of public
health.

Academic research team focused on prac2cal implementa2on of ICH Quality
Guidelines suppor2ng paradigm shiD in quality since 2005
TU Dublin PRST ac3vely engages with global industry and regulators to address the
challenges and opportuni3es of implemen3ng Science and Risk based decision making
and manufacturing approaches, with a focus on developing pa3ent-focused strategies to
ensure the availability of high-quality medicinal products.

Figure 2-2 – Pharmaceutical Sector Landscape10

10

Descriptions for BioPhorum, ISPE, PDA, PRST and ICH are taken from their respective About pages (BioPhorum, 2020; ICH, 2020; ISPE, 2020; PDA, 2020; PRST, 2020).
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2.1 Managing knowledge across the product lifecycle
Several definitions of knowledge management are presented in Table 2-1 to formally
define the concept. In the opinion of the researcher, the diversity seen across these
definitions is the first clue of the variability and lack of common understanding of what
KM is.
Table 2-1 – Definitions of Knowledge Management
Source
Cambridge Business
Dictionary (Cambridge,
2021)
ICH Q10 (ICH, 2008)
ISO Standard 30401
(ISO, 2018)

APQC11 (APQC, 2018)

Knowledge Management Definition
The way in which knowledge is organised and used within a
company, or the study of how to effectively organise and use it.
Systematic approach to acquiring, analysing, storing, and
disseminating information related to products, manufacturing
processes and components
Management with regard to knowledge.
note 1: It uses a systemic and holistic approach to improve
results and learning.
note 2: It includes optimising the identification, creation,
analysis, representation, distribution, and application of
knowledge to create organisational value.)
Systematic approaches to enable knowledge and information to
grow, flow and create value; connecting people to people and
people to content.

2.1.1 Regulatory guidance
This section includes a review of Regulatory Guidance literature and includes discussion
specifically related to explicitly stated knowledge management expectations as well as
references to expectations for managing knowledge during the product lifecycle. The
scope of literature surveyed represented diverse sources of guidance which are
common inputs to shape an organisation’s PQS as follows:
•

11

International Conference on Harmonisation (ICH) Quality Guidelines, including
o ICH Q8(R2): Pharmaceutical Development (ICH, 2009)
o ICH Q9: Quality Risk Management (ICH, 2005)
o ICH Q10: Pharmaceutical Quality System (ICH, 2008)
o ICH Q8/Q9/Q10 Questions & Answers (ICH, 2010)
o ICH Q11: Development and Manufacture of Drug Substances (Chemical
Entities and Biotechnological/Biological Entities) (ICH, 2012)

APQC, or American Productivity & Quality Center, is a global authority in KM. www.apqc.org.
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•

•
•

o ICH Q12: Technical and Regulatory Considerations for Pharmaceutical
Product Lifecycle Management (ICH, 2019)
World Health Organisation (WHO) Guidelines, including:
o WHO Good Manufacturing Practices for Pharmaceutical Products: Main
Principles (WHO, 2014)
EudraLex Volume 4 – Good Manufacturing Practice (GMP) Guidelines (Part I)
(European Commission, 2012)
Pharmaceutical Inspection Co-operation Scheme (PIC/S) Guide to Good
Manufacturing Practice for Medical Products (Part 1, Chapter 1) (PIC/S, 2018)

Perhaps of note, no specific US FDA guidance is listed above. FDA has participated in
the development of ICH Quality Guidelines listed above and has subsequently adopted
these guidelines. Therefore, FDA guidance is included through the ICH documents.

2.1.1.1 ICH Quality Guidelines
Examining the ICH Quality guidelines sequentially starting with ICH Q8, Pharmaceutical
Development (ICH, 2009), ICH Q8 establishes a risk-based approach to product
development commonly referred to as Quality by Design (QbD). While there is only a
singular reference to KM in ICH Q8 (which directly references ICH Q10 (ICH, 2008)), ICH
Q8 aptly sets the stage for the expectations of applying knowledge to increase product
and process knowledge and make scientific- and risk-based decisions. Furthermore, ICH
Q8 acknowledges that new knowledge will be gained over the product lifecycle, for
example as follows (note the specific acknowledgement for knowledge gained from
‘failed’ experiments):
Changes in formulation and manufacturing processes during development and
lifecycle management should be looked upon as opportunities to gain additional
knowledge and further support establishment of the design space. Similarly,
inclusion of relevant knowledge gained from experiments giving unexpected
results can also be useful (ICH, 2009).
ICH Q8 also introduces the concept of prior knowledge. This concept is not directly
defined – its meaning can only be inferred as appropriately vetted and managed
knowledge already existing in the organisation or other reputable source (e.g., from
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prior products, scientific literature), and industry has continued to debate this at
conferences (CASSS, 2018).
ICH Q9, Quality Risk Management (ICH, 2005) is specifically dedicated to quality risk
management as a ‘systematic process for the assessment, control, communication and
review of risks to the quality of the drug (medicinal) product across the lifecycle.’ QRM
is identified in ICH Q10 as an enabler adjacent to KM (ICH, 2008) yet there is no
acknowledgement of KM as a dual enabler, nor corresponding guidance for KM.
A comprehensive literature review of pharmaceutical regulatory guidance as it pertains
to KM was conducted recently by Kane (Kane, 2018), which covered in particular detail
ICH Q10, Pharmaceutical Quality System (ICH, 2008) and its approval. This included a
review of the positioning of KM as an enabler to the PQS, the definition of KM prescribed
by ICH Q10 and the KM-specific questions and answers in the supplemental Q8/Q9/Q10
Questions & Answers document (ICH, 2010). Therefore, the researcher will not repeat
this review but will summarise relevant key points.
1. The term knowledge management is defined in ICH Q10 as ‘[a]
systematic approach to acquiring, analysing, storing, and disseminating
information related to products, manufacturing processes and
components.’ While a valid definition, in the opinion of the researcher
and as evidenced by subsequent literature invoking the need for ‘knowhow’ and other forms of tacit knowledge (ISPE, 2018), this definition is
arguably narrow and focused primarily on explicit knowledge (i.e.,
documented knowledge).
2. The scope of KM spans the entire product lifecycle as is identified in ICH
Q10 section 1.6.1, ‘Product and process knowledge should be managed
from development through the commercial life of the product up to and
including product discontinuation.’ In addition, section 1.6.1 provides
examples of sources of knowledge, which include but are not limited to
‘prior knowledge (public domain or internally documented);
pharmaceutical development studies; technology transfer activities;
process validation studies over the product lifecycle; manufacturing
experience; innovation; continual improvement; and change
management activities.’ As one might discern, these are very broad
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buckets of knowledge collectively covering many different processes
(e.g., development studies) and activities (e.g., innovation) across the
lifecycle.
3. The supplemental Q8/Q9/Q10 Q&As (R4) document (ICH, 2010) provides
useful clarification to a variety of questions across this trio of guidelines,
including for KM within ICH Q10. Key themes from these answers include
that there is no prescribed ‘how’ to implement KM, that there are no
specific dedicated computerised information management system
requirements and there are no regulatory requirements for a formal KM
system, although ‘it is expected that knowledge from different processes
and systems will be appropriately utilised.’
The key representation of the pharmaceutical product lifecycle, the PQS and its two
enablers from ICH Q10 shown in Figure 1-2 is of foundational importance and is
referenced throughout this thesis.
The importance of managing knowledge through acquisition, application and sharing is
further reinforced in ICH Q11, Development and Manufacture of Drug Substances
(Chemical Entities and Biotechnological/Biological Entities) (ICH, 2012) as it introduces
the concept of proactive knowledge transfer across an organisation, specifically:
Knowledge gained from commercial manufacturing can be used to further
improve process understanding and process performance and to adjust the
control strategy to ensure drug substance quality…the knowledge and process
understanding should be shared as needed to perform the manufacturing
process and implement the control strategy across sites involved in
manufacturing the drug substance.
ICH Q11 further reinforces the expectation for a ‘systematic approach to managing
knowledge related to both drug substance and its manufacturing process through the
[product] lifecycle’, inclusive of technology transfer activities.
The final version of ICH Q12 Technical and Regulatory Considerations for
Pharmaceutical Product Lifecycle Management, (ICH, 2019) adopted in late 2019,
positions KM in a central role with respect to the change management process relating
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to post-approval changes. ICH Q12 builds upon the KM foundation established by ICH
Q10 in order to ensure the latest, most comprehensive, and most accurate knowledge
is applied to maintain the state of control and enable continual improvement.
Furthermore, an effective KM capability acting as a PQS enabler, helps to ensure that
knowledge is available to support other critical activities including RM and CAPA as well
as post-approval changes. A representation of the positioning of knowledge and
knowledge management in conjunction with change management in ICH Q12 is
depicted in Figure 2-3.

Figure 2-3 – Knowledge management and change management processes (ICH, 2019)

This interaction is further explained in appendix 2 of ICH Q12 as follows (emphasis in
bold added by the researcher):
An effective change management system includes active knowledge
management, in which information from multiple sources is integrated to
identify stimuli for changes needed to improve product and/or process
robustness. The connection between knowledge management and change
management is illustrated in [Figure 2-3]. These sources can include, but are not
limited to, developmental studies, process understanding documents, product or
process trending, and product-specific CAPA outcomes. Provisions should be
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made for sharing knowledge (e.g., in quality agreements and/or contracts) that
relates to product and process robustness or otherwise informs changes between
the MAH and relevant manufacturing stakeholders (research and development
organisations, manufacturers, CMOs, suppliers, etc.)… As described in ICH
Quality Implementation Working Group on Q8, Q9, and Q10 Questions &
Answers, there is no added regulatory requirement for a formal knowledge
management system.
Key concepts which may be extracted from this guidance include that:
•
•

Knowledge management is an intentional and proactive activity, covering a
diverse set of process and product knowledge.
Knowledge management is also invoked as a means to sharing knowledge across
a diverse set of stakeholders.

2.1.1.2 WHO Guidelines GMP for Pharmaceutical Products: Main Principles – Annex 2
The current version of the WHO Good Manufacturing Practices for Pharmaceutical
Products: Main Principles (WHO, 2014) includes an expectation for managing product
knowledge across the lifecycle as follows:
The PQS appropriate to the manufacture of pharmaceutical products should
ensure that…product and process knowledge are managed throughout all
lifecycle stages.
The responsibility for KM is identified as an expectation to be defined in establishing a
contract with a separate manufacturing organisation but the term is not expressly
defined.

2.1.1.3 EudraLex Volume 4 – Good Manufacturing Practice (GMP) Guidelines (Part I)
In EudraLex Volume 4 (Good Manufacturing Practice guidelines), Chapter 1
(Pharmaceutical Quality System) (European Commission, 2012), the following
expectations are established (emphasis in bold added by the researcher):
A Pharmaceutical Quality System appropriate for the manufacture of medicinal
products should ensure that…Product and process knowledge is managed
throughout all lifecycle stages
and
Continual improvement is facilitated through the implementation of
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quality improvements appropriate to the current level of process and product
knowledge.
2.1.1.4 PIC/S Guide to Good Manufacturing Practice for Medical Products
No specific expectations of KM across the lifecycle are noted within PIC/S Guide to Good
Manufacturing Practice for Medical Products (Part 1, Chapter 1) (PIC/S, 2018), with the
exception of a reference to contractual agreements where the responsibility for KM
should be appropriately noted. However, the expectations for managing knowledge are
noted as part of a firm’s PQS similar to that of EudraLex Volume 4 Part 1 (European
Commission, 2012) (emphasis in bold added by the researcher):
A Pharmaceutical Quality System appropriate for the manufacture of medicinal
products should ensure that…Product and process knowledge is managed
throughout all lifecycle stages…[and] continual improvement is facilitated
through the implementation of quality improvements appropriate to the current
level of process and product knowledge.
2.1.2 Industry guidance
This section includes a review of pharmaceutical Industry Guidance12 literature from
industry associations and other authorities. This review focused on the expectations for
KM across the product lifecycle. As discussed previously in this thesis, there is a general
lack of pharmaceutical industry guidance for KM. However, recently there have been
some developments within the industry towards addressing this gap.

2.1.2.1 ISO
In November 2018 the International Organisation for Standardisation published its first
ever guidance on KM in the form of International Standard ISO 30401:2018(E),
Knowledge Management Systems – Requirements (ISO, 2018).

This standard

acknowledges in the introduction that KM has no single accepted definition, and no
global standards predate the subject standard. The standard also stated there are many
12

The concept of industry guidance literature in the pharmaceutical industry is important as these are
typically documents authored by cross-functional SME teams and undergo a peer-review commenting
process for broad sector input. Input to these guides is often sought from industry, academia, and
regulatory authorities. These guidance documents typically help industry understand how to satisfy
regulations, adopt good practices, etc.
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well-known barriers to KM and confusion with other disciplines. In addition, the
standard describes the importance of KM in a generalised manner to an organisation’s
success.
The standard does not deeply address specific KM approaches, nor does it use the word
‘tacit’ (however it does state that at one-point knowledge includes ‘insights and knowhow’ as common vernacular for tacit knowledge). The standard is useful in particular
for organisations looking to set up or improve their KM programs. It addresses a
lifecycle of knowledge activities and inventories KM enablers, including culture. It
covers the expectations of leadership, policy, roles and responsibilities, and support
requirements (e.g., communications). The standard has not seen rapid uptake, with
nearly half of survey respondents in the Knoco13 2020 KM survey (Knoco, 2020)
unaware of the standard or not intending to buy or use it, and only a very small
percentage (2%) are seeking or have achieved certification. In the opinion of the
researcher, this should change over time as more become familiar with its contents and
the importance of KM.

2.1.2.2 ISPE
In 2019 ISPE chartered a team to create a Good Practice Guide for Knowledge
Management, and the researcher was invited to be a member of the subject matter
expert authoring team. ISPE Good Practice Guides are premier industry guidance
documents which are authored by industry subject matter experts, and through a
governance process are peer reviewed by industry. The following is an excerpt from the
ISPE Knowledge Management Good Practice Guide charter14.
Knowledge Management – one of the two identified enablers of ICH Q10. The
publication of ICH Q10 in 2008 saw the formal designation of Knowledge
Management (KM) as a key enabler for an effective Pharmaceutical Quality
System. Since then, the industry has acknowledged the importance of managing
knowledge across the lifecycle to enhance process understanding, improve
13

Knoco was established in 1999 by key members of BP’s (British Petroleum) global KM Consulting
team, who had been recognised in the 1990s as pioneers in the field of KM. www.knoco.com.
14
The charter is not published, but the charter was available to the researcher as a member of the SME
author team for the guide.
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decision making and enable more robust risk management. ICH Q10 and the
forthcoming Q12 discuss the expectations for firms to proactively manage
product and process knowledge citing the potential of more efficient and
effective regulatory oversight (e.g., ICH Q12). There are currently few resources,
and NO INDUSTRY GUIDANCE available which address the role of Knowledge
Management specifically for the pharmaceutical industry.
The chartering of an ISPE Good Practice Guide team for Knowledge Management is an
important recognition of the significance of KM and the need for industry guidance. This
ISPE Guide was published nearly concurrently with this thesis in May 2021 (ISPE, 2021b)
and will be discussed in further detail in Chapter 10.

2.1.2.3 BioPhorum
In March 2020 BioPhorum published a peer-reviewed case study titled Knowledge
Mapping for the Biopharmaceutical Industry: A Test Case in CMC15 Business Processes
from Late-Stage Development to Commercial Manufacturing (BioPhorum Operations
Group, 2020). The purpose of the document was to demonstrate a ‘best practice KM
methodology to capture a process-based knowledge map for a major business process’
– in this case for the CMC business process from late-stage development to commercial
manufacturing. The intent was to illustrate the knowledge mapping method, produce
a company agnostic knowledge map as a reference for the industry, to highlight the
common issues with ‘knowledge flows’ where improvements can be made, and to
highlight the detailed tacit knowledge which exists in the business process. This
knowledge map was created by 18 individuals from 12 different organisations, as listed
in the referenced document (BioPhorum Operations Group, 2020). The researcher was
an invited member of the team and was responsible for providing the knowledge
mapping process and trained the team on knowledge mapping. While not official
guidance, this guide will serve a model of knowledge mapping for others to follow as
well as having created a useful industry asset in the form of the subject knowledge map.

15

Chemistry, Manufacturing and Controls (CMC) of a medicinal product is the body of information that
defines not only the manufacturing process itself but also the quality control release testing,
specifications and stability of the product (Genpact, 2021)
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2.1.3 The Pharmaceutical Regulatory Science Team
The Pharmaceutical Regulatory Science Team (PRST) based in TU Dublin has continued
to progress research on quality risk management, knowledge management and related
topics covered by ICH Quality Guidelines, most recently ICH Q12 (ICH, 2019). The PRST
was founded in 2005 in response to the drive for a paradigm shift in quality from the
international regulatory community. PRST actively engages with global industry and
regulators to address the challenges and opportunities of implementing Science and
Risk based decision making and manufacturing approaches. PRST research emphasis is
on the development of patient-focused strategies to enable those involved in the
manufacture of drug products to meet the evolving international regulatory
expectations ensuring the availability of high-quality medicinal products.
An overview of the research topics, currently active researchers (with primary topic)
and key regulatory and industry developments is depicted in Figure 2-4. One of the
powerful characteristics of the PRST research structure is that research is not done in
‘silos’ – there is a high degree of research cross-over between these important PQS
topics which brings diverse viewpoints and further strengthens the validity of the
research overall. The PRST are all active members of industry conferences and publish
regularly.
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Figure 2-4 – PRST journey in regulatory science research

2.1.3.1 Research by the PRST: Knowledge management
This most relevant research for this research study is the work of Calnan and Kane.
Calnan’s 2015 thesis, Protecting the Patient: Enhancing the Quality of Pharmaceutical
Products (Calnan, 2014a) explored the unacceptable risks that patients are exposed to
due to challenges which exist in the complex pharmaceutical product lifecycle.
Calnan’s exploration of KM as an ‘orphan enabler’ to the PQS established the
foundations for the PRST in KM. Calnan discussed the concepts of tacit and explicit
knowledge, the concept of knowledge flow and the link between the importance of
capturing and applying knowledge to an effective PQS. Calnan also proposed that the
elements of the PQS (product performance and product quality monitoring system,
CAPA, change management and management review) should operate through wellintegrated and balanced enablers of KM and QRM.
Calnan explored the topics of being excellent and cultural excellence, in addition to the
aforementioned knowledge excellence focus. A key output from the research was a
construct of the Building Blocks of Cultural DNA of Quality (Figure 2-5), in which these
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elements of knowledge excellence, cultural excellence, patient focus and being excellent
converge to create a culture of quality.

Figure 2-5 – Building blocks of the cultural DNA of quality (Calnan, 2014a)

The primary research output of Calnan’s work was the Excellence Framework (Figure
2-6), a combination of the cultural excellence of a learning organisation with excellence
in knowledge creation and utilisation, in order to deliver operational excellence based
on a relentless restlessness for improvement. The model is dynamic and encourages
one to analyse the current situation for improvement opportunities, to assimilate the
findings to create new knowledge and then use this knowledge to take action, decisions
and deliver solutions. Reflection is promoted to confirm the effectiveness of the action
taken and share lessons learned.

Figure 2-6 – The Excellence Framework (Calnan, 2014a)

Calnan’s work also produced additional KM-related outputs, including a KM e-journal
published by ISPE, an informative history of product quality, and a detailed literature
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review, including that of knowledge management, found in Chapter 2 of Calnan’s thesis
(Calnan, 2014a).
The second closely related research study was carried out by Kane, culminating with the
2018 thesis on A Blueprint for Knowledge Management in the Biopharmaceutical Sector
(Kane, 2018). Kane’s focus was on exploring the level of adoption and capability of KM
in the biopharmaceutical sector. In finding a general lack of maturity in the sector,
Kane’s research produced a collection of assets for the sector to leverage to unlock their
knowledge. The primary output of the research was a new framework entitled the
Pharma KM Blueprint (Figure 2-7).

Figure 2-7 – The Pharma KM Blueprint (Kane, 2018)

This framework provided a construct of principles, models and tools summarised as
follows:
1. Managing Knowledge as an Asset – addresses the need to value and maintain
knowledge assets in the same way as physical assets within an organisation.
2. The Pharmaceutical Product Knowledge Lifecycle Model (PPKL) (Figure 2-8)
addresses the challenge of enabling knowledge flow in order to increase
visibility, to access and use the product and process knowledge assets across the
product lifecycle.
3. The House of Knowledge Excellence Framework (Figure 2-9) demonstrates a
framework developed to implement a systematic KM programme linked to
strategic objectives of an organisation, incorporating KM practices, pillars
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(people, process, technology, governance), and enablers to support the effective
management and flow of knowledge assets.
4. Knowledge Management Effectiveness Evaluation provides a practical KM
diagnostic tool that may be used to identify and evaluate areas of opportunity
and to track progress on closing knowledge gaps.

Figure 2-8 – Pharmaceutical Product Knowledge Lifecycle Model (PPKL) (Kane, 2018)

Figure 2-9 – The House of Knowledge Excellence (Kane, 2018)

Of primary relevance to this thesis is the PPKL model. The features of the model include:
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•

•
•
•

The vision for end-to-end (E2E) product and process knowledge asset visibility,
transparency, and availability in order to enable knowledge flow of critical
knowledge to those that need it throughout the product lifecycle.
The addition of a new lifecycle phase of New Product Introduction (NPI) to
replace the Technology Transfer lifecycle phase.
That Technology Transfer is an activity that may occur multiple times across the
product lifecycle.
The addition of a new E2E process to capture the Technical Product Support and
Continual Improvement activities that occur across the product lifecycle.

This model provides a helpful anchor to the management of product knowledge and the
focus on technology transfer as a focal part of this thesis, in particular to the concepts
that knowledge must be managed end-to-end throughout the product lifecycle, that
technology transfer is a repetitive activity across the product lifecycle, and capturing
the end-to-end knowledge can aid in continual improvement.
The House of Knowledge Excellence framework is relevant in particular to the chapter
in this thesis which proposes a toolkit for knowledge management during technology
transfer (Chapter 7). The researcher co-developed this framework with Kane and was
co-author of the book chapter in which it is described (Kane and Lipa, 2018).
Kane’s work also produced a thorough literature review on KM, found in Chapter 2 of
Kane’s thesis (Kane, 2018). As such, the literature review conducted in this thesis did
not repeat all of these specifics and instead builds on this literature review (and that of
Calnan), with a focus on aspects of relevance to the planned research for this study and
developments since Kane’s research concluded. Together, the combined literature
review across these three theses captures a rich and comprehensive review of the KM
literature, especially relative to the biopharmaceutical industry.
These assets will be further referenced throughout this thesis where appropriate.
Kane’s work is further summarised in a monograph entitled Advancing Knowledge
Management (KM) as an ICH Q10 Enabler in the Biopharmaceutical Industry (Kane and
Lipa, 2020).
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In addition, the results of a survey entitled Knowledge Management Implementation, A
Survey of the Biopharmaceutical Industry were published in May 2020 by ISPE (Kane et
al., 2020). This survey was a follow on from Kane’s research and reported on current
state of KM implementation, including status of KM implementation, areas of KM focus,
primary KM approaches, cultural issues. This survey report further confirmed the
relatively low maturity and high variability in which KM is being pursued in the industry.

2.1.3.2 Research by the PRST: Post-approval changes (ICH Q12)
Research is underway currently by Ramnarine (Ramnarine, 2020) examining how an
effective PQS could transform post-approval change management to, in turn, solve the
continual improvement and innovation challenge faced by the industry. Among other
challenges, this research also looks at how knowledge and knowledge management
enable post-approval changes (PACs). Figure 2-10 is a representation of how product
knowledge grows across the product lifecycle. In principle there will always be more
knowledge available than is captured in the CTD (Common Technical Document, i.e., the
regulatory filing).

Figure 2-10 – Maintaining product knowledge in the PQS vs. regulatory filings (Ramnarine,
2020)

38

‘Timely knowledge management’ is required to manage this knowledge effectively and
to in turn be able to apply a firm’s knowledge to identify the need for a change, to
manage the risk associated with the change, implement the change and to ensure the
change was successful. Of note, KM was identified as a top priority to gain regulatory
flexibility. Ramnarine et al. explain the role of KM in maintaining a state of control,
facilitating continual improvement and management of post-approval changes through
the PQS in Figure 2-11 (Ramnarine et al., 2019).

Figure 2-11 – Managing post-approval changes through the PQS (Ramnarine et al., 2019)

2.1.3.3 Additional research & contributions by the PRST
Additional work by the PRST is embedded and referenced throughout this research
study, including those works carried out by the researcher summarised elsewhere in
this thesis and the work of PRST colleagues such Kevin O’Donnell (O’Donnell, 2020). In
addition, the PRST has published multiple monographs since 2018 on the topics of QRM
and/or KM.

2.1.4 Knowledge management – Knoco 2020 benchmarking survey
The majority of significant developments since the completion of Kane’s research and
the start of this research study have been captured in other sections within this
literature review. One additional development was the issuance of the Knoco 2020
Global Survey of Knowledge Management and associated report (Knoco, 2020). Surveys
were also conducted by Knoco in 2014 and 2017 and these are reviewed in detail in the
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literature review contained in Kane’s thesis (Kane, 2018), of which select highlights are
shared here. These important surveys are the only one of their type and breadth but
are industry-agnostic and there is not a specific category for pharmaceuticals, so sectorspecific assessments of results or changes over time for pharmaceutical are not
possible. Further, the goals of KM across sectors are not as focused on the quality
management system as there are many additional drivers for KM in organisations.
Regardless, these data summarised below are useful to understand a bigger focus on
KM at the global level. Given the sector choices provided by the survey, the researcher
anticipates most participating organisations in the pharmaceutical sector would have
labelled themselves as Professional, Scientific and Technical Services or Manufacturing.
The 2020 survey received a total of 453 responses, up from 427 in 2017 and 386 in 2014.
The trend of KM importance is rising in a significant percentage of responses at 71%,
with a small 5% minority indicating the importance of KM is on the decline. The survey
also assessed cultural issues that act as barriers to KM programs, which are important
clues to a transformation change management focus in support of KM. Results are
summarised in Figure 2-12, and show that the leading barrier to KM programmes was
short-term thinking followed by lack of openness to sharing.

Figure 2-12 – Cultural issues acting as barriers to knowledge mgmt. (Knoco, 2020)
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Many additional results are available in the Knoco survey (Knoco, 2020). These specific
results were selected by the researcher based on their relevance to this research effort
and anticipated outcomes.

2.1.5 Summary – knowledge management across the product lifecycle
Reviewing regulatory expectations in aggregate for management of product and
process knowledge across the lifecycle, the researcher draws the following conclusions:
•

•
•

•
•

•

There are broad and consistent expectations across an array of authoritative
sources for product and process knowledge to be managed proactively across
the product lifecycle
Increased knowledge is the means to drive continual improvement
Knowledge lies in multiple formats, including documents (explicit knowledge),
experience (tacit knowledge) and an array of sources which in reality are a mix
of explicit and tacit knowledge, including development history, change history
(with rationale), and problem history with associated resolutions, among others
These knowledge sources are relevant to the given product, but may be
leveraged across products as ‘prior knowledge’
Knowledge leads to understanding and risk reduction which in turn leads to
improved patient outcomes. Knowledge should not only include ‘what works’
for a given product or process but also should include learning from ‘failures’
(e.g., experiments with unexpected outcomes)
There are several linkages between KM and QRM (discussed further in section
2.2)

Yet, In the opinion of the researcher, it appears there is a general lack of industry
guidance for KM, especially when compared to available literature on QRM. It is noted
that there has been recent activity which may be starting to address this gap.
There are potentially exciting developments on the research front that will continue to
raise awareness of the need to improve KM, including this research study. It is worth
mentioning the annual Knowledge Management Conference held by APQC is alive and
well and would have hosted it’s 25th Anniversary Event in May of 2020 (APQC, 2020),
although regrettably cancelled due to the COVID-19 pandemic. The researcher has
been a regular attendee and a steering committee member for 3 of the past 5 years,
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and attendance at this conference has continued to grow. This conference is a premier
event for KM globally and is an annual event which draws approximately 400 attendees
across a highly diverse industry base. The conference is on track to resume in October
of 2021.

2.2 Quality Risk Management and Knowledge Management
A detailed literature review on QRM and KM was conducted as part of this study with
two primary focus areas as outlined below. This literature review was published in a
peer-reviewed journal, the Journal of Validation Technology (Lipa, O’Donnell and
Greene, 2020c), with the findings summarised below.
The first area of focus of the literature review was an exploration of available literature
to understand how QRM and KM have been related in other studies and other
industries. The review strongly suggested that the interplay between managing risk and
managing knowledge is not new. For the last 20+ years this has been a topic of
discussion spanning finance, legal, information technology, aerospace, corporate risk
management, military, and other domains. The findings are consistent, in that there is
a direct relationship between knowledge and risk – more knowledge one has leads to
increased understanding and decreased uncertainty – and therefore to lower risk.
The second area of focus of the literature review was on regulatory guidance, examining
the relationship between risk and knowledge in the guidance as a means to better
characterise any interdependency between risk and knowledge, as well as RM and KM.
The review suggest that collectively the themes of knowledge and risk, along with KM
and RM as structured means to manage each, are prevalent and persistent across the
diverse set regulatory literature reviewed. The review also sought to look beyond
explicit and obvious descriptions stating how RM and KM are linked. The intent was to
examine the more subtle instances of how knowledge and risk are connected, in
addition to KM and RM, even though these latter terms are used less frequently
(especially KM). Further, the review also reflected on the FDA’s vision of science and
risk-based quality for the 21st century (US FDA, 2002) given the inseparability of
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knowledge and science. According to the WHO guideline on Quality Risk Management
(WHO, 2013), an ‘effective and secure knowledge management system’ is crucial to
quality risk management. This WHO guideline also highlights the expectations for using
not only documented knowledge (i.e., explicit knowledge), but also establishes the
expectation for using the knowledge 'in the heads of people’ where experience and
expertise are critical (i.e., tacit knowledge).
As this literature review demonstrated, knowledge and risk bear a clear relationship,
with knowledge being recognised as both an input and an output to quality risk
management. This leads to greater control of risks to quality through increased
understanding. The pairs are each interwoven: knowledge & risk, and knowledge
management & risk management.
Furthermore, a key concept is that ‘risk varies inversely with knowledge’ (Fisher, 1907).
The researcher challenged this as a potential over-simplification and asserted that risk
varies inversely with knowledge applied, indicating the need for the knowledge to be
created, identified, stored, accessible and ‘flow’ on demand to when and where it is
needed. The researcher developed the following figure (Figure 2-13) to illustrate this
point, that risk is a function of knowledge application, and knowledge application is in
turn a function of knowledge flow, availability, capture (and more). Therefore, risk is
also dependent on knowledge flow, availability, capture (and more), highlighting the
need for robust KM processes to maximise risk reduction.
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Risk varies inversely with Knowledge Applied
Goal: To minimize risk to the patient by applying the most complete and accurate body of knowledge
Risk = f (knowledgeapplied)

Meaning: Risk is a function of knowledge application…the more knowledge, the less risk

Knowledgeapplied = f (K flow, K availability, K capture, K accuracy, …)

Risk

Meaning: for knowledge to be applied, it must be available, it must flow to when and where it is
needed, it must have been captured, it must be accurate, …; all direct goals of a KM program

Riskactual

Riskachieveable

Riskminimum

Knowledge Applied
© Martin Lipa 2020

Figure 2-13 – Risk varies inversely with knowledge applied

Further implications from this literature review will be explored in Chapter 5 of this
thesis.

2.3 Technology Transfer and Knowledge Management
The next section of the literature focuses on KM in technology transfer.

2.3.1 Regulatory guidance
Regarding technology transfer, ICH Q10 (ICH, 2008) states technology transfer activities
including new product transfers during development through manufacturing and
transfers within or between manufacturing and testing sites for marketed products are
both in scope of ICH Q10.
In section 3.1 on Lifecycle Stage Goals, ICH Q10 provides arguably a pivotal goal
statement for technology transfer being primarily about knowledge transfer as follows
(emphasis in bold added by the researcher):
The goal of technology transfer activities is to transfer product and process
knowledge between development and manufacturing, and within or between
manufacturing sites to achieve product realisation. This knowledge forms the
basis for the manufacturing process, control strategy, process validation
approach and ongoing continual improvement.
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ICH Q10 proceeds to provide application insights for each lifecycle stage (i.e.,
pharmaceutical development, technology transfer, commercial manufacturing, and
product discontinuation) for each of the four PQS elements, including (i) Process
Performance and Product Quality Monitoring System, (ii) Corrective Action and
Preventive Action (CAPA) System, (iii) Change Management System and (iv)
Management Review of Process Performance and Product Quality. Key points relating
to technology transfer include strong interdependencies with KM practices, including
that technology transfer should be a learning opportunity to grow knowledge about a
product (‘Knowledge obtained during transfer and scale up activities can be useful in
further developing the control strategy’), that acquired knowledge should be applied
both feedback and feedforward basis (‘CAPA can be used as an effective system for
feedback, feedforward and continual improvement’) and that it sets up the role of
knowledge management to manage explicit knowledge for change management (‘the
change management system should provide management and documentation of
adjustments made to the process during technology transfer activities’).
In the introduction of Annex 7 to the WHO guideline on Transfer of Technology in
Pharmaceutical Manufacturing, the following principle is presented citing the
expectation for management of explicit and tacit knowledge as part of technology
transfer (WHO, 2011) (emphasis in bold added by the researcher):
Transfer of technology is defined as “a logical procedure that controls the
transfer of any process together with its documentation and professional
expertise between development and manufacture or between manufacture
sites”. It is a systematic procedure that is followed in order to pass the
documented knowledge and experience gained during development and or
commercialisation to an appropriate, responsible and authorised party.
Further in this guideline, KM is mentioned but not specifically defined:
In the event that the RU [receiving unit] identifies particular problems with the
process during the transfer, the RU should communicate them back to the SU
[sending unit] to ensure continuing knowledge management.

45

Management of knowledge is clearly inferred throughout the document, including in
section 5 where process history, reasons for changes, and problems and outcomes are
examples of types of knowledge referenced. Chapter 8 of the WHO guideline includes
a list of documentation (explicit knowledge) to be transferred.

2.3.2 Industry guidance (pharmaceutical industry-specific)
This section includes a review of pharmaceutical Industry Guidance literature from
industry associations and other authorities with a focus on technology transfer. The
scope of literature surveyed includes:
•
•
•
•
•
•
•

•

WHO Guidelines on Transfer of Technology in Pharmaceutical Manufacturing –
Annex 7 (WHO, 2011)
NIHS Japan: Guideline for Technology Transfer (NIHS, 2005)
ISPE: Good Practice Guide: Technology Transfer, 2nd Edition (ISPE, 2014)
ISPE: Good Practice Guide: Technology Transfer, 3rd Edition (ISPE, 2018)
PDA: Technical Report No. 65: Technology Transfer (PDA, 2014b)
PDA: Technical Report No. 65: Technology Transfer16
PDA Technology Transfer Industry Survey (via Interest Group Report out at PDA
2019 Annual Meeting and 2019 Technology Transfer Industry Survey (Seymour
et al., 2019)
Technology and Knowledge Transfer - Keys to Successful Implementation
(Gibson and Schmitt, 2014) (published by PDA, although not an official Technical
Report)

In general, these guidance present frameworks, processes, and considerations for
conducting technology transfer from which individual companies construct their
respective technology transfer business processes. Of particular interest in this review
is an evaluation of whether the guidance documents include guidance on expectations
for knowledge management and knowledge transfer, as well as any further guidance on
how this might be accomplished. The first step was an assessment of the extent to
which key concepts including knowledge transfer, knowledge management and tacit
knowledge (and synonym ‘know-how’) are present.
16

This PDA Technical Report is currently under revision, but the revision has not been published in time
for inclusion in this thesis. The researcher has been invited to provide feedback on the upcoming
revision which is further explained in section 10.3.
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A further qualitative assessment of the literature was conducted by the researcher on
how well these documents introduced these concepts, including how well they are
collectively explained, whether they provided illustrative examples, and whether they
provided guidance / tips on ‘how’. Details are provided in the corresponding paper
(Lipa, Kane and Greene, 2019), and are summarised by the researcher as follows:
•
•

•
•

Technology transfer guidance is typically very ‘document-centric’ (i.e., focused
on explicit knowledge)
Knowledge management, with a focus on explicit knowledge, is identified in
guidance but is lacking in practical application as the researcher observed the
following:
o Lack of supporting principles or guidance on how to manage or transfer
knowledge effectively
o This absence of guidance may be starting to change, but perhaps still not
enough or fast enough given lag time for industry awareness,
interpretation, and application
‘Tacit’ knowledge is rarely recognised as a source of knowledge, nor is there
guidance on how to manage or transfer
Technology transfer risks of failure do not acknowledge concepts of insufficient
knowledge transfer or availability in the future.

Regarding ISPE guidance on technology transfer, the second edition of the Good
Practice Guide (ISPE, 2014) was included as a baseline for comparison against third
edition, in order to evaluate any changes over time. The third edition (ISPE, 2018) lists
five key rationale for the revision, one of which is ‘Recognition that knowledge
management is a critical component of effective technology transfer…’. It is clear in the
results summarised by the researcher, the presence of knowledge management and
related concepts has been significantly strengthened beyond a starting baseline from
the second edition, suggesting recognition of the need to provide further details in
guidance.
Regarding PDA guidance on technology transfer, the PDA Tech Transfer Interest Group
at the 2019 PDA Annual Meeting shared the results of a recent survey which they
conducted on technology transfer (Seymour et al., 2019). The survey was intended to
47

assess the current practices and future needs for improving the technology transfer
process as an input to a planned revision of PDA Technical Report 65, Technology
Transfer (PDA, 2014b). The survey covered:
•
•
•
•
•
•

Demographics
Types of Technology Transfer Performed
The Technology Transfer Process
Use of Multi-Disciplinary Teams
Technology Transfer Tools
Challenges

The researcher attended the conference session where the PDA Technology Transfer
survey results were presented (Haas, 2019) and the results were subsequently
published by PDA (Seymour et al., 2019). In response to the survey question “What are
the top three areas for which a PDA guidance would enhance technology transfer?”,
approximately 40% of respondents included Knowledge Management as one of their
top 3 priorities as illustrated in Figure 2-14.

Figure 2-14 – PDA technology transfer survey (Haas, 2019)

In the opinion of the researcher, there are also underlying correlations with KM in many
other survey questions. For example, when asked “What do you see as your biggest
obstacles for technology transfers?”. The top two replies were Communication/
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Collaboration and Timeliness of Deliverables. While not specifically cited nor labelled as
a knowledge transfer challenge, it is highly likely that structured knowledge transfer
would dramatically address these obstacles. Notably, Risk Assessment Considerations
was the most frequent challenge area, identified as a challenge by nearly 70% of the
respondents. This suggests an indirect dependency on knowledge and knowledge
management. Risk and knowledge are interdependent, as will be explored in Chapter
5.
Of note, during the PDA conference, the discussion on KM in the Technology Transfer
Interest Group (IG) session focused heavily on a ‘master plan’ for KM which primarily
focused on documents and information with no references to tacit knowledge, ‘knowhow’, learning from failures, experience, or any other non-explicit knowledge
management inferences. These master plans are useful in that they highlight key
activities which generate knowledge, but they do not expressly identify tacit knowledge
nor assess the effectiveness of knowledge transfer.
There was also a link established at the PDA conference between KM and ‘soft skills’ as
shown in Figure 2-15. Some of these could perhaps be extended to traditional KM
practices (like a community of practice to communicate broadly). However, it is the
opinion of the researcher that in the main, these items tagged as KM ‘soft skills’ as
proposed by PDA are indeed important but are generally not KM-related skills. The
researcher sees this as a risk of possible confusion on the intent behind KM, especially
if this is carried through to the revision of Technical Report 65, Technology Transfer
ongoing in 2021.
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Figure 2-15 – Knowledge management and ‘soft skills’ (Haas, 2019)

In addition, PDA has published an insightful book on technology transfer, aptly titled
Technology and Knowledge Transfer:

Keys to Successful Implementation and

Management (Gibson and Schmitt, 2014). Aside from providing an excellent history and
outline of technology transfer, it begins to describe knowledge transfer elements.
Although many of the KM-related elements are somewhat information technology
centric (i.e., IT system), there are supportive concepts for KM (including that of tacit
knowledge) with multiple references to knowledge transfer, knowledge management,
‘know-how’ and how culture can support knowledge transfer. Although also a PDA
publication, it is not evident to the researcher whether this resource and associated
concepts within are being pulled into the revision of the PDA Technical Report on
technology transfer as it remains to be seen what emerges in the final document.

2.3.3 Exploring the foundations of Technology Transfer and Knowledge Transfer
A literature review was conducted to explore the current state of knowledge transfer
during technology transfer, in general and in the pharmaceutical industry, including
associated challenges, principles, and models or frameworks.
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2.3.3.1 Technology transfer
It was not so long ago in 2003 when Kremic (Kremic, 2003) asserted technology transfer
does not have a universal meaning but rather has broad connotations and is very
contextual. Shortly after in 2004 Reisman (Reisman, 2005) stated ‘technology transfer
is an emerging field of knowledge in which institutional interest is rapidly expanding.’
Cases are noted in use by firms for competitive advantage, governments towards
economic progress and social development, universities for commercialisation and
licensing of research outputs (Audretsch, Lehmann and Wright, 2014; de Wit-de Vries
et al., 2019) and for government research institutions to give access to new technologies
to taxpayers (Schacht, 2012). Reisman continued:
As is often the case in an emerging area or discipline, its descriptive as well as
normative theories and data available are fragmented and disjointed. There is
no general theory, model or structure for the field17…the very definition of
technology transfer differs across the many disciplines addressing technology
transfer, and the scope of transfer has rarely been delineated or systematically
analysed. Currently, transfer can be understood only in a limited way from a
strict disciplinary framework and/or a specific aspect.
Well over a decade has passed and there is little evidence to this changing significantly.
Dubickis and Gaile-Sarkane (Dubickis and Gaile-Sarkane, 2017) assert that the concept
of technology transfer is not easy to define, citing a study from Sazali and Raduan in
2011 which identified nearly 30 different viewpoints on technology transfer (Wahab,
Rose and Suzana, 2012). Ismail et al in 2016 (Ismail, Hamzah and Bebenroth, 2018)
defined technology transfer as ‘the process of transferring or disseminating technology
from its origin to a wider distribution, to more people and places.’
Specific to the pharmaceutical industry, the definition of technology transfer also
appears – surprisingly given the highly regulated nature of the industry – not singularly
defined. The definition is stated differently across a variety of less formal channels

17

The researcher found this lack of maturity very surprising, having assumed that the practice of
technology transfer would have been more established and consistent. This was a key learning for the
researcher. Furthermore, Reisman’s quote noted here could perhaps similarly be applied to knowledge
management, perhaps just a few years behind technology transfer in its own maturity journey
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including conference presentations, articles by consultants and marketing materials.
The definitions of technology transfer identified from seemingly authoritative sources
are as follows:
•

•

•

WHO guidelines on transfer of technology in pharmaceutical manufacturing
(WHO Technical Report Series, No. 961, Annex 7) (WHO, 2011): ‘a logical
procedure that controls the transfer of any process together with its
documentation and professional expertise between development and
manufacturing or between manufacturing sites.’
Pharmaceutical Research and Manufactures of America’s (PhRMA) Quality
Technical Committee in 2003 defined technology transfer as: ‘The body of
knowledge available for a specific product and process, including critical-toquality product attributes and process parameters, process capability,
manufacturing and process control technologies, and quality systems
infrastructure.’ (cited by Millili (Millili, 2011))
ICH Q10 (ICH, 2008) states the goal of technology transfer rather than labelling
it a definition. This seems to be a commonly adopted working definition by the
industry: ‘The goal of technology transfer activities is to transfer product and
process knowledge between development and manufacturing, and within or
between manufacturing sites to achieve product realisation.’

This latter was used as the definition of technology transfer in a 2015 paper titled
Overview of Best Practices for Biopharmaceutical Technology Transfers (Abraham et al.,
2015), authored by a team across six biopharmaceutical companies. The authors
explain in their paper, technology transfer is a key foundational component in product
commercialisation and is more than just the transfer of documents; it relates to all
aspects of the transfer of knowledge and experience to the commercial manufacturing
unit to ensure consistent, safe, and high-quality product. They further assert that
understanding how to streamline and improve technology transfers is complicated by
companies using different terminology and ways of working regarding technology
transfer. The authors define key terminology associated with technology transfer and
propose a process overview with key activities and milestones, from which the
researcher has re-framed from a table to the process view show in Figure 2-16.
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Figure 2-16 – Key activities and milestones in biopharmaceutical technology transfer

2.3.3.2 Knowledge transfer
Kwan et al. (Kwan and Cheung, 2006) describe knowledge transfer as ‘the process
through which one unit (e.g., group, department, or division) is affected by the
experience of another.’ In addition, they note that knowledge transfer is treated by
most researchers as a black box. They propose that a process view that emphasises the
sequence of events would provide insights on the nature of the inner workings of
knowledge transfer. However, few researchers have explicitly suggested a process
model for the knowledge transfer, and of the conceptual models and frameworks
found, they observed them to be diverse and based on theories from various disciplines.
Kwan et al. subsequently proposed a knowledge transfer management system (KTMS)
to support needs across the different stages of their proposed knowledge transfer
process model (Motivation, Matching, Implementation, Retention) in which appropriate
knowledge management tools were applied at each stage of the process.
Liyanage et al. (Liyanage et al., 2009) describe knowledge transfer as ‘the conveyance
of knowledge from one place, person or ownership to another.’ Successful knowledge
transfer means that transfer results in the receiving unit accumulating or assimilating
new knowledge. A thorough review of literature reveals that many authors and
researchers have failed to provide a clear-cut definition for knowledge transfer, and at
times, it has been discussed together with the term ‘‘knowledge sharing.’’
Dixon (Dixon, 2017) suggests ‘a general call to encourage more knowledge sharing or
transfer is not very effective because there are many ways to transfer knowledge.’
Dixon proceeds to propose a knowledge transfer framework based on two questions,
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(i) ‘What is the transfer problem you are trying to solve?’ and (ii) ‘What type of
knowledge do you want to transfer?’ From these inputs, Dixon proposes how the
knowledge can be harvested or captured, and how the knowledge can then be
transferred.
Ward et al. (Ward, House and Hamer, 2009) conducted a study of existing models and
frameworks for knowledge transfer and inventoried 28 generalised frameworks in the
literature and identified five common components. This led the authors to the proposal
of a conceptual framework embodying those five common components as:
i.
ii.
iii.
iv.
v.

the problem
the knowledge
the context barriers or supports
the interventions
the utilisation

The model developed by Liyanage et al. is presented as a figure (Liyanage et al., 2009)
and is reproduced here in Figure 2-17. This model highlights the need to address a
number of questions prior to the implementation of a transfer mechanism:
•
•
•
•
•
•
•

•
•

Who needs the knowledge (receiver)?
What units (in the supply chain) are involved in the knowledge transfer process?
What is the most appropriate ‘‘source’’ to acquire the required knowledge
(awareness)?
What is/are the type(s) of knowledge to be transferred?
How should it be transferred (modes of knowledge transfer)?
What are the factors that will influence on the process of knowledge transfer
and what is their level of impact?
What can we do to enhance the factors that positively influence on the process
of knowledge transfer and what can we do to avoid/lessen the impact of the
factors that negatively influence on the process of knowledge transfer?
What mechanisms should be used by the receiver to ultimately utilise the
knowledge?
Did the knowledge transfer process successfully achieve its goals (performance
measurement)?
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Figure 2-17 – Knowledge transfer process model (reproduced) (Liyanage et al., 2009)

Liyanage et al. (Liyanage et al., 2009) assert that knowledge leads to organisational
value when it is used to effectively make decisions, solve problems, and produce
effective performance. Thus, successful application of knowledge during a knowledge
transfer process usually results in one or more of the following:
•
•
•
•
•
•

reduced errors (e.g., by not repeating mistakes)
improved quality (e.g., by using best of breed practices)
speeding up decision making (e.g., by getting better cross-functional
coordination)
lower costs (by quickly identifying expertise) or provide value for money
speeding up training (e.g., by attending to common mistakes and learning from
best practices)
learning and innovation

Specific to tacit knowledge considerations, Foos et al. (Foos, Schum and Rothenberg,
2006) explored the factors which influence the transfer of tacit knowledge between
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partners based on a qualitative and quantitative analysis, including a study of three
companies charged with integrating external technology. They found that trust, early
involvement, and due diligence influence the extent of meeting technology transfer
expectations and tacit knowledge transfer expectations. They also assert that the
subject of tacit knowledge transfer, content, and process is poorly understood and
lacking formal process. To explore this idea further they carried out a survey on
knowledge transfer. About two-thirds of their survey respondents indicated they were
attempting to integrate tacit knowledge, while 92% reported no formal process for
tacit knowledge transfer. Foos et al. (Foos, Schum and Rothenberg, 2006) also
suggested there is clear evidence that intentional management mechanisms for tacit
knowledge management are needed, and that they will differ from those for more
explicit types of knowledge. Finally, while managers and project leaders saw the value
of tacit knowledge, there were different perceptions of the goals of successful
knowledge transfer and a lack of processes to manage its process. They noted project
managers may feel they have tacit knowledge transfer in hand, but they have not
managed to transfer the knowledge needed for long-term product management.
Malik (Malik, 2002) highlights ‘know-how’ must be learned and acquired. The difficulties
associated with embedded ‘know-how’ transfer they identified include:
•
•
•
•

Knowledge on how to use a technology
What the technology is capable of
The tacit components of knowledge embedded in the technology
Difficulties in interpreting technological codified knowledge

Kumar and Ganesh (Kumar and Ganesh, 2009) state knowledge transfer is not a
complete replication of knowledge in a new location; rather, it involves the modification
of some existing knowledge to a different context, ‘what is transferred is (usually) not
the underlying knowledge but rather applications of this knowledge in the form of
solutions to specific problems.’

This insight further highlights the need for

interpretation and context to be shared (tacit knowledge).
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The process of knowledge transfer is not, per se, a mere transfer of knowledge, (Seaton,
2002) as cited by Liyanage et al. (Liyanage et al., 2009), it requires an additional type of
knowledge: the knowledge about how to transfer knowledge. As an example, instead
of saying ‘this is what I know,’ the process of knowledge transfer goes one step further
to say, ‘this is what my knowledge means for you.’ Thus, contextualisation is important
for knowledge transfer to be effective.
Rathore et al. (Rathore et al., 2017) conducted a study specific to the biopharmaceutical
industry, looking at the role of knowledge management in development and lifecycle
management with a specific focus on knowledge management tools to support Quality
by Design (QbD) related tasks. Their paper acknowledges the shift towards extraction
of ‘know-how’ and tacit knowledge as opposed to classic explicit ‘data capture’
approaches which represent a new direction for the field [of knowledge management],
however the authors did not address this further in their paper.

They also

acknowledged that knowledge from transfer activities is not sufficiently covered by
knowledge management current tools, for which they provide a functional
classification.

2.3.3.3 Knowledge transfer and technology transfer
Galbraith (Galbraith, 1990) studied 32 ‘core manufacturing technology transfers’,
including pharmaceutical technology transfers, examining success of the transfers and
other factors such as sources of cost and lost productivity. Galbraith noted that studies
of manufacturing technology transfer underline two important facts: (i) any type of
technology transfer involves not only the movement of equipment and people, but also
the flow of critical information or ‘know-how’ between donor and recipient
organisations; and (ii), there are significant direct costs attached to the transfer and
management of this knowledge. The direct costs associated with transfers are twofold:
resource costs to perform the transfer; and productivity and ‘know-how’ loss. On
studying the 32 transfers, Galbraith reported the initial percentage productivity loss
experienced by the recipient facilities ranged between a low of 4% to a high of 150%,
averaging a 34% initial productivity loss. The time it took to recover lost productivity
ranged between 1 month to 13 months, however 10 of the transfers never reached pre57

transfer productivity levels or were considered failures for other reasons (31% failure
rate). Galbraith (Galbraith, 1990) associated a set of risks for technology transfer
success, including misplaced documents, distance between facilities, the recipient’s
previous experience with incoming transfers, and transferring complex process in early
stages of development.
Malik (Malik, 2002) asserted that a number of knowledge transfer models for
technology transfer have not recognised fully that intra-firm transfers are two-way
iterative processes and not simply one-way linear processes. Malik then proposed an
interactive model highlighting factors influencing the technology transfer process (e.g.,
culture of trust), the mode of transfer and a feedback loop. Liyanage et al. (Liyanage et
al., 2009) have reinforced the need for a feedback loop and incorporated it into their
proposed model (Figure 2-17).
Gorman (Gorman, 2002) in his paper Types of Knowledge and Their Roles in Technology
Transfer presents a taxonomy of knowledge with respective roles in technology
transfer, distinguishing between four types to refine the distinction between tacit and
explicit knowledge. The four types are:
•
•
•
•

Information (what)
Skills (how)
Judgment (when)
Wisdom (why)

Table 2-2 created by the researcher as a summary of the article text provides an
overview of each, along with the related types of each explicit and tacit knowledge.
Table 2-2 – Types of knowledge and their role in technology transfer (Gorman, 2002)

Type of
Knowledge

Description

Explicit

Tacit

Information
(what)

Declarative, knowing that

Information,
facts

Contextualisation
of facts, knowing
when and where
valid
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Type of
Knowledge

Description

Explicit

Tacit

Skills (how)

Procedural, knowing how

Algorithms

Judgment
(when)

•

Rules

Heuristics,
rules of thumb
Mental models,
case-based
experience

•

‘Why’
(wisdom)

•
•
•
•
•

Recognising a problem is similar to one
whose solution path is known, knowing
when to apply a particular procedure
Accumulated facts structured in ways
that facilitate problem solving
Ability to recognise cues
‘Feel’ for what will or won’t work
Result of accumulated implicit learning
The ability to reflect on status quo,
question prevailing mental models and
evolve
Requires moral imagination (i.e., to
step outside one’s self-view,
assumptions and bias and be able to
creatively envision new possibilities)

Codes
(e.g., code of
conduct)

Moral
imagination

Barros et al. (Barros et al., 2020) conducted a comprehensive literature review of the
interaction between knowledge management and technology transfer published in
2020 in an attempt to better define the context of the relationship between the
concepts. They found that most studies where knowledge management and technology
transfer co-occur focused on the private sector and on technology transfer for attaining
innovation, customer orientation and acquiring technological abilities. The universityindustry relationship was also observed, in which universities create and transfer
knowledge to support industry goals. There were many references to the need and
importance of knowledge transfer although no information on knowledge transfer
frameworks and no specifics to the pharmaceutical industry were given.

2.3.4 Summary – technology transfer and knowledge transfer
Given the subject literature, the researcher drew several conclusions from the review.
•

•

There exists regulatory and industry guidance for how to do technology transfer
that include expectations for knowledge management, yet these guidances are
very general in nature, provide no direction on ‘how,’ and largely neglect tacit
knowledge.
Technology transfer itself is a relatively ‘young’ practice, lacking in clear
definition – including for the pharmaceutical industry – and is highly contextual.
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•

•

Knowledge transfer models identified are quite academic and theoretical;
importantly they raise underlying drivers such as motivations, capacity and
other factors but neglect to define a pragmatic and deployable framework, nor
provide any information on the ‘how.’
Tacit knowledge (‘know-how’) is recognised as critical for overall successful
knowledge and technology transfer, yet there appears to be a general lack of
processes for formal tacit knowledge transfer. People know it’s important but
don’t know how to do it.

Notably, although there were selected pharmaceutical industry references in
aggregated studies involving technology transfer and knowledge transfer cited above
(Galbraith, 1990; Barros et al., 2020), there was no evidence of a focus on knowledge
transfer frameworks (or models or processes) for pharmaceutical technology transfer,
aside from documentation turnover lists (WHO, 2011; PDA, 2014b; ISPE, 2018).
Given the highly knowledge-dependent definitions of pharmaceutical technology
transfer, the dependence on and transfer of both explicit knowledge (e.g., documents)
and tacit knowledge (e.g., expertise) is central to the intent and paramount to the
success of a pharmaceutical technology transfer. Bruce Davis, an industry subject
matter expert on technology transfer (e.g., as demonstrated by leading the
development of the current ISPE Good Practice Guide on Technology Transfer (ISPE,
2018)) presented a paper entitled an Introduction to Technology Transfers, Basics &
Principles at the ISPE 2019 Annual Meeting (Davis, 2019) which the researcher attended
in person. Davis’ presentation focused heavily on knowledge management and its
importance to technology transfer, citing ICH Q10 (ICH, 2008). Davis shared his
professional insights during his presentation, including:
Understanding the knowledge and really solid project management coming
together is what makes for a successful technology transfer … If you don’t have
product & process understanding you cannot do a successful technology transfer.
Lastly, as stated by Malik (Malik, 2002), ‘technology transfer represents one of the most
knowledge intensive and problematic relationships in a firm.’ Yet there is no evidence
the pharmaceutical industry has solved the knowledge transfer conundrum through a
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framework, guidance or other visible progress, even though the success of the industry
is highly dependent on it.

2.4 Domains of knowledge: knowns and unknowns
Where knowledge is involved, a majority of the literature discussed to this point is about
what is known, or what one might describe as known-knowns. The researcher has an
interest in broadening this lens to understand the opportunity to explore what is
unknown as part of a more holistic approach to transferring knowledge and managing
risk.
Drew in 1999 (Drew and Whitehill, 1999), in support of how knowledge management
supports strategy development, published a knowledge portfolio matrix along two
simple axes: knowledge content and knowledge awareness. The knowledge content
axis represents ‘do we know (or not)?’, while the knowledge awareness axis represents
‘are aware that we know it (or not)?’ (Figure 2-18).

Figure 2-18 – Knowledge portfolio (Drew and Whitehill, 1999)

The researcher finds this a helpful thought model to use to think more comprehensively
about knowledge management, inclusive of knowledge transfer, and risk management
across the entire product lifecycle as it consciously prompts a reflection on recognised
gaps in our knowledge (i.e., “we don’t know what will happen if …”).
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Others have followed similar thinking such as Browning (Browning and Ramasesh, 2015)
who proposed that many unknowns are knowable and through a set of processes called
directed recognition, risk could be reduced. Many of these processes, in the opinion of
the researcher, are in knowledge management or closely related processes and related
behavioural approaches. Marshall et al. (Marshall et al., 2019) also explored ‘four states
of risk forecasting knowledge,’ following the same four quadrant categories as Drew,
with a powerful model to decrease risk through increasing one’s risk radar.
The researcher synthesised these insights to create a representation (Figure 2-19) into
a four-quadrant grid of knowns and unknowns. The labels in each of the boxes in Figure
2-19 form a helpful thought model to simplify these concepts. For example – what are
the facts (known-knowns), what questions (known-unknowns) do we have, what do we
know will work but don’t know why (intuition, or unknown-knowns) and where might
we explore next (unknown-unknowns).

These can be helpful triggers to build into

knowledge management practices to uncover important knowledge – in particular tacit
knowledge – on which to make decisions and direct future efforts to acquire new
knowledge and in turn reduce risk. The researcher expects this thought model would
also be of significant benefit to the process of quality risk management.

Figure 2-19 – Knowns and Unknowns
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2.5 Literature review summary
This literature review has covered diverse territory – regulatory guidance, industry
guidance, academic research, risk and knowledge management concepts, technology
transfer literature, knowledge transfer literature, and the arguably abstract world of
‘unknown-unknowns.’ Key points relative to each section have been summarised at the
close of each section. In aggregate this literature review helps confirm the problem
pursued by this research study, along with its complexity, and also provides substrate
to refer back to during framework development to help test the outputs from this study.
The next chapter will present the research design, methodology, and methods applied
for this study, and share various perspectives of the researcher.

63

Chapter 3: Research Design, Methodology, and Methods
The purpose of this chapter is to outline the research design, methodology, and
methods.

This includes the researcher’s worldview and insider perspective, the

research questions and associated methodology and methods applied, the research
timeline and ethics and privacy considerations.

3.1 The researcher’s worldview
It is necessary for any researcher to be conscious of how they view the world, notice
and process stimuli, formulate positions, communicate such positions, and employ a
variety of other processes. Otherwise, the researcher would risk being blind to their
assumptions and biases.

There are entire fields of study for such philosophical

concepts, including definitions of ontologies and epistemologies. Ontology involves the
study of ‘being’ and is concerned with ‘what is,’ including the nature of existence and
structure of reality (Crotty, 1998). Epistemology involves a way of looking at the
relationship between the knower and the known (Guba and Lincoln, 1994) and how we
know what we know (Crotty, 1998).
This researcher’s ontological belief is that reality is what works and is what is most useful
and practical. The researcher’s epistemological belief is that reality is known through
using many tools of research that reflect both objective and subjective evidence
(Creswell and Poth, 2017).
A worldview is defined by Guba as ‘a basic set of beliefs that guide action’ (Guba, 1990).
Creswell uses the term worldview to describe four general philosophical orientations
about the world and the nature of research that a researcher brings to a study (Creswell
and Creswell, 2020). These are widely discussed in the literature and shown below in
Table 3-1.
Table 3-1 – Four worldviews (Creswell and Creswell, 2020)
Postpositivism
• Determination

Constructivism
• Understanding
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Postpositivism
• Reductionism
• Empirical observation and measurement
• Theory verification
Transformative
• Political
• Power and justice oriented
• Collaborative
• Change-oriented

Constructivism
• Multiple participant meanings
• Social and historical construction
• Theory generation
Pragmatism
• Consequences of actions
• Problem-centred
• Pluralistic
• Real-world practice oriented

The researcher most closely associates with the worldview of pragmatism, with a
problem-centred, real-world practice-oriented study. This worldview is reinforced
throughout this thesis, including the desire to deliver meaningful and useful outcomes
as a result of this research study. The researcher has a bias toward ‘fit-for-purpose’ and
practical approaches to understand and solve problems, based on the researcher’s
experience with lean six sigma18 and a variety of other management sciences19 as a
means to improve operational performance.
Furthermore, the research topic is positioned well in the worldview of pragmatism,
given the relative immaturity in awareness and practice of KM in the pharmaceutical
industry as explored in Chapter 2. A purely theoretical view of KM can likely be
conceptually modelled, perhaps even using fluid dynamics principles as carried out by
Smith (Smith, 2005). However, it is the researcher’s belief that if KM cannot be seen as
tangible, actionable, of value, and able to deliver benefits to patients and businesses
alike in the real world, the practice risks being seen as a ‘management fad and fashion.’
In fact, some have already attacked KM as being too utopian of an idea (Wilson, 2002).
Thus, the research study aimed to solve the problem of the lack of KM adoption in the
real work of pharmaceutical manufacturing, taking a pragmatic approach focusing not
on the research methods, but on the research problem and developing solutions to
address it.

18

A methodology for improving customer satisfaction and improving business processes through a
structured set of techniques and tools to reduce variability and improve performance of processes that
are value added and aligned with customer desires. (Six Sigma Daily, 2020)
19
The use of scientific methods and ideas to understand business and management problems and
decisions, or the formal study of management; Management science is concerned with designing and
developing new and better models of organisational excellence. (Cambridge, 2020)
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Pragmatism is concerned with applications, what works and solutions (Patton, 1990);
this is the primary objective of the researcher to move the industry forward by
understanding the current state (i.e., as is) and delivering solutions to educate and
demonstrate what is possible (i.e., what could be).
Mixed-methods research is particularly well-suited for a pragmatic worldview, as the
researcher can adapt the methods to the most appropriate means to characterise the
problem and the solution (Creswell and Creswell, 2020). Further detail on these
methods is presented in section 3.4 of this chapter.

3.2 The researcher’s insider perspective
As stated in Chapter 1 (section 1.3), the researcher is employed in pharmaceutical
industry and has been for 20+ years.

Prior to his career move to knowledge

management, the researcher started his career in pharmaceutical manufacturing, in a
site-based science and technology role, on the receiving end of technology transfers
supporting process demonstrations of small molecule APIs. In this role, the researcher
gained experience as a stakeholder of technology transfer. The researcher has also
spent nearly a decade in a global engineering role starting up new GMP manufacturing
facilities, being responsible for the specification, design, build, and validation of highly
complex shop floor automation systems. As such, the researcher was part of several
technology transfers, working to automate the manufacturing of the product and
processes being transferred, typically new product introductions from research and
development. During this time, the researcher also gained deep experience with
computer system validation, including the concepts of configuration management,
which included robust processes for tracking documents and other critical information
associated with the state of a GMP control system. Unbeknownst to the researcher at
the time, these practices were a form of knowledge management and perhaps a prelude
to the researcher’s knowledge management career.
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Given the researcher’s employment in the industry, experience with technology
transfer, and decade of experience in knowledge management, the researcher
acknowledges having an insider perspective and undertaking insider research. The term
‘insider research’ is used to describe research projects where the researcher has a direct
involvement or connection with the research setting (Robson, 1993), cited by (Rooney,
2005). The idea behind the ‘insider perspective’ is that it can be seen as having both
‘pros and cons’ (i.e., advantages and disadvantages) as categorised by Greene (Greene,
2014). A synopsis by the researcher of each category based on Greene’s description is
as follows:
•

Pros (advantages):
o Knowledge: Insider researchers often do not have to worry about
orienting themselves with the research environment and/or
participants; they can ask more meaningful questions and better
understand the history and practicality of the research topic.
o Interaction: Insider researchers are more familiar with the group under
study, know how to approach individuals, and are more likely to engage
in discussing issues.
o Access: Insider researchers will know how to gain access and may have
existing contacts within the group under study.

•

Cons (disadvantages):
o Too subjective: Insider researchers risk having narrow perceptions due
to familiarity and normalisation with the group under study, thus
impacting the ability of the researcher to be objective. In addition, there
is increased risk of assumptions based on prior knowledge and/or
experience.
o Biased: Insider researchers risk bias as the researcher may be considered
too close to the group under study. This bias may influence study
methodology, design, and/or results. Insider researchers must not fear
bias, but must be aware of the potential for bias and take steps to
mitigate it.

With this awareness, the researcher sought to fully capitalise on the advantages and
work to mitigate the risks inherent in the disadvantages. There are several advantages
for this research study based on the researcher’s knowledge, past interaction, and
access, including:
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•
•
•
•

Knowledge of past KM research
A network of practitioners in the sector, inclusive of industry, academia,
regulators, and several industry organisations (e.g., ISPE, PDA, et al.)
Experience with application of KM both within and beyond the pharmaceutical
industry
Familiarity on related topics, including risk management, technology transfer
and data analytics

Specific to the risks associated with the disadvantages (i.e., subjectivity and bias), the
researcher worked to mitigate these risks through:
•
•

•
•

Using a mixed methods approach (see section 3.4), where multiple sources of
both qualitative and quantitative data were considered where possible
Balance in these research methods, which included leveraging insights from
multiple cohorts of stakeholders (i.e., academia, regulatory and industry) during
diverse interactions such as philosophical dialogues, interviews, focus groups
and surveys
Awareness of the risk of ‘group think’ and as such, partnered on research
activities with people outside of the researcher’s normal ‘circle’
Publishing and presenting through a variety of channels and venues, including
articles subject to peer review by different editorial boards, to promote further
objectivity and limit bias

While a member of industry for many years now, the researcher also recognised the
value of stepping outside of the industry view and adopting an academic persona as a
part of this research study. This allowed the researcher to bring objectivity, enhancing
the connection and access to both academia and regulators through philosophical
dialogue, interviews, and other research interactions. By this means, this research study
helped bridge the triad of industry, regulatory, and academia perspectives in delivering
its results by balancing the theory, practice, and application of regulation.
Finally, although the researcher was employed by a major pharmaceutical company at
the time of this research study, this study was undertaken as a matter of personal
interest and passion for the research topic, independent of the researcher’s employer.
Therefore, the researcher’s perspectives, methods, and results were not influenced by
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their employer nor did they hold any commitment back to the employer as a sponsor of
this research.

3.3 The research questions
The original research proposal, titled An exploration of end-to-end product knowledge
in the pharmaceutical industry, was submitted to the Technological University Dublin
(then Dublin Institute of Technology)20 College of Sciences and Health, School of
Chemical and Pharmaceutical Sciences in September 2018 and accepted in October
2018. The research proposal presented at the time was based on the following two
hypotheses21:
1. KM adoption in the pharmaceutical industry (henceforth ‘industry’) has been slow
as described by Kane in 2018 (Kane, 2018). The first hypothesis of this study is that
the industry does not have a holistic, end to end view of what it knows about its
products across the product lifecycle, nor how to best ensure this knowledge
‘flows’ to ensure the best possible product outcomes. These outcomes include
product realisation through a readily available, cost effective and high-quality
product to patients, as well as additional business outcomes of operational
efficiency and a workforce that has the knowledge it needs to do its best work.
2. A second hypothesis is, as identified by Kane (Kane, 2018), tacit (e.g., experiential)
knowledge is an afterthought during product development and not recognised as
a critical knowledge asset. The industry lacks recognition of the importance of
tacit knowledge nor has it a means to best capture and access this knowledge
across the product lifecycle in particular key activities such as technology transfer.
Concepts and associated queries were derived from these hypotheses based on
preliminary observations from the research during literature review, initial engagement
of the public during early presentations about the research study, and from
philosophical dialogues with TU Dublin PRST members. Concepts 1 and 2 were nascent
at the start of the research, based on the recent research outputs of Kane (Kane, 2018),
as follows:
20

The researcher was a student at Dublin Institute of Technology, which merged with two other Irish
institutions to become Technological University Dublin in January 2019.
21
These hypotheses statements were adapted during the course of the study for improved clarity as
presented in Chapter 1, section 1.4.
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Concept 1: Knowledge and management thereof are critical to the realisation
of an effective PQS, and knowledge management has been positioned as an
enabler to the PQS, yet there is a lack of guidance for what knowledge should
be managed or how organisations might go about this.
Associated Queries:
• Are knowledge and knowledge management important to the PQS? Why?
• Is there guidance on knowledge management for the industry, including for
knowledge-intensive processes such as technology transfer?
• Is knowledge transfer effective during technology transfer?
Concept 2: The importance of tacit knowledge is under-recognised, and the
industry lacks the means to effectively recognise, manage and transfer tacit
knowledge, putting it at risk of being under-utilised or lost. Incomplete tacit
knowledge transfer can have long term impacts on product manufacturability.
Associated Queries:
• Is tacit knowledge important to the PQS?
• How does one ‘recognise, manage and transfer’ tacit knowledge?
• What are the benefits to improving tacit knowledge transfer?
During the course of this research study with the realisation of the lack of connectivity
between QRM and KM as described in Chapter 1, a third hypothesis emerged and
influenced the direction and focus of the research study. This hypothesis is as follows:
3. Quality risk management and knowledge management are not adequately
integrated to ensure the best possible risk-based decisions. Strengthening this
relationship between QRM and KM has the opportunity to improve patientfocused outcomes across the product lifecycle through reduced risk to product
quality and availability.
Concepts and associated queries derived from the third hypothesis are as follows:
Concept 3: Knowledge and risk are inherently inter-related, yet this relationship
is not well recognised. As such, the industry has not maximised the opportunity
to apply thoughtful knowledge management to ensure the best possible riskbased decisions from quality risk management, nor for quality risk management,
to inform knowledge management.
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Associated Queries:
• What is the relationship between knowledge and risk?
• What is the relationship between knowledge management and risk
management?
• What is the benefit to patients of better understanding and exploiting the
relationship between knowledge management and quality risk
management?
Two distinct research questions evolved from the three hypotheses during the course
of the research, given as follows:
1. Research question 1 (RQ1): How can the interdependency between knowledge
management and quality risk management be clearly described in a manner that
links the two PQS co-enablers to deliver the best possible risk-based decisions?
2. Research question 2 (RQ2): How can technology transfer benefit from a robust
and standardised approach to knowledge management to ensure the effective
transfer of both explicit and tacit knowledge, leading to improved realisation of
the goals of the PQS?

3.4 Research study design, methodology, and methods
The researcher, based on his ontological and epistemological stances and resulting
worldview, selected a mixed methods approach for this study. Specifically, a mixed
methods experimental (intervention) design was selected for both research questions,
given the desire to develop pragmatic solutions that could be immediately evaluated
through an actual or simulated intervention (e.g., application of a framework). The
concept of a mixed methods experimental (intervention) design as illustrated by
Creswell is depicted in Figure 3-1 (Creswell and Creswell, 2020).
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Figure 3-1 – Mixed methods experimental (intervention) design as illustrated by Creswell
(Creswell and Creswell, 2020)

From Figure 3-1, it can be seen that experimental intervention can include exploratory,
sequential, convergent, and explanatory sequential designs.
The design for this research followed a similar concept to Figure 3-1 and utilised both
qualitative and quantitative methods with exploratory sequential, convergent, and
explanatory sequential core designs in series [(QUAL à Quan) + QUAL + (QUAN à
Qual)]22. This design was selected to establish a baseline understanding prior to the
intervention (i.e., exploratory), assess the effectiveness of the intervention (to inform
refinement of the intervention), and follow the intervention with an explanatory phase.
Figure 3-2, developed by the researcher, illustrates the methodology with supporting
rationale and research methods (RM-1a through RM-1e) for research question 1 (RQ1).

22

Notations used to designate mixed methods research design; capitalisation indicates emphasis over
lowercase, “+” indicates convergent design,”à” indicates sequential design, “[…]” indicates a series
(Creswell and Creswell, 2020)
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Mixed methods experimental (intervention) design for RQ1
[(QUAL à Quan) + QUAL + (QUAN à Qual)]

Qualitative
Before
(RM-1a)
Quantitative
Before
(RM-1b)
Exploratory Sequential
RQ = Research Question
RM = Research Method(s)

Experimental Intervention
(e.g., test framework)

Qualitative
During
(RM-1c)

Quantitative
After
(RM-1d)
Qualitative
After
(RM-1e)
Explanatory Sequential

Convergent

Rationale:
• To document the need for an
intervention
• To compile baseline information

Rationale:
• To understand how the
participants are experiencing the
intervention

Rationale:
• To receive participant feedback
to revise / change the
intervention
• To help explain how the
mechanisms may have worked

RM-1a (Qualitative):
• Literature review
• Focus Group
• Philosophical dialogues

RM-1c (Qualitative):
• Philosophical dialogues

RM-1d (Quantitative):
• Structured survey
RM-1e (Qualitative):
• Case studies
• Focus Group
• Philosophical dialogues

RM-1b (Quantitative):
• Structured survey

Figure 3-2 – Research Methodology and Methods for Research Question 1

For research question 2 (RQ2), the same overall methodology was used (i.e., mixed
methods experimental (intervention) design), with minor variations to the research
methods applied (RM-2a through RM-2e) as appropriate for RQ2. This is illustrated in
Figure 3-3.
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Mixed methods experimental (intervention) design for RQ2
[(QUAL à Quan) + QUAL + (QUAN à Qual)]

Qualitative
Before
(RM-2a)
Quantitative
Before
(RM-2b)
Exploratory Sequential
RQ = Research Question
RM = Research Method(s)

Experimental Intervention
(e.g., test framework)

Qualitative
During
(RM-2c)

Quantitative
After
(RM-2d)
Qualitative
After
(RM-2e)
Explanatory Sequential

Convergent Core

Rationale:
• To document the need for an
intervention
• To compile baseline information

Rationale:
• To understand how the
participants are experiencing the
intervention

Rationale:
• To receive participant feedback
to revise / change the
intervention
• To help explain how the
mechanisms may have worked

RM-2a (Qualitative):
• Literature review
• Semi-structured interviews
• Philosophical dialogues

RM-2c (Qualitative):
• Semi-structured interviews
• Focus Group
• Philosophical dialogues

RM-2d (Quantitative):
• Case studies (impact measures)

RM-2b (Quantitative):
• Structured survey

RM-2e (Qualitative):
• Case studies
• Focus Group
• Philosophical dialogues

Figure 3-3 – Research Methodology and Methods for Research Question 2

Once the initial research methodology was identified, the researcher applied for ethics
approval from the TU Dublin Research Ethics & Integrity Committee, as is discussed in
the next section.

3.5 Ethics and privacy
The initial research plan was submitted to Technological University Dublin (at the time
Dublin Institute of Technology) on 21-Nov-2018 and received approval from the
Research Ethics & Integrity Committee on 28-Jan-2019. All research activities were
conducted in accordance with TU Dublin’s Ethical Guidelines (TU Dublin, no date).
Specifically, the researcher:
•

•

Sought formal consent from interview participants prior to any research activity
being undertaken.
Formalised consent forms were provided to the
interviewees, along with information packets in advance of interviews. The
interviews did not proceed without consent granted.
Handled and stored personal information in a strictly confidential manner, in a
secure and password protected location, using TU Dublin IT systems.
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•
•

Used data gained during this research study solely for the purpose of this
research study.
Did not (and will not) have any power over any of the involved research subjects,
each of whom agreed voluntarily to participate.

The researcher also undertook formal Research Integrity Training sponsored by TU
Dublin and received competency-based certificates for the domains of Engineering and
Technology and Social and Behavioural Sciences. These modules train researchers on
their professional responsibilities and on how to deal with complex issues that can arise
while planning, conducting, and reporting research.
Part Two of this thesis follows (including Chapters 4 through 7) and presents many of
the research activities and corresponding outputs, including a process model for KM, a
framework to integrate knowledge and risk, and a framework to enhance knowledge
transfer during technology transfer.
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Part Two: Advancing KM and Developing QRM-KM Connectivity
Part Two explores the relationship between knowledge and risk and the opportunity to
better integrate knowledge management and quality risk management. In response to
findings of this exploration, potential solutions are provided through a newly proposed
model and multiple frameworks.
•

Definition of a Process Model for Knowledge Management (Chapter 4)

•

Re-imagining the QRM-KM interdependency with a novel framework to connect
QRM and KM (Chapter 5)

•

A definition of requirements to improve knowledge transfer during technology
transfer (Chapter 6) and associated framework and toolkit to enhance
knowledge transfer effectiveness (Chapter 7)
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Chapter 4: A Process Model for Knowledge Management
Anticipating the opportunity for KM to be better integrated with QRM, the purpose of
this chapter is to propose a Knowledge Management Process Model as a means to
advance the understanding of the ‘how’ behind high level KM concepts.
Not only is the integration between QRM and KM severely lacking in practice today
(Lipa, O’Donnell and Greene, 2021) but also the level of adoption and maturity of KM in
the pharmaceutical industry is far behind that of QRM as presented in Chapter 1. While
many factors highlighted in Chapter 1 are well out of the control of the researcher (e.g.,
the existing body of literature for QRM vs. KM), there was one concept identified where
the researcher could work to influence immediately: The understanding of what
knowledge management is. The following section describing a process model for
knowledge management is a summary of a peer-reviewed paper by the researcher
published in the Journal of Validation Technology (Lipa, O’Donnell and Greene, 2020a).

4.1 Introducing a Knowledge Management Process Model
The practice of KM presents a diverse and adaptive set of practices to enhance
knowledge flow and application. A well-designed, holistic, and systematic KM program
will strengthen QRM through the availability of critical knowledge, including product
knowledge, process knowledge, platform knowledge, and other relevant knowledge.
Such a KM program can support the curation, sharing, and dissemination of knowledge
which can subsequently be transferred and applied to inform decisions and achieve
other objectives.
Typically, this knowledge resides in documents housed in repositories or can be found
within communities, lessons learned, best practices, experiences, and expertise. This
can also include knowledge from other products, other sites, or other modalities, as well
as knowledge from past changes, from prior risk assessments, and a wide variety of
other sources.
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The researcher had long recognised that it was challenging to concisely explain the
‘how’ behind KM, often using the analogy that ‘knowledge management is about getting
knowledge to flow.’ But what is the ‘double-click’ on this flow concept? Upon reflection
of this question – on how best to explain KM and how to do so in a manner familiar to
the pharmaceutical sector – the researcher decided to attempt to do so by using the
quality risk management process diagram as the basis.
The ICH Q9 QRM process model (ICH, 2005) is depicted in Figure 4-1 and provides an
informative visualisation of the process of risk management. Included in the process
model is a depiction of the key steps and sub-steps within a risk management process,
the sequence of steps including relationships between steps and feedback loops, and
supportive or enabling elements to the core process (e.g., Risk Management tools).

Figure 4-1 – ICH Q9 QRM process model (ICH, 2005)

Starting with the ICH Q9 QRM process model as a framework and then applying
common definitions of KM included in Chapter 2 (section 2.1), drawing upon multiple
philosophical dialogs with thought leaders in QRM and KM, and over 10 years of
professional experience, the researcher through multiple iterations created a
Knowledge Management Process Model as depicted in Figure 4-2.
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Figure 4-2 – Knowledge Management Process Model

This new Knowledge Management Process Model features traceability to the definition
of KM in ICH Q10 (i.e., ‘systematic approach to acquiring, analysing, storing, and
disseminating information…’) (ICH, 2008). Each of these activities defined in ICH Q10
are represented in the model. In the opinion of the researcher, this process model
further significantly enhances the ICH Q10 definition through additional context, details,
and mapping of interactions within the model. Similar to the QRM process model, this
model includes a depiction of the key steps and sub-steps within a KM process, the
sequence of steps including relationships between steps and feedback loops, and
supportive or enabling elements to the core process (e.g., Knowledge Management
Practices).
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The following are highlights of the model:
1. Knowledge is acquired (created) through a variety of important processes and
activities. This knowledge must flow into the knowledge management construct
to be ‘managed’ (i.e., to be systematically curated, shared, and disseminated for
future use).
2. The overall process of knowledge management is divided into two main
activities. A phase for knowledge curation, where knowledge is intentionally
captured and subsequently identified, reviewed, and analysed as appropriate.
Curation23 is defined as ‘the action or process of selecting, organising, and
looking after the items in a collection’.

This activity involves proactively

stewarding and caring for the knowledge assets of the organisation to ensure
they are available and suitable for use when needed. The second phase is
knowledge dissemination, where the importance of not only knowledge storage
but also visibility and availability (inclusive of accessibility) are highlighted. Of
note, knowledge dissemination may be on a ‘pull’ and/or a ‘push’ basis, meaning
it can be ‘pulled’ on demand by a process (e.g., obtain specifications for
technology transfer) or it can be ‘pushed’ to those that need to know (e.g.,
sharing a lesson via a community or by building into a business process).
3. The ‘how’ for these two major activities is accomplished through KM practices24.
Practices should be employed for both explicit knowledge (e.g., content
management, taxonomies, search) and tacit knowledge (e.g., communities of
practice, expertise location, lessons learned). These KM practices are best
supported by a series of enablers (e.g., standardised processes, sponsorship, and
training) (Kane and Lipa, 2018).
4. Knowledge communication, exchange, and sharing represents the sharing of
knowledge and learning based on the mindsets and behaviours of an effective
knowledge culture (Kane and Lipa, 2018), where people can ask questions, learn

23

https://www.lexico.com/en/definition/curation
KM practices, also referred to as KM approaches, capabilities, methods and tools, are the standard
and repeatable means by which knowledge is managed. These are akin to the QRM practices, such as
the “Risk Management Methods and Tools” found in Annex 1 of ICH Q9 (ICH, 2005)

24
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from each other, and make connections to learn and grow their individual
knowledge and collectively that of the organisation.
5. Knowledge is applied to a variety of important processes and activities.
Knowledge is an indispensable asset which powers a variety of critical processes
and enables the best possible DECISION (or other desired process outcome) for
QRM and many other processes.
6. A feedback loop is included for the growth and evolution of knowledge which
provides an input to future processes and also grows the knowledge base of the
organisation.
To illustrate the similarity to the ICH Q9 QRM process model (ICH, 2005), Figure 4-3
provides a side-by-side comparison of the two process models.
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Figure 4-3 – KM Process Model as an analogue to QRM process model

This new process model was reviewed as part of the industry SME author team
developing the ISPE Good Practice Guide for Knowledge Management (ISPE, 2021b), of
which the researcher is a member. The industry SME author team ratified use of this
Knowledge Management Process Model as a central element to the ISPE Guide,
featured as its own chapter in the guide. The researcher made a further original
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contribution to the ISPE Good Practice Guide for Knowledge Management by providing
a detailed discussion on each activity in the model. This is presented as Chapter 4 in the
ISPE Guide (of which the researcher was the lead author).
One can envision the benefit to improved understanding and decreased uncertainty by
‘unlocking’ the knowledge of the organisation in the manner described in the
Knowledge Management Process Model, as well as to many other benefits of knowledge
access and availability for resolving investigations, post-approval changes, and more. It
is the discipline of KM that makes this a reality. Having aligned KM and QRM as dual
enablers, the researcher was curious to further explore their interrelationship. Chapter
5 of this thesis describes this work.
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Chapter 5: Re-Imagining the QRM–KM Interdependency
The purpose of this chapter is to investigate the current state of integration between
QRM and KM as dual PQS enablers and to introduce a framework to convey a vision for
improved integration and the benefits which could arise as a result of this integration.
This chapter first builds on a detailed literature review conducted by the researcher
(Lipa, O’Donnell and Greene, 2020c) and published in a peer-reviewed journal, the
Journal of Validation Technology. Subsequently, the development of the framework to
connect risk and knowledge is described in detail in a peer-reviewed paper by the
researcher (Lipa, O’Donnell and Greene, 2020a). The following sections of this thesis
represent key insights from these papers.

5.1 A look at the connectivity between QRM and KM
Arguably, the most familiar representation of the QRM and KM relationship originates
from the ICH Q10 PQS model (ICH, 2008) where the two enablers are positioned
adjacent to each other, but notably not connected (Figure 5-1).

Figure 5-1 – KM and QRM as adjacent yet disconnected enablers of the PQS

Key insights gained during the course of this research from literature review and other
inputs on risk, risk management, knowledge, and knowledge management, include:
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•

•

•
•

•
•

Risk varies inversely with knowledge, or more accurately risk varies inversely
with knowledge application, suggesting that knowledge has to be available and
actively used in the reduction of risk; given the overarching goal of risk
management is to minimise risk, this relationship suggests one should maximise
knowledge and its application to inform risk
Knowledge is both an input and an output to the risk management process which
in turn informs risk; essentially, knowledge weaves in and out of the various
activities within the risk management process
Knowledge management is about knowledge flow and ultimately knowledge
application
Quality risk management can enable the best outcomes and further reduce risk
to patients by leveraging the best available knowledge about products,
processes, and platforms, including prior knowledge
Quality risk management is a discrete event in applying knowledge to inform
decisions (i.e., the basis of risk-based decision making)
The goal of KM is to deliver the best available knowledge to the right person, at
the right time in order to make the right decision and/or give the right advice

It would then seem logical that QRM and KM should be thoughtfully connected in some
manner to ensure the best knowledge is available and applied to ensure the best
possible risk-based decisions are made in support of an effective PQS. In a manner of
speaking, knowledge is the currency of managing risk.
There is broad agreement on the concept that QRM and KM should be linked in some
way as confirmed through a survey by the researcher issued to industry and regulators.
The full details of this survey are published in Level3 (Lipa, O’Donnell and Greene, 2021),
and will be discussed in detail when considering the holistic impact of this research
study in Chapter 10. But for now, focusing on the question which solicited their opinion
of how interdependent QRM and KM are as theoretical concepts, 97% of respondents
indicated QRM and KM are highly interdependent (Figure 5-2).
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Figure 5-2 – How Interdependent are QRM and KM as theoretical concepts? (Lipa, O’Donnell
and Greene, 2021)

However, when asked about how integrated QRM and KM are in practice today, the
answer was very different. Eighty-four percent (84%) indicated QRM and KM are only
partially integrated in practice and 13% indicated QRM and KM are not integrated at all.
Only one respondent (3%) indicated QRM and KM were intentionally integrated (Figure
5-3).
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Figure 5-3 – Across the industry and in general terms, how integrated do you think QRM and
KM are in practice today? (Lipa, O’Donnell and Greene, 2021)

The reasons for this may not be surprising given the lagging nature of KM adoption in
the industry (Chapter 1), suggesting that KM is not adequately understood and/or
sufficiently defined and mature.
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Furthermore, in the opinion of the researcher, there is a fundamental gap in
understanding of the opportunity (and expectation) to exploit the synergy between
these two critical disciplines. The discipline of QRM – with good intent – has been
focused on how to “do QRM,” and the discipline of KM has similarly been focused on
how to “do KM.” Yet there is little evidence QRM has fully engaged with KM (e.g.,
through the definition of QRM requirements of KM), nor has KM fully embedded itself
in QRM as a practice. However, should not the pursuit of the best possible risk-based
decisions (and the associated risk reduction to patients) be a sufficiently important
reason to address this gap?

5.2 Development of the Risk-Knowledge Infinity Cycle
In response to this important opportunity, the researcher sought to address this gap
through better defining the QRM-KM relationship. The researcher believed there is an
opportunity for broad impact across many stakeholder groups with an increased
appreciation of such a synergistic relationship, including QMS practitioners, KM
practitioners, the leadership, and other stakeholders in a firm’s PQS, regulators, and
ultimately patients.
Building off of the rudimentary cyclical concept depicted in Figure 1-3, in partnership
with a thought leader on QRM25 and after several philosophical dialogues and iterations,
the researcher worked to develop a new and novel framework to connect QRM and KM.
The researcher desired to convey certain attributes – including connectivity, balance,
flow, and duality. The researcher also wanted to convey the continuous, ongoing
learning that should happen across a product lifecycle, during which knowledge is
routinely growing (even if it is a reaffirmation of what is already known). Finally, the
researcher sought to ensure the framework featured a ‘closed-loop’ process26 to
reinforce that risk and knowledge are inextricably linked. In response to these inputs,

25

The researcher solicited input from Dr. Kevin O’Donnell who is a recognised thought leader on QRM
and is the rapporteur of the current team to revise ICH Q9.
26
“the complete path followed by a signal as it is fed back from the output of a system to the input and
then back to the output” (dictionary.com)
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the researcher proposed a new framework, the Risk-Knowledge Infinity Cycle (or RKI
Cycle), as presented in Figure 5-4.

Figure 5-4 – The Risk-Knowledge Infinity Cycle

This framework is intended to enable the visualisation and understanding of the RiskKnowledge relationship in a new and practical way, supported with descriptive details
and an example provided in the referenced peer-reviewed paper (Lipa, O’Donnell and
Greene, 2020a). In summary, key features of this framework include:
(i)

the interwoven relationship between knowledge and risk, where knowledge
feeds in to inform risk and risk informs what is known, including the need to
acquire new knowledge: knowledge and risk inform each other.

(ii)

the inverse relationship previously established, where increased knowledge
leads to decreased risk. Figure 5-5 below provides a visualisation of this
concept over time for a product. In the early stages of a product’s lifecycle,
risk is high since knowledge is low. Risk can be immediately reduced through
the application of prior knowledge, and risk is further reduced through
increasing and applying knowledge by other means, including development
activities, manufacturing experience, and risk review. A well-characterised
product for which there is an abundance of knowledge will result in lower
risk.
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Figure 5-5 – Decreasing risk though increasing applied knowledge over time

(iii)

the concept of flow: that knowledge should effortlessly flow to inform risk,
and likewise, risk seamlessly informs knowledge.

(iv)

the cycle is continuous and perpetual, as suggested by the use of the infinity
symbol and the word infinity appearing in the framework title. Knowledge
is always evolving and should be applied to inform risk (even if it reaffirms
what is already known to grow confidence in risk controls), and one will
always learn about new risks and the performance of risk controls, thus
generating both new knowledge and the need for new knowledge.

Turning attention to an example of RKI Cycle application focused on the PQS as defined
by ICH Q10 (ICH, 2008) can help illustrate the relationship between quality risk
management and knowledge management as illustrated in Figure 5-6.
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Figure 5-6 – The Risk-Knowledge Infinity Cycle applied to ICH Q10

As illustrated in Figure 5-6, QRM and KM are interdependent and in unison enabling the
PQS. The two ICH Q10 co-enablers are not distinct but are in fact interwoven:
knowledge informing quality risk, quality risk creating knowledge, knowledge informing
quality risk…. This is consistent with research by Lengyel (Lengyel, 2019) who asserts
‘risk management and knowledge management have been shown to exhibit a reciprocal
relationship. Risk management identifies knowledge gaps and knowledge management
is a means of identifying resources to fill those gaps.’ Observations in applying the RKI
Cycle framework to ICH Q10 include the following:
(i)

The recognition of QRM (node 2) and KM (node 5) being separate, distinct
disciplines in support of the PQS yet interdependent on each other for
ultimately reducing risk to patients.

(ii)

This cycle can repeat for each phase of the QRM cycle, including when new
knowledge is acquired, and with each pass through the cycle, knowledge is
increased while risk is decreased.

(iii)

Consistent with the underlying framework, the interwoven relationship
between knowledge and risk (and knowledge management and risk
management), the inverse relationship of increasing knowledge leading to
decreased risk, the concept of flow, and the continuous and perpetual cycle
are each relevant to the goals of the PQS.
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Further details on the RKI Cycle, a description of each of the six nodes in the cycle and
an example of the cycle for a Sterile Filling Line risk assessment are available in the
referenced paper (Lipa, O’Donnell and Greene, 2020a).
Upon socialisation of this framework within the sector via the survey discussed earlier
in this chapter (Lipa, O’Donnell and Greene, 2021), preliminary feedback has been
overwhelmingly positive. When asked whether this framework is helpful in visualising
the relationship between risk and knowledge, 84% responded ‘yes’ as illustrated in
Figure 5-7.
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20

25
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Figure 5-7 – Do you find this framework helpful in visualising the relationship between risk and
knowledge

Additional feedback to this framework will be discussed, along with anticipated
benefits, in Chapter 10.
Linking back to the origin of this chapter where QRM and KM are represented as distinct
enablers, the researcher proposed that the PQS could be better represented with QRM
and KM as the basis for a united PQS foundation, and also directly linked to the PQS
elements which they enable as represented in Figure 5-8.
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Figure 5-8 – A re-framed and united PQS foundation

Having first established a Knowledge Management Process Model as a means to
improve understanding of KM (Figure 4-2) and now having further established the RKI
Cycle framework to address the important disconnect between QRM and KM, the
researcher was ready to shift focus to improve KM for the product lifecycle. The
researcher selected the lifecycle stage of technology transfer, given the challenges
typically associated with technology transfer as reported by Kane (Kane, 2018),
highlighted during the literature review, and witnessed by the researcher in his
professional experience. Furthermore, not only does technology transfer have a direct
impact on the ability to achieve the goals of the PQS, but industry trends suggest that
the frequency and complexity of technology transfers is expected to increase (McKinsey
& Company, 2019a, 2019b; O’Halloran, Heavey and Ciccarelli, 2019), making technology
transfer a key area to drive improvement. The following chapter will explore this
opportunity in further detail.
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Chapter 6: The Opportunity to Improve Knowledge Transfer
During Technology Transfer
The purpose of this chapter is to characterise the current state of KT during technology
transfer and define requirements for a future framework to address as a means to
improve KT.

6.1 Current state of knowledge transfer during pharmaceutical technology
transfer
To understand the current state of KT during a pharmaceutical technology transfer, a
series of research activities were undertaken, including a literature review (see Chapter
2, section 2.3), a survey, and interviews with industry experts and regulatory authorities.
This work has been published in a peer-reviewed paper in the Journal of Validation
Technology (Lipa, Kane and Greene, 2019). This section presents a summary of this
peer-reviewed paper which notably received external recognition in the form of the
2020 Author of the Year Award by the Journal of Validation Technology (IVT Network,
2020).

6.1.1 Survey on knowledge transfer during technology transfer
The researcher, as a presenter at the seminar, An Audience with Regulatory, Academia,
and Industry, on The Role of Effective QRM & KM in Product Realisation for Patients in
the 21st Century on 04-April-2019 at Technological University Dublin conducted an
audience survey. The presentation and survey results are presented in detail as part of
a published monograph (Lipa and Kane, 2019) and summarised below. The survey was
designed to assess the audience perspectives on each the importance and effectiveness
of KT to enable an effective and efficient technology transfer. The survey forms were
filled out by hand in session and no identifying information was collected. Fifty-six (56)
responses were received.
While several insights can be derived from the survey, the primary finding is depicted in
Figure 6-1 evaluating the importance versus the effectiveness for each explicit KT and
tacit KT.
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Figure 6-1 – Importance vs. effectiveness for explicit and tacit knowledge transfer

In summary, while explicit and tacit knowledge are each considered highly important to
effective and efficient technology transfer (axis y1 (blue)), explicit KT effectiveness is
only marginally effective with notable room for improvement (axis y2 (orange)).
Furthermore, tacit KT is regarded as somewhat ineffective.

6.1.2 Expert interviews: international industry experts and regulatory authorities
Four experts were interviewed in mid-2019 to explore their perspectives on the
importance of KT as a part of technology transfer, on the effectiveness of each explicit
and tacit KT, and expectations for tacit KT. The experts were selected in a matrix fashion
where two were based in the EU and two based in the USA, and two were industry SMEs
and two represented regulatory authorities. An analysis is included in the associated
paper (Lipa, Kane and Greene, 2019).
Upon analysis of the interview transcripts, the following key themes emerged:
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1. Knowledge transfer could be improved and would have meaningful positive
impact to technology transfer outcomes, including cost, quality and product
availability.
2. Some companies appeared to do well but this is the exception, not the norm.
3. Transparency on the level of process understanding was critical to a productive
regulatory dialog.
4. Often knowledge gets ‘stuck’ (e.g., someone’s judgement it is not important,
buried in long documents, captured in an unusable format).
5. On average, knowledge transfer effectiveness of explicit knowledge was
marginal and there is wide variation.
6. On average, knowledge transfer effectiveness of tacit knowledge was ineffective
to marginal and there is wide variation.
7. Successful technology transfer requires human to human interactions,
preferably face to face and time to walk through the details of a process to
explore details, sensitivities, what is not known, etc.
8. There was a clear desire that we must get better at technology transfer as an
industry.
6.1.3 Current state of technology transfer knowledge transfer
A current state assessment was drawn from three independent research activities
(literature review, survey, and expert interviews). The findings across these three
distinct activities correlated well and suggested these key observations:
1. Overall, knowledge transfer is critical to a successful and sustainable
technology transfer. Ineffective knowledge transfer can have a long-lasting
impact on the ability of the receiving site to provide cost-effective, high-quality
products with the desired availability.
2. Knowledge to be transferred associated with a technology transfer is biased
toward explicit knowledge (e.g., documents). This explicit knowledge is critical
to the success of the transfer, yet the industry is only marginally effective at it –
it is clearly not a strength. There is some supporting guidance on explicit
knowledge that should be transferred, but not prescriptive means on how to do
this or how to measure effectiveness.
3. Tacit knowledge associated with technology transfer is not widely recognised
as an asset to be transferred, nor is there evidence to suggest the
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pharmaceutical industry does it effectively. There is limited understanding on
what tacit knowledge is, why it was important, and how it can be transferred,
including how to measure effectiveness of the transfer. Furthermore, there is
little acknowledgement of tacit knowledge in industry guidance for technology
transfer, although there are a few recent developments where tacit knowledge
and related concepts (e.g., ‘know-how’) were acknowledged to be important to
transfer but without any guidance on how this might happen (Lipa, Kane and
Greene, 2019).
4. Regulators and industry are generally well aligned on these issues and their
impact. Both recognise the opportunity – and the need – to improve KM for the
good of patients.
These findings supported the problem statements being explored at the start of this
research, namely, that knowledge does not ‘flow’ readily through technology transfer,
and that tacit knowledge is critical but is not effectively managed or transferred. The
subsequent research activities to develop a KT framework and associated toolkit to
improve KT proceeded with the aim to address this opportunity.

6.2 Defining requirements for knowledge transfer during technology transfer
The purpose of this section is to explore the KT challenges associated with technology
transfer (i.e., the problem) to gain a clearer understanding of the needs, and from this
deeper understanding to identify the requirements a framework for technology transfer
KT (i.e., the solution) should address. This section is presented as a summary of a peerreviewed paper published in the PDA Journal of Pharmaceutical Science and Technology
(Lipa, Greene and Calnan, 2021).

6.2.1 Common challenges to technology transfer knowledge transfer
There are many potential challenges for effective KT during technology transfer. Each
one of these potential challenges presents a failure mode to effective KT and therefore,
to sustained technology transfer success. Based on the current state assessment,
literature review, interviews with experts (both industry and regulatory authorities), the
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experience of the researcher (both in KM and in technology transfer), and various
philosophical dialogues, the researcher identified six KT challenges.

Figure 6-2

developed by the researcher illustrates these challenges in the context of technology
transfer as a stage in the pharmaceutical product lifecycle. A brief description of each
challenge follows.

Figure 6-2 – Challenges associated with technology transfer knowledge transfer

Challenge 1: Narrow focus on the ‘golden batch’27 which was often regarded as the
‘minimum required’ by the receiving site to successfully manufacture the product. The
focus tended to be on transferring the knowledge required for ‘what goes right.’
Knowledge associated with ‘what goes wrong’ is often not transferred.
Challenge 2: Knowledge transfer was heavily biased toward documents, while tacit
knowledge (‘know-how’) was not methodically transferred. KT was typically focused
on document transfer (i.e., explicit knowledge). While some tacit KT activities do occur
on an ad hoc basis (e.g., staff at the receiving unit witnessed a batch being
manufactured at the sending unit), these attempts at tacit KT tended to be unstructured

27

The term ‘golden batch’ has been commonly attributed to batch process automation. The researcher
uses this term with some caution not intending this to be the ‘perfect batch trend’ but rather to convey
the scenario which progresses to plan without any deviations from the expected outcomes.
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and highly variable in approach. Therefore, while explicit knowledge may be transferred
to the receiving unit, often valuable tacit knowledge was not transferred and may be
lost.
Challenge 3: Knowledge ‘leakage’* occurred when valuable experience and learnings
were not captured, recognised, or considered relevant.

This included useful

knowledge such as failed experiments, the ‘why’ behind decisions, unexplored risks,
improvement opportunities (quality, cycle time, yield), other product/process
experience known by experts but never written down, and knowledge that is less
structured or formal that figuratively ‘went to PowerPoint to die’ (e.g., lessons learned,
important decisions in governance reviews, etc.).
*A word about knowledge leakage: The researcher would like to call out the usage of the
concept knowledge ‘leakage’ in these challenges. The researcher naively (and at the time,
hoped creatively) labelled these challenges with this concept when trying to describe what
was happening in practical terms. Simply – that knowledge was being lost, or dissipating, or
‘leaking’ from the boundaries where it was once known to be (e.g., the project team). Upon
a review of the literature, the researcher was surprised to learn knowledge leakage was an
established concept, and there are nominally two broad definitions of ‘knowledge leakage’
in existing literature: (i) ‘knowledge and capability shortage. This refers mainly to
turnover, i.e., individuals retire, move to another organisation, or leave an organisation due
to other reasons. Regardless of the specific form of turnover, those individuals take their tacit
knowledge and relational capital with them and it is often the case that there is no one in the
organisation experienced and skilled enough to replace them.’ (Durst and Ferenhof, 2014).
And (ii) simply, ‘the loss of knowledge intended to stay within a firm’s boundaries’ (Durst,
Aggestam and Ferenhof, 2015). This latter definition seems to have received more attention
in the literature, due to attention on risk of loss of intellectual property and associated
competitive advantage – whether the loss is intentional or not – through partnerships,
technology transfers, software development projects or other collaborations. However, the
literature also states that the topic of knowledge leakage is not well characterised or
understood, and more research is required (Durst, Aggestam and Ferenhof, 2015).
Given this ambiguity about the concept of knowledge leakage the researcher proposes a
practical definition of knowledge leakage for the purposes of this thesis with the hope it will
garner further study: that knowledge leakage refers to unintended loss, dissipation,
mismanagement, lack of structure or any other mechanism which renders knowledge
which was known to no longer be:
a) Accessible
b) Findable (whether one cannot find the knowledge or who has the knowledge)
c) Usable (e.g., through missing context)
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d) One simply does not know the knowledge exists
Like a hole in a bucket of water – what was once there and available is no longer able to be
applied to the benefit of the product or process. And of note, it does not need to leak beyond
a firm’s boundaries to cause a negative impact to a product or process, just out of control,
memory or some other boundary. Perhaps this definition could be argued to be a subset of
definition (i) above in that it represents a ‘knowledge and capability shortage’ at the point of
need. Regardless, if knowledge is viewed as an asset, it should not be allowed to leak, just as
one would not want money to unintentionally leak out of one’s bank account.

Challenge 4:

Knowledge ‘leakage’ due to lack of structured and standardised

knowledge management approaches. Knowledge was not findable or accessible when
needed.
Challenge 5: Knowledge ‘leakage’ through loss of staff experience due to turnover.
Knowledge dissipated and was not available when needed due to routine staff
transitions, especially over the lengthy duration of the product lifecycle.
Challenge 6:

The technology transfer itself caused obstructed knowledge flow

(project context and/or process). This was due to certain knowledge transfer barriers
between pharmaceutical development and commercial manufacture during technology
transfer activities. Such barriers related to process complexity, low staff competency at
the receiving site, differences in time zones, language issues, cultural differences, etc.
Furthermore, based on a review of the guidance documents, the researcher concluded
that technology transfer is typically seen as a linear, once-through process. Given the
absence of focus on KT to begin with, there is no evidence whatsoever to suggest a
mechanism to reflect if and how knowledge transfer outcomes were achieved (or were
not). Such a pause to reflect on progress to a plan would seem to be a valuable
opportunity in pursuit of effective transfers, ongoing learning, and continual process
improvement. A closed-loop KT framework – enabled by robust KM approaches – could
address this gap and would in turn improve the corresponding technology transfer
outcomes. This is supported by the literature (Malik, 2002; Kremic, 2003) suggesting
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that knowledge transfer during technology transfer should include a feedback loop to
ensure the effectiveness of KT and a learning opportunity for the sending site.

6.2.2 Defining requirements for a technology transfer knowledge transfer framework
Having identified the key challenges believed to cause ineffective KT during technology
transfer, the research focus turned toward exploring the requirements for a KT
framework to proactively prevent this loss of critical knowledge. First, returning to the
six challenges to KT identified previously and employing a CTQ tree28, five high-level
requirements of a KT framework were identified and listed below (I-V):
I.
II.
III.
IV.
V.

Knowledge transfer is guided by an intentional and robust plan
Knowledge transfer is best enabled by a culture that values knowledge as an
asset
Standardised approaches for KM are established both for explicit and for
tacit knowledge
Tacit knowledge is uncovered and transferred during technology transfer
Knowledge transfer effectiveness is measured and an action plan to address
any gaps and opportunities is prepared

From the five high-level requirements, 16 detailed requirements were identified to
provide further granularity of solution requirements.

While the five high-level

requirements essentially act as principles, these next level requirements were identified
to be more specific and actionable. These were grouped as follows:
•
•
•
•

Knowledge to be transferred
Knowledge transfer process
Knowledge flow enablers and detractors
Degree of change from sending unit to receiving unit

Further details on the requirements and processes used to define them can be found in
the referenced peer-reviewed paper (Lipa, Greene and Calnan, 2021). A summary

28

A CTQ tree or, Critical to Quality tree, is a technique used to identify the needs of the customer (i.e.,
the outputs from a process) and translate the needs into measurable product and process requirements
(Six Sigma Daily, no date)
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diagram linking the problem statement to the detailed requirements is provided in
Figure 6-3.

Detailed Requirements for a Knowledge Transfer Framework
Challenges

(2) Knowledge transfer is heavily
biased toward documents, while
tacit knowledge is not
methodically transferred

Ineffective Knowledge Transfer
during Technology Transfer
(both explicit and tacit
knowledge)

(3) Knowledge leakage as valuable
experience and learnings not
captured, recognized or
considered relevant
(4) Knowledge leakage due to lack
of structured and standardized
knowledge management
approaches
(5) Knowledge leakage through
loss of staff experience

(6) Context of the technology
transfer causing obstructed
knowledge flow

(I) Knowledge Transfer is guided by
an intentional and robust plan

(II) Knowledge Transfer is best
enabled by a culture that values
knowledge as an asset
(III) Standardized approaches for KM
are established both for explicit and
for tacit knowledge
(IV) Tacit knowledge is uncovered
and transferred during technology
transfer
(V) Knowledge transfer is measured
and results in an action plan to
address gaps and opportunities

A holistic plan for knowledge transfer
Tacit knowledge is recognized as important
Knowledge leakage is minimized through systematic
knowledge capture
Knowledge leakage is minimized through retention of
critical knowledge
Knowledge exists (it was created to begin with)
Knowledge is identified (a ‘known known’)

Knowledge
transfer processes

(1) Narrow Focus on the “golden
batch”

Knowledge to be Transferred

High Level Requirements
Drivers for effective Knowledge Transfer

Knowledge leakage minimized through standard KM
approaches

Knowledge flow enablers &
detractors

more specific problem statements

Barriers / obstruction to knowledge flow recognized

Degree of
change

Problem Statement

Change recognized as a risk & learning opportunity

Standard KM processes followed
Standard KM processes are effective

Organizational pressure / motivations recognized
Capability & Competency of Receiving Unit known
Mindsets & behaviors for managing knowledge
KM processes ‘in the flow’ of work

Plan to capture / grow knowledge

Figure 6-3 – Mapping problem statement to requirements for a technology transfer knowledge
transfer framework

6.3 Evaluation of knowledge transfer framework requirements
With the KT problem better defined and the solution requirements preliminarily
identified, it was a good opportunity to pause and benchmark against the findings from
the literature review. In the absence of a definitive framework, recall Ward et al. (Ward,
House and Hamer, 2009) conducted a study of existing frameworks for knowledge
transfer and inventoried 28 generalised frameworks in the literature and identified five
common components. They then proposed a conceptual framework embodying those
five common components including:
i.
ii.
iii.
iv.
v.

the problem
the knowledge
the context barriers or supports
the interventions
the utilisation
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Figure 6-4 – Conceptual framework of the knowledge transfer process (Ward, House and
Hamer, 2009)

A gap assessment of the KT framework requirements proposed by the researcher
(depicted in Figure 6-3) was conducted against the proposal by Ward et al. The
assessment result is shown in Table 6-1, as a means to evaluate whether the
requirements are complete in addressing all components identified by Ward et al.
(Ward, House and Hamer, 2009).
Table 6-1 – Proposed requirements by researcher vs. conceptual knowledge transfer
framework by Ward et al. (Ward, House and Hamer, 2009)
Component
from
conceptual
framework
Problem
Knowledge
Context barriers
or supports
Interventions
Utilisation

How researcher’s technology transfer knowledge
transfer framework addresses this component
The subject technology transfer with associated context,
assessed by the holistic plan for knowledge transfer
Knowledge to be transferred (requirements grouping)
Knowledge flow enablers & detractors (requirements
grouping), degree of change (requirements grouping)
Knowledge transfer processes (requirements grouping)
The subject technology transfer with associated progress
versus technology transfer plan, including assessment by
the holistic plan for knowledge transfer outcomes of the
technology transfer and sustained performance,

Addressed in
Researcher
Framework
Requirements?
Yes
Yes
Yes
Yes
Yes

While highly qualitative, the detailed KT framework requirements derived
independently within this thesis are verified to address all five common components of
KT frameworks found in the literature, suggesting this set of requirements addresses all
key components commonly found in KT frameworks.
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Armed with this basic understanding of the needs of a solution, the researcher
proceeded to develop a framework to enhance KT during technology transfer, the
details of which are discussed in Chapter 7.
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Chapter 7: A Proposed Framework and Toolkit to Enhance
Knowledge Transfer during Technology Transfer
The purpose of this chapter is to present a framework to enhance the effectiveness of
KT during technology transfer, the Knowledge Transfer Enhancement Framework, or KTE
Framework. The framework is further supported by a corresponding toolkit, the KTE
Toolkit which is also presented. This section is presented as a summary of a peerreviewed paper published in the PDA Journal of Pharmaceutical Science and Technology
(Lipa, Greene and Calnan, 2021).
In addition to the framework and toolkit, this chapter also provides supporting materials
for implementation of the framework, including a mapping of the framework to the
technology transfer process and a high-level metrics plan.

7.1 A knowledge transfer framework for pharmaceutical technology transfer
Having identified the detailed requirements in Chapter 6 (section 6.2) and given the
desire to have a simple, closed-loop process that was both widely known and pragmatic
in nature, the researcher selected the PDCA, or Plan-Do-Check-Act model, as a starting
basis to build upon. This model made popular by Deming (ASQ, 2019) is an iterative and
cyclical means to improve a given process.
To leverage the cyclical nature of the PDCA and make the framework more relevant to
KT during technology transfer, the intent and description of each stage was adapted as
follows and depicted in Figure 7-1 which is presented as the Framework for Knowledge
Transfer Enhancement, or KTE Framework:
1.
2.
3.
4.

Knowledge Transfer (KT) Readiness Planning (Plan)
KT Execution (Do)
KT Effectiveness Assessment (Check)
KT Action Plan (Act)
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Figure 7-1 – The KTE Framework on a page

The referenced paper (Lipa, Greene and Calnan, 2021) by the researcher includes
further details on each stage of the KTE Framework.
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7.2 A knowledge transfer toolkit for pharmaceutical technology transfer
Supporting the KTE Framework is a KTE Toolkit, consisting of a series of practices to
support the ‘how’ behind knowledge transfer. These KM practices are introduced in the
referenced peer-reviewed paper (Lipa, Greene and Calnan, 2021). Table 7-1, KTE Toolkit
on a Page, provides a listing of the tools and practices, a brief intent statement for each
(“Use it to…”), and next steps to implement each tool or practice, which in some cases
may involve future research study. While further development of this toolkit will
certainly be of value through thoughtful definition and identification of proven
practices, in the opinion of the researcher with the intent of each framework stage and
tool defined, organisations should feel empowered to start to address these gaps on
their own.
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Table 7-1 – KTE Toolkit on a Page
KTE Stage | KTE Tool
KT Readiness Planning

Use it to…

1.1 – KT Risk Factor Assessment

Reduce risk to technology transfer

1.2 – KT Plan

Build knowledge transfer into technology transfer

1.3 – KT Mindsets & Behaviours

Create shared team understanding of the need to
manage knowledge as an asset

Next steps to implement tool / practice
Define through future study; Based on socialisation of these concepts of knowledge transfer
challenges, organisations can immediately incorporate into technology transfer risk
assessments
Basic outline to define knowledge to be transferred (e.g., from knowledge map) and how
(KM/KT practices to be utilised and built into project) can be immediately built into
technology transfer plans or supporting knowledge transfer plans. This should include a plan
for appropriate training. Future study to define a template would likely be of benefit.
These concepts are preliminary explored in Chapter 9 and warrant future study

KT Execution
2.1 – KT Community of Practice
(CoP)
2.2 – Standard KM Practices

KM best practice to standardise knowledge flow
KM best practice(s) to standardise knowledge flow

2.3 – KT Knowledge Map

Identify knowledge to be transferred

2.4 – KT ‘What if’ Assessment
2.5 – Tech Transfer Knowledge
Sharing

KM practice to surface and transfer tacit knowledge
KM practice to surface and transfer tacit knowledge,
enable rapid continual improvement

Best practices for CoPs exist (Kane and Lipa, 2018); Define tech transfer-specific CoP through
future study
Many common practices exist and can be applied (Kane and Lipa, 2018; ISPE, 2021b)
Define through future study; basic expectations exist via BPOG Knowledge Map (BioPhorum
Operations Group, 2020) and explicit document lists found in ISPE (ISPE, 2018), PDA (PDA,
2014b) and other technology transfer guidance documents
Refer to Simple Practices paper (Lipa, Kane and Greene, 2020)
Refer to Simple Practices paper (Lipa, Kane and Greene, 2020)

KT Effectiveness Assessment
3.1 – Explicit KT Checklist
3.2 – Tacit Knowledge Turnover
3.3 – Lessons Learned
3.4 – KT Summary Report

KM best practice to standardise knowledge flow
KM practice to surface and transfer tacit knowledge
KM best practice – use to surface and transfer tacit
knowledge & foster continual improvement
Assess completion of KT

Audit against KT Plan and knowledge map
Refer to Simple Practices paper (Lipa, Kane and Greene, 2020)
Leverage existing proven practices for Lessons Learned / After Action Review (ISPE, 2018;
Kane and Lipa, 2018)
Audit against goals in KT Plan and completion of items 3.1 through 3.3

Act on learnings, including process improvement,
knowledge capture and informing control strategy
KM best practices to maintain and grow transferred
knowledge at RU

Basic action plan resulting from above actions, including open items from knowledge transfer
summary report, actions identified during tacit knowledge transfer and lessons learned
KM plan for the receiving unit to sustain and grow product knowledge; Potential to define
through future study

KT Action Plan
4.1 – KT Action Plan
4.2 – Receiving Unit KM Plan
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One area in particular the researcher explored was that of tacit knowledge transfer.
Given the general neglect of tacit knowledge (as characterised multiple times in previous
chapters), the researcher had an interest in advancing the dialogue on meaningful tacit
knowledge transfer techniques, while also creating a model for several of the tools
proposed in the KTE Toolkit. The results are captured via a case study in a paper by the
author, Simple Practices to Facilitate the Flow of Valuable Tacit Knowledge during
Biopharmaceutical Technology Transfer: A Case Study (Lipa, Kane and Greene, 2020).
This case study was also presented as part of a presentation at the 2021 PDA Annual
Meeting (Lipa, 2021a) and is featured in the ISPE Good Practice Guide on Knowledge
Management (ISPE, 2021b).
In summary, the researcher, while involved with a complex technology transfer for a
multi-valent vaccine, led the design of two tacit knowledge transfer practices
(Technology Transfer Batch Execution Review and Tacit Knowledge Turnover Assessment)
and consulted on a third (What if…?). Drawing on best practices in KM, each of the tacit
knowledge transfer practices share common elements, including:
•
•
•

Standardised business processes for knowledge capture and transfer (and
codification to explicit knowledge, where appropriate)
Basic governance to ensure prioritisation and follow through on important
actions
Enabling mindsets for sending and receiving site personnel, including ‘safe to
share’ and a sense of inquisitiveness, including active engagement and
participation from people, such as experts from the sending site and members
from the receiving site

The general process for Technology Transfer Batch Execution Review is illustrated in
Figure 7-2, highlighting a relatively simple set of questions that can be pursued before
and after batch execution to create meaningful dialogue, ideas, questions, and exchange
of information. Coupled with the common elements (e.g., governance), these processes
were highly effective in generating valuable insights.
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A. Pre-batch review
Create focus, alignment & situational awareness
• What is new, unique or difficult?
• What changed since last time?
• How did it go last time?
• What do we need to get right today?

B. Post-batch review
Pause to reflect, learn and improve
• What was supposed to happen?
• What actually happened?
• Was there a difference and why?
• What can we learn?
• Who needs to know?

Receiving Sending
Site
Site (SME)

Receiving
Site

Sending
Site (SME)

© Martin Lipa 2020

Figure 7-2 – Technology Transfer Batch Execution Review

These three tacit knowledge transfer processes delivered significant positive impact to
the success of the technology transfer in reducing cost and risk through proactive
learning and improved right-first-time execution. Technology Transfer Batch Execution
Review, for example, resulted in 52 proactive actions which in turn prevented 43
potential deviations in the quality system. Furthermore, there was overwhelmingly
positive stakeholder feedback on the contribution of this process to continual
improvement ‘on a near real-time basis.’

This practice and the other two tacit

knowledge transfer processes are presented in further detail in the referenced paper
(Lipa, Kane and Greene, 2020).

7.3 Feedback on the KTE Framework
Importantly, the KTE Framework was not developed in a vacuum. In addition to the
experiences of the researcher, the framework was informed by the literature, the
current state assessment and resulting derived requirements, and by feedback via
interviews.

Interviews to solicit feedback on a preliminary iteration of the KTE

Framework were conducted between December 2019 and February 2020 to solicit
feedback from industry SMEs on technology transfer, senior leaders, and a regulatory
authority. The intent was to gain insights on potential benefits from the framework,
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whether the framework was logical, and whether it was workable (i.e., practical to
implement).

7.4 Practical application of the KTE Framework to technology transfer
To demonstrate the application of the KTE Framework and associated KTE Toolkit to a
technology transfer project, the researcher leveraged a five-step overview of the
technology transfer process described by Abraham et al. (Abraham et al., 2015) to
create the following process flow.

Figure 7-3 – Key activities and milestones in biopharmaceutical technology transfer

Using the technology transfer flow steps as headings, a matrix was developed by the
researcher and is shown in Figure 7-4. Beneath each of the five steps of the technology
transfer process, a mapping of the respective KTE stages and KM practices are
presented.
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STAGE 1:
KT PLANNING

STAGE 2:
KT EXECUTION

RISK FACTOR ASSESSMENT

◉

KT PLAN

◉

MINDSETS & BEHAVIORS

◉

◉

◉

◉

◉

TECH TRANSFER COP

◉

◉

◉

◉

◉

STANDARD KM

◉

◉

◉

◉

◉

“WHAT IF…?”

◉

◉

TT KNOWLEDGE SHARING

◉

◉

◉

KNOWLEDGE MAP

STAGE 3:
KT
EFFECTIVENESS
ASSESSMENT

STAGE 4:
KT ACTION
PLANNING

EXPLICIT K CHECKLIST

◉

TACIT KNOWLEDGE

◉

TURNOVER

LESSONS LEARNED

◉

KT SUMMARY REPORT

◉
◉

KT ACTION PLAN
RECEIVING UNIT
KNOWLEDGE MANAGEMENT

◉

◉

PLAN

Figure 7-4 – A matrix indicating where the KTE Framework and KTE Toolkit can be applied to the
technology transfer process

7.5 Metrics for the KTE Framework
A measurement system is critical to ensure an objective is achieved and to provide a
tangible means to assess progress. The ultimate outcome of an effective KT is in support
of the goals of ICH Q10 (ICH, 2008) and informing QRM to, in turn, reduce risk to patients
(Chapter 5). However, in practice, measurement of these outcomes is difficult since
they come along after the technology transfer is complete, and they are often
confounded with other improvement initiatives (i.e., improvements often cannot be
attributed specifically to KT effectiveness). Also, in the experience of the researcher,
success in KM is often about what didn’t happen rather than what did happen in the
future (said differently, with effective KM, issues can be averted or solved quickly and
risks can be managed before major issues occur, therefore attribution to the success of
KM can be difficult to establish).
It is envisaged that the KTE Framework will be primarily measured by a set of leading
metrics proposed by the researcher, intended to assess progress and activity in applying
the framework. These metrics are typically considered leading indicators as they are
predictive in nature of an outcome. In the case of the KTE Framework, the research
activities to determine the current state and challenges with technology transfer KT
(Chapter 6) have already established the impact of not having structured KT approaches
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in place. Therefore, metrics tied to the KTE Framework deployment can establish an
initial baseline to demonstrate structured KT approaches. When used, they can provide
a degree of confidence in improving both KT and technology transfer outcomes. It is
fully anticipated these metrics will evolve and be refined over time based on feedback.
A preliminary metrics plan for the KTE Framework is listed in Table 7-2.
Table 7-2 – KTE Framework metrics plan
Leading Indicator
Knowledge transfer Plan: plan in place and approved,
including KT Risk Factor Assessment and KT Readiness
Assessment
Knowledge transfer plan: progress to plan
Team enrolled in knowledge transfer mindsets and
behaviours, through onboarding, team chartering or
other appropriate means
Knowledge management maturity at sending site
Knowledge management maturity at receiving site
Closure of knowledge-related actions identified during
technology transfer (e.g., those identified during risk
assessments and tacit knowledge transfer exercises such
as What If? and Tacit Knowledge Turnover)
Closure of actions from lessons learned / after action
reviews conducted in-process during technology transfer
and at the conclusion of technology transfer
Closure of actions identified in Knowledge Action Plan ,
including feedback and feed forward actions on the
transferred product and process, as well as on the
business processes of technology and knowledge transfer
Knowledge transfer completion is measured as part of
overall technology transfer metrics
KM-practice specific measures, as appropriate based on
KM practices selected

Target Value
Yes
Execution is on plan (scope and
schedule)
>95% enrolled
At least standardised (mid-level
maturity)
At least standardised (mid-level
maturity)
>90% of high priority items
closed within 3 months
>90% of high priority items
closed within 3 months
>90% of high priority items
closed within 3 months
Yes
Varies, based on knowledge
management practices applied.

Lagging indicators, which indicate past performance, can also be used for technology
transfer outcomes, are listed in Table 7-3. Due to the latency to measure such
outcomes, a mix of leading and lagging measures is recommended.
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Table 7-3 – Lagging measures for technology transfer using the KTE Framework
Lagging Indicator
Deviations during PPQ
Process reproducibility
Process robustness / performance
Measures of risk reduction for successful
technology transfer
Technology transfer completed on schedule
Technology transfer completed on budget

Target
directional and qualitative, relative to
company’s baseline performance
Fewer deviations
Increased reproducibility
Increased robustness performance
Lower residual risk
Tighter schedule adherence
Tighter budget adherence

7.6 Summary – KTE Framework
In summary, the KTE Framework presented in this chapter is positioned as one potential
solution to improve KT during technology transfer. This framework has been based on
learnings from the literature, other KT models, a well-informed set of requirements,
feedback from industry experts, leaders and regulatory authorities, peer reviewers of
the related paper, and the experience of the researcher. Further information on how
the KTE Framework provides a means for feedback (e.g., to inform future transfers) and
feed-forward (e.g., to inform the control strategy) is explored in the referenced paper
(Lipa, Greene and Calnan, 2021).
Part three which follows, including Chapters 8 and 9, which explored how the RKI Cycle
could be applied across the product lifecycle to extend its reach and impact.
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Part Three: The RKI Cycle across the Product Lifecycle and
Knowledge Culture as a Catalyst
Part Three demonstrates how the RKI Cycle can be applied across the product lifecycle,
including:
•

Three examples with a focus on each KM across the product lifecycle, change
management during commercial manufacturing, and the link between QRM,
KM and data analytics (Chapter 8).

•

This part also explores the concept of knowledge culture, including a review of
current cultural issues which are barriers to knowledge management in the
pharmaceutical industry, existing definitions of knowledge culture outside of
the pharmaceutical industry, and benchmarking the corollary of quality culture.
This section concludes with proposing a preliminary ‘ideal knowledge culture’
(Chapter 9).
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Chapter 8: Demonstrating How the RKI Cycle Can be Applied
Across the Product Lifecycle
Given the findings of this research on the importance of connecting QRM and KM and
ensuring the effective management of knowledge – coupled with the evidence that this
is not done well in practice today – an important opportunity to maximise the impact of
these findings is presented. The purpose of this chapter is to demonstrate examples of
how the RKI Cycle can be applied across the product lifecycle as depicted in ICH Q10
(ICH, 2008) (Figure 8-1).

Figure 8-1 – The product lifecycle as depicted by ICH Q10 (ICH, 2008)

The first of three examples focuses on managing knowledge across the product lifecycle
to ensure knowledge availability for managing risk (in addition to operational benefits).
This first example takes a broad view across all four stages of the end-to-end product
lifecycle and is centred primarily on node 5 of the RKI Cycle (Figure 8-2, as presented in
Chapter 5 and the related peer-reviewed paper (Lipa, O’Donnell and Greene, 2020a).

Figure 8-2 – The Risk-Knowledge Infinity Cycle as applied to ICH Q10

The second example features an application of the RKI Cycle within a single lifecycle
stage, the commercial manufacturing stage of the product lifecycle. Specifically, this
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example highlights the PQS element of change management and illustrates how the RKI
Cycle is ‘continuous and perpetual’ (Chapter 5, section 5.2). This example presents four
common change triggers flowing through the RKI Cycle, each starting at a different
node, either 1, 3, 4, or 6 (Figure 8-2).
The third example demonstrates how the RKI Cycle can provide a tangible mechanism
for data analytics to generate knowledge and enable risk reduction, by injecting new
knowledge derived from data analytics into node 4 (Figure 8-2).
These first two examples have been published in two separate papers and are
summarised in the following sections of this chapter. The first paper which maps stageappropriate KM methods and tools across the lifecycle was published in Level3 (Lipa and
Kane, 2021) and subsequently used in Chapter 5 of the ISPE Good Practice Guide on
Knowledge Management (ISPE, 2021b). At the time of this thesis submission, the
second paper featuring the RKI Cycle for change management during commercial
manufacturing has been accepted by ISPE and is planned to be released in May 2021 as
the subject of a global webcast (Lipa and Mulholland, 2021). The third example was the
subject of a presentation given by the researcher at the launch of the Guide to Data
Analytics for Pharmaceutical Manufacturing (PMTC, 2020) by the Pharmaceutical
Manufacturing Technology Centre29.

8.1 Managing knowledge across the product lifecycle (Example 1)
A key concept inherent in the product lifecycle is that knowledge will grow over time
through planned (e.g., development studies, prospective process changes) and
unplanned (e.g., investigations, risk control failures) activities. A key tenant of the RKI
Cycle is that knowledge should be effectively managed (at node 5) to ensure it is
available and can be applied to reduce risk and support continual improvement (as
illustrated by Figure 5-5).

29

The Pharmaceutical Manufacturing Technology Centre (PMTC), http://www.pmtc.ie
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To date, this thesis has focused on the technology transfer stage of the product lifecycle.
Stepping back to take the entire product lifecycle into account, one can envision that
knowledge is increasing at every stage as depicted in Figure 8-3. This depiction by no
means suggests there are a finite number of RKI cycles for the four lifecycle stages;
rather, this RKI cycle is always repeating (‘continuous and perpetual’) across the product
lifecycle.

Figure 8-3 – The RKI Cycle as knowledge increases across the product lifecycle

One might expect the emphasis of KM plans and practices to vary slightly from stage to
stage based on the applicable knowledge-intensive activities in each stage.

The

following sections consider each of the lifecycle stages separately, including
considerations of each phase introduced by Kane’s PPKL model (Kane, 2018) as
introduced in Chapter 2 (section 2.1.3.1).

8.1.1 Pharmaceutical Development
Considering Pharmaceutical Development, labelled as Product Development in the PPKL
model (Kane, 2018), examples of knowledge-related activities include (ISPE, 2011):
•
•
•

Application of prior knowledge for risk assessments to determine areas of study
Development work to capture new knowledge
Ongoing risk assessment and risk control
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Knowledge management should be a key enabler to Product Development through
standardised methods and tools delivering on the following capabilities:
•

•
•

Access to prior knowledge (platform technologies, other products, expertise in
the company (individuals & CoEs), external scientific literature, prior learnings &
lessons, etc.)
Capture of new knowledge during early development work (both what worked
and what did not), including both explicit and tacit knowledge
The record of product development, including scientific knowledge, supporting
design choices, and other decision rationale

8.1.2 Technology Transfer
Considering Technology Transfer (new product introduction and In-line transfers),
examples of knowledge-related activities (WHO, 2011; PDA, 2014b; ISPE, 2018), as
explored in detail in Chapter 6, include:
•
•
•
•

Application of knowledge for risk assessments
Comprehensive knowledge transfer, including tacit knowledge
Opportunity to learn more about the product and process
Supporting the goal to ensure a right-first time transfer, robust process and a
fully capable receiving site

Knowledge management should be a key enabler to Technology Transfer through
standardised methods and tools delivering the following capabilities, as explored in
detail in Chapter 7:
•

•
•

Access to comprehensive product and process knowledge, including
development and manufacturing history (e.g., key decisions, learnings from
failures, changes, etc.)
Access to subject matter experts / personnel with process experience
Capture of new learnings including increased knowledge and understanding of
product/process, lessons learned, etc.
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8.1.3 Commercial Manufacturing
Considering Commercial Manufacturing (inclusive of Continual Improvement) examples
of knowledge-related activities include (ICH, 2008):
•
•
•

Ongoing knowledge build through accumulated manufacturing experience
Lifecycle management, including planned and unplanned changes
Seeking to minimise disruptions to product availability by rapid problem solving
and solving problems at root cause

Knowledge management should be a key enabler to Commercial Manufacturing
through standardised methods and tools delivering the following capabilities:
•
•

•

Capture of new learnings, including increased knowledge and understanding of
product/process, lessons learned, etc.
Knowledge visibility and availability across the full product lifecycle (including
development) to ensure broad access to knowledge to support process
monitoring, continual improvement, change management, investigations, etc.
Support for problem solving and sharing of best practices and improvements
across the supply chain and back to development organisation

8.1.4 Product Discontinuation
Considering Product Discontinuation, examples of knowledge-related activities include
(ICH, 2008):
•
•

Knowledge transfer for archival and future access on demand
Harvesting learnings to inform 'prior knowledge'

Knowledge management should be a key enabler to Product Discontinuation through
standardised methods and tools delivering the following capabilities:
•
•

Capture of knowledge in a complete and structured manner to allow for future
access (e.g., stability, complaints, etc.)
Capture of learnings including insights for platform knowledge and other
potential 'prior knowledge'
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Given these high-level understandings of the necessary knowledge capabilities for each
stage of the product lifecycle, the researcher suggested suitable KM methods and tools
can be applied to each stage, which are presented in the next section.

8.1.5 Product lifecycle stage-appropriate KM methods and tools to ensure knowledge
availability
The researcher suggested that current established KM methods and tools can be
employed to provide the necessary means to effectively manage knowledge in a
standardised and consistent manner, ensuring the best possible knowledge is available
to maximise the reduction of risk via the RKI Cycle.
To illustrate this, Table 8-130, created by the researcher, provides a preliminary mapping
of KM methods and tools required to satisfy the conceptual needs of each product
lifecycle stage. This table has been accepted by the ISPE Good Practice Guide on
Knowledge Management SME author team and is featured in Chapter 5 of the ISPE
Guide. Following Table 8-1, a description for each KM method or tool is provided in
Table 8-2.

30

Note – column heading labels have been adjusted post-publication in Level3 to improve clarity of the
text as it relates to this thesis
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Table 8-1 – Stage-appropriate KM methods & tools across the product lifecycle
KM Methods & Tools

X

The record of product development, including scientific
knowledge and supporting design choices and other decision
rationale

X

Common KM elements for Technology Transfer phase

Commercial
Manufacturing /
Continuous
Improvement

Product
Discontinuation

- Knowledge transfer for archival and
future access on demand
- Harvesting learnings to inform 'prior
knowledge'

X

X

X

Decision Rationale Capture

X

X

X

X

X

X

X

X

X

X

X

X

X

Tacit Knowledge Retention &
Transfer Practices

Expertise Location

After Action Review /
Lessons Learned

Communities of Practice

Product Knowledge Base

Platform Knowledge Base

Taxonomy & Search

Content Management

X

X

Access to subject matter experts / personnel with process
experience

X

X

X

X

Capture of new learnings including increased knowledge and
understanding of product/process, lessons learned, etc.

X
X

X

X

X

X

X
X

X

X

X

X
X

X

X

X

X

X
X

X

X

X

X

X

X

X

X

Knowledge visibility and availability across the full product
lifecycle (including development) to ensure broad access to
knowledge to support process monitoring, continual
improvement, change management, investigations, et al

X

X

X

X

X

X

X

X

Support for problem solving and sharing of best practices and
improvements across the supply chain and back to
development organization

X

X

X

X

X

X

X

X

X

Capture of knowledge in a complete and structured manner to
allow for future access (e.g. stability, complaints, etc.)
Capture of learnings including insights for platform knowledge
and other potential 'prior knowledge'

© 2020 Lipa & Kane
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X

X

X

X

X

X

X

X

X

X

X

X

X

X
X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

Common KM elements for Product Discontinuation phase

X

X

X

Capture of new learnings including increased knowledge and
understanding of product/process, lessons learned, etc.

X
X

X

Access to comprehensive product and process knowledge,
including development and manufacturing history, including
key decisions, learnings from failures, changes, etc.

Common KM elements for Commercial Manufacturing phase
- Ongoing knowledge build through
accumulated manufacturing experience
- Lifecycle management, including
planned and unplanned changes
- Seek to minimize disruptions to
product availability by rapid problem
solving and solving problems at root
cause

X

X

Sponsorship, Governance,
Metrics & Other enablers

Capture of new knowledge during early development work
(both what worked and what didn't)

X

Enabling elements
Knowledge-valuing culture

New Product
Introduction /
Technology
Transfer

- Application of knowledge for risk
assessments
- Comprehensive knowledge transfer
- Opportunity to learn more about the
product/process
- Supporting the goal to ensure a rightfirst time transfer, robust process and
capable receiving site

X

Mostly Tacit-based

KM Training

Product
Development

X

Access to prior knowledge (platform technologies, other
products, expertise in the company (individuals & CoEs),
external scientific literature, prior learnings & lessons, et al)

Mostly Explicit-based

KM Roles

Common KM elements for Product Development phase
- Application of prior knowledge for risk
assessments to determine areas of study
- Development work to capture new
knowledge
- Ongoing risk assessment and risk
control

Site / Functional Area
KM Plan

Note 1: Illustrative concepts, not an exhaustive listing
Note 2: References below to knowledge refer to both explicit and tacit knowledge
Note 3: Additional concepts or complexity may be introduced when multiple entities are involved

Knowledge Transfer Plan

Knowledge Capabilities Required

(activities where knowledge is required) (How Knowledge Management can provide benefit)

Product KM Plan

Knowledge-related activites

Knowledge Mapping

Lifecycle Stage

KM Maturity Assessment

Planning & Requirements
Definition

X
X
X

X
X

X

Table 8-2 – Description of KM methods & tools
KM Method or Tool
Description
Planning & Requirements Definition
KM Maturity Assessment
Knowledge Mapping
Product KM Plan
Knowledge Transfer Plan
Site / Functional Area KM
Plan

A means to objectively measure maturity of KM effectiveness based on
various attributes such as process, culture, technology, etc.
A structured means to document the knowledge needed for a business
process, a functional group, a role, etc. Used to understand knowledge
requirements and identify gaps.
A strategy document to define the plan for how the knowledge associated
with a product will be managed across the lifecycle of the product.
A strategy document to define the plan for how the knowledge transfer will
be managed.
A strategy document to define the plan for how the knowledge associated
with a site or functional group will be managed.

Mostly Explicit-based
Content Management

Taxonomy & Search
Platform Knowledge Base
Product Knowledge Base

A structured31 means to manage documents and other explicit knowledge
(e.g., videos, pictures, etc.). Typically includes the end-to-end lifecycle of
content (e.g., creation, tagging, storage, delivery). Applies to both GMP and
non-GMP content which may be managed in separate systems.
Taxonomy is a structured means to describe and tag content (and potentially
other features such as synonyms, semantics, etc.), and a means to deliver
results through a robust, integrated search enabled by such a taxonomy.
A structured means to define the scope of platform knowledge (explicit and
tacit) and corresponding approaches to manage this in a consistent way to
ensure knowledge visibility and availability across the product lifecycle.
A structured means to define the scope of product knowledge (explicit and
tacit) and corresponding approaches to manage this in a consistent way to
ensure knowledge visibility and availability across the product lifecycle.

Mostly Tacit-based
Communities of Practice
After Action Review /
Lessons Learned
Expertise Location
Decision Rationale
Capture
Tacit Knowledge
Retention & Transfer
Practices

A structured means to connect groups of people with a shared need or
interest
A structured means to surface learnings from the experiences of people,
often associated with a project or other business process, and subsequently
capture and implement these learnings to support continual improvement.
A structured means to identify important expertise and/or experience in the
organisation and connect to it on demand.
A structured means to capture decision rationale and ensure it is available in
the future when needed.
A variety of structured means to identify, prioritise, transfer and retain tacit
knowledge (i.e., ‘know-how’ and other knowledge ‘in people’s heads’)

Enabling Elements
KM Roles
KM Training
Knowledge-valuing
culture
Sponsorship, Governance,
Metrics & Other enablers
31

Standardised roles for managing knowledge consistently, such as community
stewards, KM leads, and others.
Training on appropriate KM topics to build awareness and competency of
individuals in the organisation.
Mindsets and behaviours which value the knowledge of the organisation as
an asset (e.g., capturing and sharing lessons, seeking to leverage prior
knowledge)
Best practices to enable effective and sustainable KM.

Structured = Standardised and inclusive of people, process, technology, and governance
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The capabilities and corresponding mapping of KM methods and tools presented in
Table 8-1 and Table 8-2 above is preliminary in nature and based on the experiences of
the researcher. While an in-depth study was conducted for technology transfer (Chapter
6 and Chapter 7), resulting in the KTE Framework and KTE Toolkit, defining additional
requirements for the other three lifecycle stages (i.e., product development,
commercial manufacturing, and product discontinuation) would further expand this
research and suitable frameworks for the other three stages could be developed.

8.2 RKI Cycle application to change management during commercial
manufacturing stage (Example 2)
While the previous section on managing knowledge across the product lifecycle
illustrated an end-to-end application of the RKI Cycle, this second example focuses more
in depth on change management during commercial manufacturing.
Commercial manufacturing is typically the longest stage of the product lifecycle and as
such provides an abundance of opportunities for knowledge capture, flow, and
application across numerous activities. ICH Q10 lists four PQS elements (ICH, 2008) that
are substantially dependent on the application of QRM and KM, as Process Performance
and Product Quality Monitoring, Corrective Action / Preventative Action (CAPA), Change
Management and Management Review of Process Performance and Product Quality.
Effective change management is central to the achievement of one of the objectives of
ICH Q10, being the objective of continual improvement. Thus, change management was
selected as an appropriate element to illustrate the application of the RKI Cycle, as it is
the element that is typically the most standard across companies.
The triggers for change management may vary as described in a recent PIC/S
recommendation paper (PIC/S, 2019), which lists examples of potential change triggers
(or reasons to raise a change proposal), as follows:
•
•
•

Upgrades to equipment or facilities
Improvements in raw materials
Improvements in manufacturing performance and consistency (to reduce
variability, improve yield, etc.)
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•
•
•

Enhancements in manufacturing capacity
Corrections of quality issues
Addressing signals from the PQS such as deviations, complaints/adverse events,
corrective action and preventative action (CAPA), product quality review,
operational review metrics, management review, new regulations, compliance
gaps, implementing innovation, or continual improvement initiatives

The list above gives a diverse range of reasons for triggering a change. Some changes
are evidence-based, supported by existing process and product knowledge. However,
others, particularly those proposing new or innovative changes, may have a level of
uncertainty and, consequently, will rely more on QRM for successful outcomes
(Mulholland and Greene, 2020). At a practical level, these differences mean that the
change proposals can commence at different nodes on the RKI Cycle.

Figure 8-4 – Potential 'entry points' for the RKI Cycle

To demonstrate this, four change triggers were evaluated and their ‘entry points’ on the
RKI Cycle are determined as follows:
•
•
•
•

Novel, new or innovative changes: entry at node 1
A risk control failure: entry at node 3
Introducing a Disruptive or Transformational Technology: entry at node 4
Continuous Improvement or Process Optimisation: entry at node 6
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An example of each was reviewed via a case study, which is available in the referenced
webinar (Lipa and Mulholland, 2021) and upcoming paper.
For the purpose of this thesis, the first case study which was for a novel, new or
innovative change, is presented below.

Case Study 1
Novel, new or innovative
changes:
Entry at Node 1

A change enters at the earliest point in the RKI Cycle. This is the entry point for
anything new, novel, or innovative. This is because, while the change proposal will be
supported by a certain amount of information, probably of external origin, there will
usually be a deficit of tacit knowledge about the ‘to-be’ process within the
organisation, leading to uncertainty and risk. The impact on the current and future
states must be fully understood in order to approve the change and to have a
controlled implementation plan. The change proposal must be supported by a quality
risk management process to identify the hazards, understand their significance, and
establish the correct risk controls. This requires the application of the complete RKI
learning cycle, starting with knowledge-driven risk assessments, where knowledge is
an input to those risk assessments.
Example: Company X identifies an improvement opportunity based on changing an
in-process test method. The ‘new’ method will reduce the cycle time between
sampling and result. The proposed method is an established technology in other
industries. Therefore, there is a volume of literature on its application and the
supplier of the technology can supply training and technical support. However, it is
‘new’ to this operation and process. There is concern whether the data produced by
the new technology will be readily interpretable with respect to product and process
control, and whether the higher sensitivity of this technology will result in unknown
outcomes and unforeseeable results. These are uncertainties that represent real
hazards and concerns.
In this case, the change proposal should be treated with the full RKI Cycle, from the
initial starting point (node 1). QRM will establish the hazards and risks that must be
controlled. It will evaluate the likelihood of those hazards occurring, the risk levels
associated with them and the appropriate controls and/or responses. Any concerns
or uncertainties that are deemed to be unacceptably high will require further
research or off-line studies to resolve. (Nodes 1-3 on RKI Cycle). The change proposal,
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when approved, will be implemented with a supporting implementation and
monitoring plan to ensure that knowledge and understanding are gained, evaluated,
and used to refine or improve the implementation plan, where necessary. (Nodes 46 on the RKI Cycle).

8.3 The RKI Cycle as a mechanism for data analytics to reduce risk (Example 3)
A third example of applying the RKI Cycle involves data analytics. This opportunity was
realised when the researcher was invited to present at the launch of the Guide to Data
Analytics for Pharmaceutical Manufacturing (PMTC, 2020) by the Pharmaceutical
Manufacturing Technology Centre. The paper introducing the RKI Cycle (Lipa, O’Donnell
and Greene, 2020a) is cited by this PMTC guide, and in preparing for the speaking
engagement (Lipa, 2020b) the researcher reflected on the role the RKI Cycle could play
as a mechanism for data analytics to generate knowledge and enable risk reduction. The
PMTC guide acknowledges such a need, stating:
Data and data analytics are drivers for knowledge and knowledge generation,
and can support KM and QRM systems, which should better inform risk
management activities.
Furthermore, the PMTC guide states:
Data becomes knowledge through the vehicle of data analytics. Knowledge is a
critical milestone that can be integrated and built upon to develop process
understanding. Value is realised through such understanding.
This can be envisaged through a common representation linking data, information, and
knowledge (Figure 8-5) as presented to PMTC (Lipa, 2020b). This figure, adapted from
work by Rowley (Rowley, 2007) and Kane (Kane, 2018), represents the ‘top’ of the
pyramid as insight & understanding, created starting from data and information
contextualisation to create knowledge, and then from knowledge application through
insight and understanding to support evidence-based decision making. Data analytics
is a means of contextualisation of data.
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Evidence-based
decision making

Figure 8-5 – Data, Information, & Knowledge in support of evidence-based decision making

Relating this to the RKI Cycle, the focus of node 4 is to acquire, grow, capture, and retain
new knowledge. It is here that new knowledge derived from data analytics should be
injected into the cycle so that this knowledge becomes effectively managed and made
visible and available via nodes 5 and 6 (Figure 8-6). This knowledge can then be applied
to risk management via nodes 2 and 3 to support evidence-based decision making.

Figure 8-6 – Data analytics can inject new knowledge into the RKI Cycle

Further details linking data analytics, knowledge, and risk reduction are available in the
presentation at the PMTC data analytics guide launch (Lipa, 2020b) and are discussed in
Chapter 10.
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While the pyramid shown in Figure 8-5 is often cited to descriptively relate data,
information, and knowledge, this example application is about the ‘vertical integration’
of this pyramid (i.e., via data analytics to provide context to data and create knowledge),
which has not been extensively studied. Further study on this is an opportunity
highlighted in Chapter 12 of this thesis.

8.4 Summary – RKI Cycle application across the product lifecycle
As these examples illustrate, there are many potential applications where the RKI Cycle
can be applied to relate and connect important activities throughout the PQS elements
and across the product lifecycle. The researcher believes this is just the beginning of
how the RKI Cycle can be used in this manner; the RKI Cycle has the opportunity to
become a central, integrating framework with seminal impact for the industry and can
lead to improved risk- and evidence-based decision making.
Chapter 9 follows describing an exploration into the concept of a knowledge culture as
a means to define mindsets and behaviours for an organisation to excel in effectively
managing knowledge across the lifecycle and further accelerate the impact of the RKI
Cycle.
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Chapter 9: Knowledge Culture as a Catalyst to Accelerate RKI
Cycle Adoption and Impact
Having presented the RKI Cycle, with examples of its application across the product
lifecycle, this final chapter in this part of the thesis explores a key factor: knowledge
culture.

Understanding and addressing the current organisational barriers to

widespread KM adoption was an important factor in unlocking knowledge for use across
the product lifecycle.
Organisational culture32 is a major barrier to change in many organisations. While there
are many aspects to the culture of an organisation, this chapter focuses on exploring
what a knowledge culture could be for the pharmaceutical industry. Industry-specific
insights on the concepts of quality culture and cultural issues that act as barriers to KM
are explored, including a view to understanding how they impact the RKI Cycle. A
formative knowledge culture position for an organisation is proposed by the researcher
with the intent of initiating dialogue and future research on the topic.

9.1 Attributes of quality culture
When developing a position of what a knowledge culture could look like for a
pharmaceutical organisation, the researcher started first by exploring quality culture as
a theme, as it has received significant attention in recent years. A 2014 survey by
Corporate Executive Board (CEB), Creating A Culture of Quality (Srinivasan and Kurey,
2014), identified substantial savings opportunities for a company with a highly
developed ‘culture of quality’ where an average savings of $350 million per year could
be gained as a result of not having to fix mistakes. The survey authors concluded that
only four attributes need to be reviewed to actually predict a culture of quality:
Leadership Emphasis, Message Credibility, Peer Involvement and Employee Ownership,
as described in Table 9-1.

32

An organisation's culture consists of shared beliefs and values established by leaders and
communicated and reinforced through various methods, ultimately shaping employee mindsets and
behaviours for how to act. Organisational culture sets the context for everything an enterprise does
(adapted (SHRM, 2021))
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Table 9-1 – The four essentials of quality as per 2014 CEB Culture of Quality Survey (Srinivasan
and Kurey, 2014)
Attribute
Leadership
Emphasis
Message Credibility

Peer Involvement

Employee
Ownership

Description
Managers are told that quality is a leadership priority. Managers
‘walk the talk’ on quality. When evaluating employees, bosses
emphasise the importance of quality.
Messages are delivered by respected sources. Workers find that
communications appeal to them personally. Messages are
consistent and easy to understand.
Most employees have a strong network of peers for guidance.
Peers routinely raise quality as a topic for team discussion. Like
members of a sports team, peers hold one another accountable.
Workers clearly understand how quality fits with the job. Workers
are empowered to make quality decisions. Workers are
comfortable raising concerns about quality violations and
challenging directives that detract from quality.

PDA published a Quality Culture Survey Report in 2015 (Patel et al., 2015) and identified
the top five attributes that can serve as surrogates for quality culture as:
•
•
•
•
•

Management communication that quality is everyone’s responsibility
Site has formal quality improvement objectives and targets
Clear performance criteria for feedback and coaching
Quality topics included in at least half of all-hands meetings
Collecting error prevention metrics

PDA have aggregated these results and other content related to quality culture and
launched a website dedicated to the topic, PDA Quality Culture – PDA Resources for
Developing a Mature Quality Culture (PDA, no date).
ISPE published a Cultural Excellence Report in 2017 (ISPE, 2017) describing quality
culture as follows (bold added for emphasis by the researcher):
Quality culture is a feature of organisational design that fosters cross-functional
ownership of quality. It treats quality not as a hindrance for success, but as a
necessity that allows the company to make decisions that best benefit patients
…Quality culture refers to the expressed and implied ways in which an
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organisation operates, affects quality performance and supply chain
excellence, and ensures patient-focused outcomes.
From these three sets of insights (i.e., from CEB, PDA and ISPE), there appears no evident
singular definition of quality culture, but clear themes emerge, including visible
leadership commitment, the omnipresence of quality outcomes in all actions, the
active engagement of all staff, and of the importance of related mindsets, attributes
and cultural enablers.

9.2 Attributes of a culture effective in managing knowledge
To understand what a culture effective in managing knowledge could look like (i.e., a
knowledge culture), the researcher also found it was helpful to start by understanding
cultural issues that act as barriers to use and adoption of knowledge management and
their impact to the RKI Cycle. Literature on barriers to KM was also reviewed.

9.2.1 Cultural attributes that act as barriers to KM in the pharmaceutical industry
The Knoco Survey on Knowledge Management 2020 (Knoco, 2020) included a question
on barriers to KM. Cultural issues was one of eight choices given, and it ranked as the
highest barrier to KM, with more votes for it than for lack of prioritisation and support
from leadership, lack of KM incentives, lack of KM roles and accountabilities, lack of
defined KM approach, and three additional barriers. Similarly, in the pharmaceutical
industry-specific KM implementation survey published by ISPE in May 2020 (Kane et al.,
2020), cultural issues also ranked as the top barrier, tied with lack of prioritisation and
support from leadership, from a list of the same potential barriers.
Both surveys went a step further and also asked a question on specifically which cultural
issues have proven to be barriers from 10 provided choices. The choices of cultural
issues as barriers were the same in both surveys. Table 9-2 created by the researcher
summarises the top five cultural issues from each of the two surveys.
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Table 9-2 – Top cultural issues as barriers to KM
Barrier Rank

Knoco Survey (Knoco, 2020)

ISPE Survey (Kane et al., 2020)

1

Short term thinking*

Short term thinking*

2

Lack of openness to sharing*

Lack of performance drive

3

Secrecy

Lack of acceptance of new ideas

4

Lack of challenge to the status quo

Lack of honesty in sharing

5

Lack of empowerment

Lack of openness for sharing* (tie)
Preferring invention to reuse (tie)

*Items in bold were identified as top 5 barriers in both surveys

Only the top five barriers were selected (of 10 total choices) to allow for simple
prioritisation, and there was also an evident gap between the barrier five and the next
highest-ranked barrier in both surveys, which supports this rationale. On review of the
results, short-term thinking is a clear cultural issue, ranking as the top barrier in both
surveys. Lack of openness to sharing is the other cultural issue that ranked in the top
five of both surveys. Selecting these two barriers and for the purpose of this research,
the additional barriers from the ISPE survey with its specific focus on the pharmaceutical
industry, a prioritised list of six cultural issues facing KM in the pharmaceutical industry
is proposed as follows:
•
•
•
•
•
•

Short term thinking
Lack of openness for sharing
Lack of performance drive
Lack of acceptance of new ideas
Lack of honesty in sharing
Preferring invention to reuse

Furthermore, the researcher in his professional experience has witnessed each of these
cultural issues as barriers to KM; with this in mind, the next section explores the impact
these six cultural issues can have on adopting the RKI Cycle.

9.2.2 The impact of cultural issues on the RKI Cycle
Considering the overarching goal of the RKI Cycle is to connect the disciplines of QRM
and KM to ensure the best possible knowledge supports the best possible risk-based
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decision, one can immediately see by mapping the six cultural issues onto the RKI Cycle
how they can be barriers to supporting optimal QRM and KM (Figure 9-1).

Figure 9-1 – Cultural issues as threats to the RKI Cycle (illustrative)

Although each cultural issue is likely to impact multiple steps of the RKI Cycle, Figure
9-1 highlights illustrative examples. For example, at RKI Cycle node 3, if short-term
thinking is prevalent, knowledge associated with risks and through their risk
assessments may not be captured optimally for future reuse. Short-term thinking has
also been identified as a cultural barrier for effective KM (node 5) and can impact
capturing sufficient context for future use during QRM (node 2). Lack of a performance
drive will impact continuous improvement at node 6. If there is lack of openness or
honesty in sharing, the best available knowledge of the organisation certainly is not
flowing into QRM activities (nodes 1 and 2).
These cultural issues almost certainly impact QRM and other processes as well. The
culture of an organisation – which starts with values and manifests in mindsets and
behaviours – is not confined to KM alone, but is rooted across many, if not all, processes
within an organisation.
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9.2.3 Cultural attributes that are supportive of KM in the pharmaceutical industry
When exploring cultural attributes that are supportive of KM, a literature review
revealed insights into the meaning of a ‘knowledge culture’. Oliver and Kandadi (Oliver
and Reddy Kandadi, 2006) on a study of literature propose the following definition of
knowledge culture:
A way of organisational life that enables and motivates people to create, share
and utilise knowledge for the benefit and enduring success of the organisation.
Oliver and Kandadi then identified 10 factors which influenced the development of
knowledge culture in large, distributed organisations as follows:
1. Leadership
2. Organisational structure (to include knowledge management roles (as opposed
to knowledge management jobs))
3. Evangelisation (of the value of knowledge management activities to employees)
4. Communities of practice
5. Reward systems
6. Time allocation
7. Business processes (through embedding knowledge management in important
knowledge intensive processes)
8. Recruitment (through consideration of knowledge sharing etiquette of potential
employees)
9. Infrastructure (e.g., knowledge portals)
10. Physical attributes (e.g., office layout)
The researcher found the proposed definition insightful, although in the opinion of the
researcher, the factors, while entirely valid, are more ‘physical’ or ‘environmental’ than
behavioural-based. Milton and Lambe (Milton and Lambe, 2016) proposed a model
consisting of 10 dimensions to an organisational learning and knowledge management
culture summarised by the researcher in Table 9-3. Dimension 1 (supportive) is
associated with learning culture and knowledge-valuing behaviours (e.g., open), and
Dimension 2 (detracting) represents the antonym (e.g., defensive).
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Table 9-3 – Organisational learning / Knowledge management culture dimensions (Milton and
Lambe, 2016)
Dimension 1
(Supportive)

Dimension 2
(Detracting)

Open

Defensive

Honest

Dishonest

Empowered

Disempowered

Learner

Knower

Need to share

Need to know

Challenge

Acceptance

Collaborative

Competitive

Remembering

Forgetting

Strategic
patience

Short-termism

Relentless
pursuit of
excellence

Complacency

Definition (abridged)
The extent to which people feel comfortable having their
performance (including mistakes) analysed for learning
purposes.
The extent to which people will filter knowledge and
information when communicating with peers or senior
leaders; sometimes known as ‘transparency’.
The extent to which people feel able to act on knowledge,
independent of approval from their leaders.
The extent to which people put a value on acquiring new
knowledge.
The extent to which people offer their knowledge to others
rather than keeping it secret.
The extent to which people seek to understand why things
are the way they are; about intellectual curiosity and
challenge the status quo.
The extent to which people identify with and share in the
success of others.
The extent to which people acknowledge and incorporate
the past when making plans for the future and the extent to
which they consciously record decisions, judgments,
knowledge, etc. for future reference.
The extent to which people consider the ‘bigger picture’ and
try to understand how their actions fit into the broader
organisational vision.
The extent to which organisations acknowledge there is
always room for improvement.

Finally, ISO 30401 Knowledge management systems – Requirements addresses
knowledge management culture in Annex C (ISO, 2018) as follows:
Knowledge management culture is a supportive element of the organisational
culture. A culture where the behaviours of seeking, sharing, developing and
applying knowledge are encouraged and expected supports the establishment
and application of the knowledge management system within the organisation.
There is also a personal dimension to a knowledge management culture, where
ultimately each individual has responsibility to demonstrate commitment
through their own behaviour and interactions. A knowledge management
culture acknowledges the value of individual and shared knowledge, as it
benefits the organisation.
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These insights were considered in the following section in the development of a
proposed ideal knowledge culture for the pharmaceutical industry.

9.3 A proposed ideal ‘knowledge culture’ for the pharmaceutical industry
The researcher, having reflected on a philosophical dialogue with a senior leader
responsible for pharmaceutical product commercialisation, proposed a knowledge
culture must be engrained in an organisation much like that of a safety mindset: safety
is everyone’s responsibility, not just those who report into the safety organisation. The
same analogy holds true for quality and should also be adopted for managing
knowledge. Ensuring safety in everything one does, building in quality, and managing
knowledge are each ways of working, formed by how people think and act (i.e.,
mindsets and behaviours) in the organisation, which is a key component of an
organisational culture. Furthermore, these ways of working are not unique to safety,
quality, or managing knowledge but can be synergistic with each other. For example,
using KM processes to reflect after a safety incident or connecting quality risk
management practitioners in a community of practice built on KM best practices. In the
opinion of the researcher, it is the convergence of these ways of working where
organisations can create clarity for their staff in how they are expected to act on a daily
basis, rather than having distinct sets of behaviours across many topics (e.g., safety,
quality, knowledge management, diversity & inclusion, operational excellence, etc.).
The researcher explored how the convergence of these ways of working could evolve
by applying the insights gained in the previous sections, including the definition of
quality culture (section 9.1), the top cultural issues facing knowledge management
(section 9.2.1), the literature review on knowledge culture (section 9.2.3), and the
researcher’s professional experience. A formative definition of knowledge culture was
proposed as follows:
A knowledge culture is one that demonstrates excellence in applying the best
knowledge through an inherent bias to continuously reflect, learn, improve,
share, grow, and transfer knowledge in order to positively affect quality
performance, supply chain excellence, and ensure patient-focused outcomes.
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This definition covers the what and the why of a knowledge culture. How such a
knowledge culture might be achieved can also be benchmarked from the recurring
themes in the definitions of quality culture, described through four attributes as follows:
•
•

•
•

Visible leadership commitment to establish a vision, set expectations, and to
create organisational alignment.
Managing knowledge as a way of working is linked to the organisation’s
strategic objectives, delivering value in quality, operational benefits, and
organisational and individual development opportunities.
Active engagement of all staff, through application of organisational change
management techniques.
Well communicated mindsets and behaviours (as informed by the top cultural
issues identified in section 9.2.1), reinforced by reward systems
o Big picture thinking
o Seeking and sharing ‘by default’
o Pursuit of excellence (including to pause, reflect and learn)
o Embracing inclusion and innovation
o Leading with transparency
o Managing knowledge as an asset

An early illustration of this knowledge culture proposal is given below in Figure 9-2.

Thinking
Big Picture

Managing
Knowledge as
an Asset

Improved risk-based
decision making
and operational outcomes
Seeking &
Sharing
“by default”

Active engagement
by all staff
Leading with
Transparency

Visible leadership
commitment to
set expectations
and create
organizational
alignment

Pursuing
Excellence

Embracing
Innovation

Figure 9-2 – The researcher's view on knowledge culture for the pharmaceutical industry
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This proposal of a knowledge culture is preliminary in nature and is based on two key
assumptions: the validity of the definition of a quality culture and the accuracy of the
cultural barriers facing KM in the pharmaceutical industry. Further insight will be gained
as the industry advances in quality culture and these learnings in what quality culture is
and how it is achieved can inform the journey on knowledge culture. In regard to
advancing the understanding of the cultural barriers to KM, this could be through
additional data gathering (e.g., surveys) as well as feedback during application of the
RKI Cycle and other outputs of this study.
Lastly and most importantly, any such knowledge culture needs to be adapted to fit the
specifics of an organisation, including alignment with the mission of the organisation
and consideration of the current organisational culture. Although well-suited for this
study, this is certainly a topic which warrants further research.

9.4 Summary – A proposed ‘knowledge culture’ for the pharmaceutical
industry
Imagine an organisation where such a knowledge culture exists and can bring to bear
the power of the collective knowledge of the entire organisation to innovate, solve
problems, and make the most informed risk-based decisions. Indeed, such a culture
would be a catalyst for RKI Cycle adoption and acceleration of its impact. Patients, as
stakeholders of the product produced by the industry should not expect any less,
especially as they await innovative new therapies for unmet medical needs or face
product availability issues for critical therapies they depend on.
Chapter 10 which follows provides a review of outputs, outcomes and impacts of this
study.
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Part Four: Outcomes and Impact, Conclusions, and Opportunities
for Future Research
Part Four brings this research study thesis to a close by:
•

Examining outputs, outcomes and impact (Chapter 10)

•

A review of conclusions drawn from the research findings (Chapter 11)

•

Presenting opportunities for future research (Chapter 12)
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Chapter 10: Outputs, Outcomes, and Impacts of this Research
Study
The purpose of this chapter is to describe the outputs, outcomes, and impacts of this
research study (where applicable and known at the time of writing this thesis) as related
by Figure 10-1 (UCD, no date).

Figure 10-1 – The link between inputs and impacts (UCD, no date)

The approach at the outset of this study was to regularly consult and seek opinions and
insights of various stakeholders across the pharmaceutical sector with the research
activities to ensure the research was focused on problems that ultimately have an
impact to the patient. This approached worked well for this study.
This study used a mixed methods approach and resulted in a series of outputs, the
majority of which were disseminated in peer-reviewed papers and discussed in previous
chapters of this thesis. These outputs include:
•
•
•

•

Knowledge Management Process Model (Chapter 4)
RKI Cycle (Chapter 5) and related contexts and concepts derived from this
framework (e.g., RKI Cycle as applied to ICH Q10) (Chapter 5 and Chapter 8)
KTE Framework and KTE Toolkit (Chapter 7), including the related outcomes of:
o A current state assessment of knowledge transfer during technology
transfer (Chapter 6)
o Processes for tacit knowledge transfer (Chapter 7)
Case studies for extending the RKI Cycle and mapping KM methods and tools
across the product lifecycle (Chapter 8)
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These outputs were disseminated in many fora through a variety of methods (e.g.,
papers, presentations, direct dialogue, formal/informal interviews, etc.) with sector
stakeholders through an equally diverse set of channels (e.g., industry groups, advisory
boards and committees, etc.), as illustrated in Figure 10-2.

Channels of research dissemination

Methods of research dissemination

(with whom research was disseminated)

• Total papers (as lead author): 10
• Peer-reviewed journal articles: 6
• Additional papers (case studies & survey reports): 4
• Works as a co-author: 3
• Conference presentations: 6
• Book Chapter: 2
• Panelist: 7
• Poster Session: 1
• Podcast & Webinar*: 2
• Industry Guidance: 2
• Guest lectures (Columbia + TU Dublin): 2
• Advisory Board invitation: PDA Regulatory Affairs &
Quality Advisory Board: 1
• Surveys: 2

•
•
•
•
•
•
•
•
•
•
•
•

ISPE
PDA
IVT Network
Biophorum
KENX
PharmTech
PMTC
PIC/S QRM Expert Circle Coordinating
Committee
Technological University Dublin
Columbia University
Interviews (regulatory authorities, industry
leaders & SMEs)
TU Dublin PRST

*Webinar is scheduled for 20-May-2021

Figure 10-2 – Methods and channels of study dissemination

This approach has resulted in a high level of interaction with sector stakeholders on
most every facet of this research study, allowing immediate outcomes and impacts of
the study to be observed. Perhaps as a consequence of this approach, the research
study and associated outputs have generated noteworthy media attention in recent
months. The first example is from the EU-based GMP Verlag Peither AG, who publishes
GMP news for the industry and featured the researcher’s 2021 PDA Annual Meeting
presentation (Lipa, 2021a) in a feature titled Innovations in Pharmaceutical
Manufacturing (Peither, 2021). This GMP Newsletter article featured only 4 of the 38
presentations given at the conference. The second and perhaps more significant media
attention was that from International Pharmaceutical Quality (IPQ), entitled Regulators
Are Exploring with Industry How to Strengthen Quality Risk Management Practices, with
Revision of ICH Q9 a Key Focal Point (IPQ, 2021). One part of this article was entitled
Industry / Academia Research on QRM/KM Relationship which featured several key
outputs from this research study, including the RKI Cycle and KTE Framework.
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To demonstrate the significant outcomes and impacts, the researcher grouped them
into five major themes, recognising the themes are not mutually exclusive and some
overlap exists. Furthermore, any given output may affect more than one theme. These
five themes are as follows:
1. A framework to address the untapped synergy between QRM and KM
2. Inaugural industry guidance on KM from a premier industry association
3. A comprehensive framework and toolkit for knowledge transfer during
technology transfer, inclusive of tacit knowledge
4. A mechanism for data analytics to grow knowledge and reduce risk
5. Impact across the entire PQS
The outputs of the research grouped under these themes are discussed in the following
sections of this thesis, with associated outcomes and impacts, as applicable and known.

10.1 Theme 1: A framework to address the untapped synergy between QRM
and KM
Arguably the most exciting outcome of this research study is the progress on the
relationship between QRM and KM, perhaps already of seminal importance given the
preliminary response from stakeholders across the pharmaceutical sector. This focus
on the QRM-KM intersection marked novel research for the industry in moving beyond
the concepts presented in ICH Q10 to look more holistically across the regulatory
guidance landscape at the relationship between knowledge and risk, and knowledge
management and risk management. A key finding as explored in Chapter 5 was that
there is near universal agreement that QRM and KM are highly interdependent yet
there was broad agreement that they are only partially connected at best. This suggests
there is an important gap to be filled to show how QRM and KM co-enable the PQS and
lead to the best possible risk reduction for patients. In response to this, an output of
this research is a framework, the RKI Cycle (Figure 5-6), which illustrates the relationship
between risk and knowledge and demonstrates how QRM and KM are connected. As
detailed in Chapter 8, outcomes of this framework are presented as examples and case
studies which illustrate the broad applicability and importance of the RKI Cycle across
the product lifecycle, and to the four elements of the PQS (e.g., change management,
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etc.) proposed in ICH Q10 (ICH, 2008). The RKI Cycle was published in a peer-reviewed
journal and was considered to be a significant contribution and of enough importance
to potential stakeholders, that a regulator successfully petitioned the journal to allow
open access to the paper to ensure broad global reach and dissemination. It was further
made available openly with permission from the peer-reviewed journal through the TU
Dublin Level3 journal (Lipa, O’Donnell and Greene, 2020b).
This framework has been greeted with great interest and support across the
pharmaceutical sector. One example of this is found in the results of a survey (Lipa,
O’Donnell and Greene, 2021) to industry and regulators33, summarised in the following
points:
•

When asked if the RKI Cycle was helpful as a means of depicting the relationship
between QRM and KM 84% agreed the framework was helpful, and only 9%
disagreed.

•

When asked “Would you support deploying such a framework within your
organisation, in pursuit of better integration of QRM and KM?”, 92% of industry
respondents answered Yes, while 0% answered No (8% answered Not sure).

•

When regulators were asked “Can you envisage companies deploying this
framework within their organisations?” 83% of regulators answered Yes, while
0% answered No (17% answered Not sure).

•

When asked to identify and rank benefits (impacts) of improved QRM-KM
integration, there was acknowledgement that many important benefits could
follow. Table 10-1 lists the top five potential benefits of improved QRM-KM
integration identified by each industry and regulator participants. The top two
ranked items (in bold) were aligned across both sets of participants.

33

The ‘regulator’ responses cited in the survey report represent the opinions of six members of the
PIC/S QRM Expert Circle Coordinating Committee as of 21-February-2021, and do not represent the full
view of the Coordinating Committee nor of the wider PIC/S organisation.
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Table 10-1 – Top ranked potential benefits (impacts) of RKI Cycle
Rank
1
2

Top 5 Benefits (impacts) identified by Top 5 Benefits (impacts) identified by
industry participants
regulator participants
Better risk-based decisions –where
decisions are informed by risk and
knowledge
More data/knowledge-driven risk
assessments

3

Increased ability to leverage off of prior
knowledge

4

Improved control strategies –which
better reflect risk and knowledge

5

Improved PQS effectiveness –where an
integrated approach to risk and
knowledge supports decision making,
validation, change management, outsourcing, etc.

Better risk-based decisions –where
decisions are informed by risk and
knowledge
More data/knowledge-driven risk
assessments
Improved PQS effectiveness –where an
integrated approach to risk and
knowledge supports decision making,
validation, change management, outsourcing, etc.
Improved protection and value for
patients –reduced risks of defects, drug
shortages, etc.
A better ability to deal with advances in
manufacturing which utilise big-data,
automation, artificial intelligence, etc.

•

When asked about improvement opportunities of the RKI Cycle, the main
suggestion was the interest in more detail through examples, case studies, etc.

•

Open-ended feedback was solicited and was generally supportive, in alignment
with the preceding highlights. Illustrative open-ended comments include:
o It is a simple and very useful graphic of the inverse relationship between
risk and knowledge.
o This Infinity loop is intuitive, easy to comprehend, and logical.
o It visually clarifies the interdependency of both QRM and RM.
o The linkage is [quite] clear to me. Knowledge informing risk and risk
informing knowledge as a continuous process makes great sense.
o KM is not well in practice today as compare to QRM could be a reason for
just partial integration.
o It explains very clearly how they are related and need to stay connected
through long lifecycle in a constant state of learning and inertia.
o Great work that will catalyse new thinking in this important area.

Perhaps the most important impact will be the opportunity the RKI Cycle presents to
improve QRM-KM integration. While the effort to apply the RKI Cycle has commenced
and is discussed in Chapter 8, the researcher recommends additional stakeholder
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guidance be developed to support implementation and move more quickly towards
patients fully reaping the benefits of this important output.
In addition to the results of the survey, evidence of the RKI Cycle’s immediate influence
on industry stakeholders can be seen through interactions by the researcher with
multiple industry associations as follows:
•

The RKI Cycle is one of many outputs of this thesis featured in the ISPE Good
Practice Guide for Knowledge Management in the Pharmaceutical Industry (ISPE,
2021b) as described in section 10.2. Furthermore, the RKI Cycle is featured as
an element of the ISPE Guide cover artwork, which underscores the importance
as viewed by industry KM SMEs authoring the ISPE Guide.

•

The researcher presented several elements of this research study at the 2021
PDA Annual Meeting (Lipa, 2021a). This sparked significant interest from PDA,
including a request to re-broadcast the recorded presentation to other
geographic regions. Most notably, the PDA Regulatory Affairs and Quality
Advisory Board (RAQAB) requested the researcher to attend the April 2021
board meeting to brief the board on the research and propose how PDA might
advance the topic of KM for their membership. The researcher obliged, and
provided a briefing (Lipa, 2021b). The main outcome of the PDA RAQAB meeting
was that the board better understood KM and its criticality to QRM, and as a
direct result of this briefing, PDA RAQAB is currently in the process of proposing
a Task Force to develop a ‘long range plan’ for KM, of which the researcher has
already been invited to participate (and possibly lead). A key deliverable of such
a Task Force is likely to include a Technical Report on Knowledge Management
(i.e., an additional industry guidance document).

•

The RKI Cycle has also been cited by the recently published Pharmaceutical
Manufacturing Technology Centre (PMTC) Guide to Data Analytics for
Pharmaceutical Manufacturing (PMTC, 2020), given its relevance to translating
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information from data analytics into knowledge and applying this knowledge to
reduce risk.
A final point of relevance for the RKI Cycle was made by Dr. Edward Hoffman, retired
Chief Knowledge Officer from NASA. Dr. Hoffman participated in the Confirmation
Examination for the researcher in November 2020. During the discussion following the
confirmation exam, Dr. Hoffman provided supportive feedback for this model and
acknowledgement of the underlying challenges in connecting risk management and
knowledge management based on his experiences at NASA. Dr. Hoffman remarked:
I love the model – I love the connection between risk and knowledge. I’ve always
seen it. It’s essential. For 20 years I’ve been stunned by the lack of connection
between QRM and knowledge, and partly is that there are so many silos in
organisations.
These insights by Dr. Hoffman were important as they verified the fundamental
underlying assumption of the importance of connecting risk and knowledge, and
furthermore that Dr. Hoffman had witnessed similar challenges in another highly
technical and complex industry.
The strong interest, supportive feedback, and potential for significant impact of the RKI
Cycle appears evident through these early reactions across the sector stakeholders,
even though the RKI Cycle was published barely six months prior to the submission of
this thesis. The researcher is delighted with this response and the dialogue it has
created within the sector. Future work is planned and will be discussed in Chapter 12.

10.2 Theme 2: Inaugural pharmaceutical industry guidance on KM from a
premier industry association
Perhaps the most visible, tangible, and immediate outcome of this research is the
inclusion of significant elements of it in an upcoming pharmaceutical industry guidance
document on knowledge management from a premier industry association, ISPE. ISPE
‘is the world’s largest not-for-profit association serving its members by leading
scientific, technical, and regulatory advancement through the entire pharmaceutical
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lifecycle’ (ISPE, 2021a). ISPE has over 18,000 members in 90 countries (ISPE, 2021c) and
produces industry guidance documents as characterised by the ISPE website (ISPE,
2021d):
Produced by pharmaceutical manufacturing industry professionals, ISPE
Guidance Documents provide the practical, "real world" information you need to
help your company build on current best practices to meet and exceed regulatory
standards…Reflecting current regulatory expectations and best practices, Good
Practice Guides (GPGs) help to narrow interpretation of regulatory standards for
improved compliance and quality, efficiency, and cost reductions. They typically
focus on the “how”.
These guidance documents are created through a robust process including authorship
by a team of SMEs, industry review and feedback, and internal ISPE processes for quality
control.

This new guidance document, ISPE Good Practice Guide, Knowledge

Management in the Pharmaceutical Industry, was published in May 2021 (ISPE, 2021b).
As mentioned in Chapter 4 (section 4.1,) the researcher was a member of the team of
SME authors of this ISPE Guide on KM, comprised of 10 industry SMEs on knowledge
management.
While the overall guide itself was not a direct output of this research, this research study
significantly informed and shaped the ISPE Guide and was instrumental in addressing
industry feedback. In particular, the Knowledge Management Process Model, an output
of this research introduced in Chapter 4 of this thesis (Figure 4-2), plays a central role in
the ISPE Guide and is featured as a standalone chapter in the Guide (Chapter 4).
Consistent with the intent of the ISPE Guide, this Knowledge Management Process
Model provides a previously missing ‘how’ to facilitate understanding and application
of KM. In all, a total of seven outputs from this research study are featured in the ISPE
Guide, as listed in Table 10-2.
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Table 10-2 – Thesis outputs used by ISPE Good Practice Guide: Knowledge Management
ISPE Guide
Reference
Figure 2.3
Section 2.1.3
Figure 4.1
Section 4.1
Figure 5.4
Section 5.2.2
Figure 5.1
Section 5.2.6
Figure 11.1
Appendix 5
Figure 14.1
Appendix 8
Figure 14.2
Appendix 8

Reference to output from this thesis
Figure 5-5 – Decreasing risk though increasing applied knowledge over time
Figure 4-2 – Knowledge Management Process Model
Figure 6-2 – Challenges associated with technology transfer knowledge
transfer
Table 8-1 – Stage-appropriate KM methods & tools across the product
lifecycle
Figure 5-6 – The Risk-Knowledge Infinity Cycle applied to ICH Q10
Figure 7-1 – The KTE Framework on a page *
Figure 7-2 – Technology Transfer Batch Execution Review

*A simplified version was used in the ISPE Guide, this version is available in the PDA article (Lipa, Greene
and Calnan, 2021)

Throughout the development of the Guide, it was not the researcher’s intention to selfadvocate or ‘market’ use of these outputs. Rather, as some on the ISPE SME author
team were aware of the ongoing research effort and research progress was being
regularly published, these inclusions were typically a ‘pull’ from the ISPE SME author
team members and were subsequently vetted through the full ISPE SME author team
and industry review processes34. During the review process, 258 comments were
received from 27 pharmaceutical industry and health authority representatives and
addressed by the SME author team.
These outputs used by the ISPE Guide cover a broad scope from this thesis, lending
further credibility and visible endorsement of this research study. The publishing of the
ISPE Guide will immediately make these outputs broadly visible and available to the
industry where its impact will become apparent over time.

34

ISPE Guides go through a robust guidance document process involving pharmaceutical industry
professionals. The Guides are authored by pharmaceutical industry representatives and subject matter
experts (SMEs). Once authored, Guides are reviewed and approved by pharmaceutical industry
representatives in the same subject matter but not the group who authored the Guide. (ISPE, 2021d)
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10.3 Theme 3: The first comprehensive framework and toolkit for knowledge
transfer during technology transfer, inclusive of tacit knowledge
This research study started with an initial focus on improving knowledge transfer during
technology transfer, in particular of tacit knowledge transfer, and one of the first
outputs of the research was a framework for enhanced knowledge transfer, the KTE
Framework. The research study started with the characterisation of the current state
of knowledge transfer during technology transfer. The results of this assessment,
published in a peer-reviewed paper (Lipa, Kane and Greene, 2019), verified that there
is little guidance for knowledge transfer overall, and almost none for tacit knowledge
(inclusive of ‘know-how’), leading to explicit knowledge transfer being only marginally
effective, and tacit knowledge as being somewhat ineffective. This paper subsequently
received recognition as the IVT 2020 Author of the Year Award (IVT Network, 2020), a
testament to the interest in and relevance of the topic.
The subsequent development of the KTE Framework (Figure 7-1), as detailed in Chapter
7, led to several meaningful interactions with stakeholders, including feedback sessions
with several pharmaceutical companies and a presentation at the 2020 PDA Europe
Quality & Regulations Conference (Lipa, 2020a) where the research insights on
technology transfer and knowledge transfer were shared. This presentation was well
received and triggered a request by the PDA SME team authoring a revision to PDA
Technical Report No. 65, Technology Transfer (PDA, 2014b) to solicit input for the PDA
Technical Report from the researcher on knowledge transfer. The revision of this PDA
Technical Report was being planned in 2019 and was a subject of the researcher’s
critique during the literature review, as detailed in Chapter 2 (section 2.3.2). The
researcher used this opportunity to influence the revision to the PDA Technical Report,
providing several comments for consideration, with a focus on improving knowledge
transfer and the recognition of tacit knowledge. This PDA Technical Report is still in
revision as of the date of this thesis, so the extent to which these comments are
incorporated is not yet known.
Also related to knowledge transfer and of great interest to the researcher is the subtopic
of tacit knowledge transfer. To this end another output of the study was the design and
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deployment by the researcher of new KM practices to focus on tacit knowledge transfer
as discussed in Chapter 7 (section 7.2) of this thesis. The results – captured as a case
study (Lipa, Kane and Greene, 2020) – are promising as they are shown to drive
proactive interventions and a significant reduction in deviations in the quality system
for the company involved in the case study. The impact of this was an immediate and
direct reduction of risk and improvement in right-first-time qualification batch
execution. This in turn benefited patients as this vaccine product was designated a
breakthrough therapy35 by the FDA, and successful on-time qualification meant patients
would have access to an important new therapy more quickly. Furthermore, there were
benefits to the company in the form of meeting cost and schedule commitments (as
well as avoiding reputational risk if delays were encountered).
Lastly, a late-breaking development for this research study is an unsolicited case study
of KTE Framework application. Upon reading the peer-reviewed article in the PDA
Journal of Science and Technology in which the KTE Framework was published (Lipa,
Greene and Calnan, 2021), a team from a Singapore manufacturing facility who had
previously been a receiving unit in a technology transfer created a matrix36 based on
their challenging experience with a technology transfer as shown in Figure 10-3.

35

Breakthrough Therapy designation is a process designed to expedite the development and review of
drugs that are intended to treat a serious condition and preliminary clinical evidence indicates that the
drug may demonstrate substantial improvement over available therapy on a clinically significant
endpoint(s). (https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approvalpriority-review/breakthrough-therapy)
36
The matrix in the figure has been anonymised to blind the identity of the organisation and the
associated product.
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Figure 10-3 – A gap assessment against the KTE Framework (case study)

The green boxes in Figure 10-3 (‘Gap Category’ as per included legend) depict the
knowledge transfer challenges identified by the researcher (e.g., knowledge leakage, as
detailed in Chapter 6, section 6.2.1). The blue boxes in Figure 10-3 (‘Principles’ as per
included legend ) depict the high-level requirements identified by the researcher (e.g.,
KT is guided by an intentional and robust plan, as detailed in Chapter 6, section 6.2.2).
Figure 10-4 highlights these linkages (in green and blue boxes respectively), mapped
back to the detailed requirements for a knowledge transfer framework as defined in
Chapter 6 (section 6.2.2), Figure 6-3.

150

Detailed Requirements for a Knowledge Transfer Framework

(2) Knowledge transfer is heavily
biased toward documents, while
tacit knowledge is not
methodically transferred

Ineffective Knowledge Transfer
during Technology Transfer
(both explicit and tacit
knowledge)

(3) Knowledge leakage as valuable
experience and learnings not
captured, recognized or
considered relevant
(4) Knowledge leakage due to lack
of structured and standardized
knowledge management
approaches
(5) Knowledge leakage through
loss of staff experience

(6) Context of the technology
transfer causing obstructed
knowledge flow

(I) Knowledge Transfer is guided by
an intentional and robust plan

(II) Knowledge Transfer is best
enabled by a culture that values
knowledge as an asset
(III) Standardized approaches for KM
are established both for explicit and
for tacit knowledge
(IV) Tacit knowledge is uncovered
and transferred during technology
transfer
(V) Knowledge transfer is measured
and results in an action plan to
address gaps and opportunities

A holistic plan for knowledge transfer
Tacit knowledge is recognized as important
Knowledge leakage is minimized through systematic
knowledge capture
Knowledge leakage is minimized through retention of
critical knowledge
Knowledge exists (it was created to begin with)
Knowledge is identified (a ‘known known’)

Knowledge
transfer processes

(1) Narrow Focus on the “golden
batch”

Knowledge to be Transferred

High Level Requirements
Drivers for effective Knowledge Transfer

Knowledge leakage minimized through standard KM
approaches

Knowledge flow enablers &
detractors

Challenges
more specific problem statements

Barriers / obstruction to knowledge flow recognized

Degree of
change

Problem Statement

Change recognized as a risk & learning opportunity

Standard KM processes followed
Standard KM processes are effective

Organizational pressure / motivations recognized
Capability & Competency of Receiving Unit known
Mindsets & behaviors for managing knowledge
KM processes ‘in the flow’ of work

Plan to capture / grow knowledge

Figure 10-4 – Mapping of KTE Framework case study to knowledge transfer framework
requirements

The Singapore manufacturing site contacted the researcher directly, as the researcher
was the corresponding author with contact details listed on the published paper. As the
KTE Framework was published only two months prior to this contact, this is clear
evidence of the research having an immediate, direct, and global impact on how people
view knowledge transfer during technology transfer. This is especially true as this case
study identified clear issues which demonstrate the need for why the framework was
created. The team in Singapore indicated to the researcher that they plan to develop a
knowledge management playbook for technology transfer based on the KTE Toolkit,
aligned with the researcher’s intended use.
As these examples demonstrate, the KTE Framework and associated KTE Toolkit as
outputs from this research study have already demonstrated tangible outcomes and
impact, including:
•

•

Increased awareness of the current issues with knowledge transfer and its
effectiveness, including looking at technology transfer through a knowledge
transfer lens
Improvements in quality and right-first-time outcomes through new tacit
knowledge-focused KM practices
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•

Influence on an additional industry guidance document (PDA Technical Report
No. 65, Technology Transfer (PDA, 2014b))

10.4 Theme 4: A mechanism for data analytics to grow knowledge and reduce
risk
Preliminary research into the link between data analytics and KM marks another area
of novelty in this research study. As described in Chapter 8 (section 8.3), the RKI Cycle
can act as a mechanism to connect data analytics to risk reduction. Currently the topic
of linking data analytics (a topic receiving significant attention recently due to the focus
on digital transformations in industry (CIO, 2018)), to KM and to QRM has not been well
defined.
The PMTC Guide to Data Analytics for Pharmaceutical Manufacturing (PMTC, 2020)
states:
data & analytics are central to informing quality systems … Data and data
analytics are drivers for knowledge and knowledge generation, and can support
KM and QRM systems, which should better inform risk management activities.
The description for Figure 6.1 from the PMTC Guide (PMTC, 2020) (Item A in Figure 10-5)
includes:
[Figure 6.1] highlights the quality systems and regulatory guidelines that enable
a state of control to be maintained during the product manufacturing lifecycle …
the figure shows data and data analytics as central to informing these quality
systems, which can provide even greater opportunity to ensure the safety of the
public health and patients.
The researcher, during his presentation at the launch of the PMTC Guide launch (Lipa,
2020b), demonstrated how the RKI Cycle can provide the missing mechanism for the
‘how’ to connect data and data analytics to KM and QRM to achieve these outcomes
(Item B in Figure 10-5).

152

A: Figure 6.1 from PMTC Guide
B: Alternate view proposed by researcher

RKI Cycle as a mechanism for
data analytics to
generate knowledge and
enable risk reduction

?

Figure 10-5 – RKI Cycle as a mechanism for data analytics to inform KM and QRM

These concepts were well received and have initiated dialogue with PMTC for future
cross-discipline research and connectivity. This is an important topic for future research
as will be presented in Chapter 12, which can also help further clarify the relationships
between data, information, and knowledge.

10.5 Theme 5: Impact across the entire Pharmaceutical Quality System
Another major outcome of this research study is the potential for broad application
across the PQS, ‘top to bottom’ (i.e., across all PQS enablers and elements) and ‘end to
end’ (i.e., across all PQS lifecycle stages). Although this study started with a focus on
technology transfer, it has reshaped the understanding of KM as a PQS enabler, engaged
the practice of QRM to truly co-enable the PQS, proven the impact of improved
knowledge management and knowledge transfer to the lifecycle stage of technology
transfer, and has been mapped to demonstrate how many of these outcomes can
extend to impact the entire product lifecycle. Figure 10-6 captures the essence of this
concept, where KM and QRM are interconnected to each other, directly to the PQS
elements and applicable across the product lifecycle.
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Figure 10-6 – A re-framed and united PQS foundation

This holds exciting promise for the reach and significance of the RKI Cycle, warranting
further research and further development of support materials (e.g., a training and
application package).

10.6 Summary of research study outputs, outcomes, and impacts
Table 10-3 provides a summary of the five research impact themes with associated
mapping of outputs, outcomes, and impacts, as defined in Figure 10-1 at the start of
this chapter. Note that several of the outputs (e.g., RKI Cycle) apply to more than one
impact theme, as these outputs are not mutually exclusive to any single outcome or
impact.
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Table 10-3 – Mapping impact themes to outputs, outcomes, and impacts
Impacts | Consequences of people using

Impact Theme

Outputs | Products of research

Outcomes | Awareness and use of outputs

1: A framework to
address the untapped
synergy between QRM
and KM

• Various publications & presentations
• Report: QRM-KM current state
integration
• Framework: RKI Cycle

• Recognition within pharma sector that QRM & KM
should be well connected but are not in practice
• RKI Cycle verified beneficial, made publicly available
• ISPE Good Practice Guide: Knowledge Management
• PMTC Guide to Data Analytics for Pharmaceutical
Manufacturing
• PDA RAQAB evaluating a Task Force for KM
• Media coverage by IPQ and GMP Verlag Peither AG

•
•
•
•

2: Inaugural industry
guidance on KM from a
premier industry
association

• Various publications & presentations
• Model: Knowledge Management
Process Model
• Framework: RKI Cycle
• Framework: KTE Framework
• Case study: Tacit knowledge transfer

• ISPE Good Practice Guide: Knowledge Management

• Better risk-based decisions, leading to improved
patient value and safety*
• Operational outcomes for organisations
managing knowledge as an asset (cost savings,
time savings, reduced risk, improved right-firsttime execution, more competent workforce)*

3: The first
comprehensive
framework and toolkit
for knowledge transfer
during technology
transfer, inclusive of
tacit knowledge

• Various publications & presentations
• Current state assessment: Technology
transfer KT effectiveness
• Framework: KTE Framework
• Toolkit: KTE Toolkit
• Processes: Tacit knowledge transfer
• Case Study: Tacit knowledge transfer

•
•
•
•
•

Increased recognition of poor knowledge transfer
ISPE Good Practice Guide: Knowledge Management
Case study: Tacit knowledge transfer
Case study: KTE Framework gap assessment
Further consideration of KM for PDA Technical
Report No. 65, Technology Transfer
• Media coverage: IVT Author of the Year Award

• Improved outcomes of technology transfer,
including reduction of risk and fewer quality
defects
• Knowledge available during commercial
manufacturing to support KM and QRM (e.g.,
better risk-based decisions and operational
outcomes)*

4: A mechanism for
data analytics to grow
knowledge & reduce
risk

• Various publications & presentations
• Framework: RKI Cycle

• Recognition as an area of future study with PMTC,
with post-graduate research opportunities being
explored

• To be determined, but ultimately reducing risk
through ensuring data analytics-driven insights
are recognised as knowledge and made
available through KM

5: Impact across the
entire Pharmaceutical
Quality System

• Various publications & presentations
• Framework: RKI Cycle

• Recognition of the broad applicability and centrality
of the RKI Cycle to the PQS and opportunities to
further develop RKI Cycle application packages

• To be determined, but ultimately scaling impacts
above across lifecycle for greater impact
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outputs (*planned / future)

Better risk-based decisions*
Improved control strategies*
Improved PQS effectiveness*
Improved protection and value for patients
(e.g., reduced risks of defects, drug shortages)*
• A better ability to deal with advances in
manufacturing which utilise big-data,
automation, artificial intelligence, etc.*

There are likely additional outcomes and impacts to emerge from this research study,
perhaps including:
•

Further application of the RKI Cycle, both across the lifecycle but also to other
types of risk beyond quality risk, as the underlying relationship between
knowledge and risk is not unique to quality. The concepts of the RKI Cycle are
broadly applicable to other types of risk, such as technical risk, supply chain risk,
and financial risk.

•

The creation of additional KM frameworks for other stages of the product
lifecycle, based on the principles defined in the KTE Framework.

•

The global pharmaceutical supply chain may be reshaped in the wake of the
COVID-19 pandemic, in response to ‘re-shoring’ efforts driven by supply chain
security concerns. This in turn could lead to a tidal wave of technology transfers,
for which the KTE Framework could see accelerated uptake and relevance.

•

Subsequent refinement of the concept of knowledge culture for the
pharmaceutical industry.

•

A notable approach to this research study is the systems thinking37 applied by
the researcher, including focus on previously unstudied intersections between
these related but distinct disciplines of KM, QRM, quality culture, and data
analytics. As such, this research study has also reached a diverse audience given
the nature of this research and identified many opportunities for future
research, as will be explored in Chapter 12.

The researcher believes this research study has broad reach, as it has the potential to
affect many in the pharmaceutical sector in how to manage knowledge to reduce risk
and improve operational performance. The research study outcomes are arguably
significant since they have the opportunity to have a favourable impact on patient
protection, as well as the already proven impact to increase quality and right-first-time
37

Systems thinking as defined by Arnold and Wade is “a set of synergistic analytic skills used to improve
the capability of identifying and understanding systems, predicting their behaviours, and devising
modifications to them in order to produce desired effects.” (Arnold and Wade, 2015)
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execution during technology transfer. Furthermore, the researcher believes this study
has ‘planted many seeds to germinate’ which will grow over the months and years
ahead and deliver yet unknown outcomes and impacts.
The following chapter presents a conclusion to this research study and includes a
summary of the primary outputs mapped back to the relevant areas of the PQS to which
they relate.
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Chapter 11: Conclusions to this Research Study
The purpose of this chapter is to draw final conclusions for this research study.
As stated in Chapter 1 (section 1.1), the overarching goal of this research study was to
provide tangible benefit to the patient by improving PQS effectiveness through
meaningful advancement of KM as a PQS enabler. Stated simply, improving KM will
improve the PQS effectiveness and corresponding product quality, and in turn providing
important benefits to patients.
On reflection of the research activities and outputs described in this thesis and as a
means to summarise the research progression, the researcher created Figure 11-1 to
illustrate the research study context as the starting point of this research and a
roadmap of this research study.

The study roadmap illustrates the cascading

requirements for the dual PQS enablers of QRM and KM. Furthermore, the study
roadmap includes the starting point for several levels of KM and its connectivity to QRM
(FROM: … with red text) and defines what is now possible (TO: …) as a result of the
contributions of this study.
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Figure 11-1 – A roadmap of this research study
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The introduction of ICH Q10 positions an effective PQS as a means to enhance the
quality and availability of medicines in the interest of public health:
ICH Q10 demonstrates industry and regulatory authorities’ support of an
effective pharmaceutical quality system to enhance the quality and availability
of medicines around the world in the interest of public health. Implementation
of ICH Q10 throughout the product lifecycle should facilitate innovation and
continual improvement and strengthen the link between pharmaceutical
development and manufacturing activities.
As introduced in Chapter 1 (section 1.6) and explored throughout this research study,
these research outputs have the opportunity to impact several areas of the PQS as first
presented in Figure 1-6:
1. KM as an enabler to the PQS, via a Knowledge Management Process Model
2. KM with QRM as dual enablers to the PQS, via the RKI Cycle
3. Technology Transfer as a stage in the product lifecycle via the KTE Framework
4. The end-to-end product lifecycle, via broad application of the RKI Cycle
Figure 11-2 was created by the researcher to illustrate where primary research study
outputs map to the various areas of the PQS.

Figure 11-2 – Mapping of selected research study outputs to the PQS
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The impact of each of these research outputs to the PQS is summarised as follows:
1. The new Knowledge Management Process Model, as presented in Chapter 4 and
designed based on the QRM Process Model from ICH Q9, can broadly impact
how KM is understood as an enabler to the PQS, through a more pragmatic,
structured, and sequential breakdown of the KM process. This new Knowledge
Management Process Model addresses the definition KM provided by ICH Q10,
and goes further to include the concepts of tacit knowledge, the connection of
KM to business processes, and enablers to successful KM (e.g., standardised
processes and sponsorship). Through a better understanding of the mechanics
of KM, the industry can better utilise KM to enable all facets of the PQS and
beyond for operational effectiveness, employee engagement, and more.
2. The Risk-Knowledge Infinity Cycle, or RKI Cycle, a novel framework to connect
QRM and KM as presented in Chapter 5, can (and has already started to) define
the understanding of the relationship between risk and knowledge, the
relationship between risk management and knowledge management, and the
importance of linking the two. Linking these two disciplines offers the promise
of improving fundamental PQS outcomes, including better risk-based decision
making, more data and knowledge driven risk assessments, better use of prior
knowledge and improved protection and value for patients, to name a few. This
framework links QRM and KM and has a resulting impact on every facet of the
PQS.
3. The KTE Framework and KTE Toolkit to enhance knowledge transfer effectiveness
(Chapter 7) are specifically designed as a knowledge management approach for
the lifecycle stage of technology transfer and have proven their effectiveness to
technology transfer. The underlying principles to this framework and toolkit
have the potential to be rapidly scaled across the product lifecycle.
4. The RKI Cycle has broad applicability across the end-to-end product lifecycle, as
explored in Chapter 8, as well as the potential to be a uniting mechanism for
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QRM, KM, and data analytics, ensuring the best possible risk-based decisions are
made across the product lifecycle, whether for product development,
technology transfer, change management, or any other element (or lifecycle
stage) of the PQS.
The preliminary outcomes and impact of each one of these research outputs are
described in detail in Chapter 10 of this research study through a set of themes intended
to convey tangible and meaningful advancements. Collectively, these outcomes make
a substantial contribution to the PQS, with significant impact and broad reach.
As introduced in Chapter 1, the aim of this research study was to benefit the patient by
improving the effectiveness of the PQS (Figure 1-1). In reflecting on this goal, with the
study outputs and their impact to PQS effectiveness well characterised, the researcher
created Figure 11-3 (based on Figure 1-1 and Figure 11-2) as a means to ‘close the loop’

Unlocking knowledge to benefit the patient
Connecting KM and QRM to strengthen
science and risk-based decision making

Patient

Regulations with associated
guidance and enforcement
ensure safe and efficacious
products for patients
(ICH, et al)

❸
The KTE Framework &
associated toolkit for
Knowledge Transfer
Effectiveness

❹
Demonstrating
the impact of
the RKI Cycle

Illustrative processes

Development
Studies

CPV
QRM

Change
Management

Technology
Transfer

…

Knowledge Creation
Newly acquired knowledge
(product, process & platform knowledge)

Basis for prior knowledge

Knowledge Availability

Growing and evolving knowledge

Knowledge Capture
Knowledge Identification,
Review & Analysis

Knowledge Storage & Visibility

Knowledge Management Practices
for both explicit and tacit knowledge

Knowledge Curation

Knowledge
Dissemination

(product, process & platform knowledge)

Knowledge Management
Knowledge communication,
exchange & sharing (via knowledge culture)

Closing the loop to the Patient

back to the patient by illustrating how these outputs lead to patient benefits.

❶
A new
Knowledge
Management
Process Model

Knowledge Application, Growth & Transfer
QRM

Product
Filing

Technology
Transfer

Change
Management

CAPA
…
Illustrative processes

DECISION
© Lipa & O’Donnell 2020

RISK

Quality Risk
Management

KNOWLEDGE
Knowledge
Management

❷
The RKI Cycle, a
novel new
framework to
connect QRM
and KM

Will allow the industry to…
• Improved risk-based decision making
• Acceleration of product development
• More robust processes
• Solving problems at root cause
• Right-first time and on-time technology transfer
• and more…
And will benefit the patient through
• Increased product quality (e.g., reduced variability)
• Accelerated availability of new therapies
• Fewer drug shortages
• and more…

Figure 11-3 – Connecting this study back to the patient
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Indeed, an opportunity to unlock knowledge is presented through the outputs and
outcomes of this study with many promising and important benefits.
While this research study started with a focus on improving knowledge transfer for
technology transfer (i.e., element 3 in Figure 11-2), this study has led the researcher on
an exciting, educational, and thought-provoking journey which expanded the horizons
of the researcher’s knowledge, experience, perspectives, and influence.

The

opportunity to apply systems thinking and explore the intersections between the
disciplines of QRM and KM in particular, as well as that of KM and data analytics, has
been an enlightening opportunity.

Doing such an exploration both across the

pharmaceutical sector and on a global scale has made the experience all the more
enriching for the researcher. This research study has allowed the researcher to reflect
and engage with other stakeholders he would not normally have a reason to and to test
new ideas. Furthermore, while the researcher has been a long time KM professional in
industry, this research study allowed the researcher to shed the constraints of the views
and association of a single company and explore perspectives and engage with
audiences from across the sector.
An unavoidable reality that emerged during the course of this study was the global
COVID-19 pandemic and the undeniable impact it had and will have on our society and
the pharmaceutical sector. While COVID-19 impacts are still emerging, the impact of
travel restrictions and market demand has already prompted changes to the industry
(e.g., at least a temporary shift specifically in how technology transfers are done
leveraging smart glasses and other technologies). In light of all of this, one must ponder:
•
•
•

How effective is knowledge transfer in such scenarios?
Employees are also being onboarded remotely, perhaps without even meeting
their peer groups in person. How will relationships and trust develop?
Will there be a surge of technology transfers to ‘re-shore’ production within a
country’s home borders, to reduce supply chain risk and complexity, and reduce
dependence of a nation’s drug supply on other nations?
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•

How can the learnings about rapid product development and technology
transfer be applied to accelerate access (and hopefully reduce cost) to future
therapies, and what role can KM play?

It is anticipated that more of these scenarios will unfold over time. While this
development did not change the course of the research study, it is quite possible that
the COVID-19 pandemic may expedite the adoption of these outputs.
The researcher is gratified by the response to this study and all those who contributed,
in ways big and small. The early results are promising, with the potential to drive a
paradigm shift on how people think about knowledge management and its
indispensable role in an effective PQS, and how knowledge management can be applied
for meaningful and sustained benefits beyond the PQS.
The researcher hopes this study will have a significant and lasting impact on the
pharmaceutical sector, through the outputs delivered and outcomes already in motion
as a result of this study, and others to follow inspired by this study. This is especially
relevant considering society is arguably facing a time of rapid and unprecedented
change, already facing the complexity and need for speed with ATMPs, disrupted by the
COVID-19 pandemic, and now confronting geopolitical forces which may well realign
supply chains, and make accelerated development and new technologies the ‘new
normal.’ Never before has it been more important to integrate knowledge and risk.
Many exciting opportunities lie ahead, and the most important stakeholders of the
industry’s success – the patients, who are not abstract and nameless entities but who
are family members, friends, and colleagues – are waiting.
The next and final chapter in this research study, Opportunities for Future Research, will
present a variety of topics to further examine to further extend the impacts of this
research study.
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Chapter 12: Opportunities for Future Research
The purpose of this chapter is to identify areas for future research. Although the
researcher believes this study can help the sector take a step change forward in the
adoption of KM and its connectivity with QRM, this study also explored many new
aspects of KM and its interdependency with other disciplines. As such, many exciting
research opportunities were identified, including the opportunity to directly advance
the outputs from this study (e.g., through application guides or software applications)
and to further explore many important interdependencies and adjacencies (e.g., data
analytics). The following sections identify several exciting opportunities for further
study.

12.1 Extension of the Risk-Knowledge Infinity Cycle Framework
One recommendation for future research efforts is to supplement the work done in this
study with supporting materials to extend and accelerate the impact of the RKI Cycle
across the product lifecycle and to other elements within the PQS. These concepts
were briefly explored as part of this study, but further work is warranted to better
position the RKI Cycle for expansion. As part of this effort, supporting materials such as
an application or deployment guide with associated training to enable a team to quickly
understand, apply, and benefit from the RKI Cycle will be needed. Additional case
studies, both prospective (i.e., how the RKI Cycle can provide benefit) and retrospective
(i.e., how the RKI Cycle could have provided benefit) can also assist in communicating
and refining the framework. Other cases of how the framework can be applied should
also be explored, such as to inform a learning curriculum. Furthermore, exploring
commonality with other industries (e.g., aerospace, as identified during the
confirmation exam feedback), is an opportunity to further extend the reach of the
framework beyond the pharmaceutical industry.

12.2 Integrated knowledge management frameworks across the product
lifecycle
A feature of this study was the focus on KM for the technology transfer stage of the
product lifecycle. This study established a KM framework to standardise knowledge
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management during technology transfer, the Knowledge Transfer Enhancement (KTE)
Framework. The researcher believes the underlying basis of a PDCA cycle as used for
the KTE Framework as a closed-loop continual improvement process should be a
suitable basis from which to build a KM framework for the other three stages of the
product lifecycle (product development, commercial manufacturing, and product
discontinuation). Furthermore, a majority of the tools in the KTE Toolkit will also be
portable across stages. Additional areas of focus could include:
•
•
•

•
•

Further definition of practices specified in the KTE Toolkit (i.e., as identified in
Table 7-1).
A training package to support use of the KTE Framework and KTE Toolkit .
A maturity model for knowledge transfer (including a gap assessment so
companies can assess their current processes and quickly identify areas of
improvement).
Simplification of the KTE Framework and KTE Toolkit as warranted based on initial
use and feedback.
Exploration of the Information-space (“I-space”) model defined by Boisot (ISpace Institute, 2008) for mapping strategic knowledge. This model has been
used to further define and prioritize mission-critical knowledge for complex
industries, as described by Kennedy-Reid and Ihrig (Kennedy-Reid and Ihrig,
2013) and Ihrig and MacMillan (Macmillan and Ihrig, 2015), and could potentially
be applied for each stage of the product lifecycle.

12.3 The link between knowledge management and data analytics
As introduced in Chapter 8, the link between KM and data analytics is an area of novel
research that will better link data and data analytics more systematically into the PQS.
The researcher sometimes describes this opportunity as the ‘vertical integration’ of the
data-information-knowledge pyramid (Figure 8-5). Given the industry focus on digital
transformation (CIO, 2018), more data will become available, and the RKI Cycle and
effective KM practices will be instrumental in how that data is surfaced as knowledge
through data analytics, as illustrated in Figure 12-1.
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Figure 12-1 – The opportunity to feed KM from data and data analytics

12.4 KM competency building
It is likely KM could further benchmark the QRM journey towards effectiveness to seek
other areas for development of guidance and supporting materials. One of these areas
is that of KM competency building, through an associated KM competency model to
define target competency levels, related training assets, and delivery thereof. This work
could also define best practices for KM roles.

12.5 Additional opportunities
There are other, more focused topics of interest to the researcher that are not covered
in detail as part of this research study which could benefit from further study, as follows:
•
•
•

•

An expansion on knowledge culture, based on the work in this thesis.
Further exploration and modelling of knowledge leakage, as characterised by
the researcher in Chapter 6 (section 6.2.1).
The concept of ‘democratisation of knowledge,’ and how to determine what
knowledge is required on a role-specific basis, and how this knowledge can be
‘democratised’ to enable maximum efficiency and effective decision making.
Topics introduced (or at least accelerated) by the COVID-19 pandemic, including:
o Virtual technology transfers and critical success factors, considering the
principles for knowledge transfer during technology transfer presented
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•

•

during this study in Chapter 6 and Chapter 7 (e.g., is remote support for
a technology transfer using smart glasses as effective as a person in plant
supporting the transfer?).
o How the outputs of this research study could be positioned to enhance
the potential wave of ‘re-shoring’ technology transfers, if such a need
emerges, to increase speed, reduce cost, and help ensure sustained
supply.
Examining the feasibility and defining associated requirements for applications
(e.g., checklists or gap assessments) or other software to accelerate the reach
and impact of the RKI Cycle or KTE Framework and KTE Toolkit would be an area
of valuable research, given the focus on digital. Such software applications
would also support the standardisation, consistent use, and portability of the
frameworks and supporting elements.
Further explore the relevance and application of work by Teece et al. (Teece,
Pisano and Shuen, 1997) on dynamic capabilities and strategic management,
specifically that of dynamic knowledge based on increasing complexity (e.g.,
ATMPs) and accelerating rate of change for the industry (e.g., COVID-triggered
acceleration of new therapies, merger and acquisition activity, etc.).

At the time of this thesis submission, work is underway to evaluate opportunities for
further research on a variety of these topics. An immediate research project is being
proposed in which the researcher will act as supervisor to a full time Ph.D. student,
which will include (at a minimum) further exploration and development of the link
between KM and the RKI Cycle to data analytics in partnership with PMTC. This proposal
will also include an opportunity to follow up with NASA on the potential impact of the
RKI Cycle for aerospace, as well as further exploration of how the RKI Cycle can support
the sharing of lessons and risk-based decision making.
This research study has opened the door to many exciting opportunities, and the
researcher is excited for the story to continue to unfold through these proposed next
steps.
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Appendix 1 – Researcher’s Prior Experience
The researcher’s formative experience in knowledge management prior to commencement of this research study, presented in chronological
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Quality Systems (ICH Q10) Conference (Lipa, 2011a)
Knowledge Management: An Iterative Process. In 2011 ISPE/PDA/FDA/EMA Pharmaceutical
Quality Systems (ICH Q10) Conference (Lipa, 2011b)
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Virtual Technical Network (VTN). In APQC 2012 KM Conference. (Guenard, Bruno and Lipa, 2012)
Knowledge Management: An Iterative Process. In 2012 PDA/FDA/JPMA/PMDA Pharmaceutical
Quality Systems (ICH Q10) Conference (Lipa, 2012)
Enabling a New Way of Working through Inclusion and Social Media: A Case Study. OD
Practitioner, 45(4), 9-16. (Fall 2013) (Guenard et al., 2013)
Knowledge Management: An Iterative Process. In 2013 ISPE/FDA Pharmaceutical Quality System
(ICH Q10) Conference. (Lipa, 2013)

MSD internal

n/a

Member of MSD
contingent
Facilitator
Member of MSD
contingent
LSS Black Belt Certification
Project Leader and Lead
Author
Black Belt Certification

ISPE

Washington, DC

Speaker & Panellist

Arlington, VA

Speaker & Panellist

Brussels,
Belgium

Speaker & Panellist

Houston, TX
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Tokyo, Japan
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Publication - Author

Beijing, China

Speaker & Panellist

FDA-Conformia-PhRMA Pharmaceutical Development / Risk Management Industry Workshop (1213 Sep 2007) (FDA-Conformia CRADA, 2007)
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FDA-Conformia-PhRMA Summit - Pharmaceutical Development / Risk Management (20-21 Feb
2008) (FDA-Conformia CRADA, 2008)
MSD KM Strategy Project initiated via Lean Six Sigma Black Belt Methodology (DMADV) (2008)
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Manufacturing Leadership Council 2014 Manufacturing Leadership Award (Workplace Leadership
Category) for MMD's Virtual Technical Network (VTN). (Frost & Sullivan, 2014)
The Know-How and Know-Why: An Interview with Merck. ISPE Pharmaceutical Engineering
Supplement - Knowledge Management E-Journal, 33(6), 20-24. (2014) (Calnan, 2014b)
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A Practical Approach to Managing Knowledge in Merck’s Manufacturing Division. In KM Dublin
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International
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Baltimore, MD

Author
Speaker & Panellist
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PDA
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Planning Committee &
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Science Ireland
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Member
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APQC

Houston, TX

Steering Committee
Member

CASSS

Washington DC
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Book Editor
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Book Chapter
Author

n/a

Author
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Author

n/a

Author

Book Chapter
Author

n/a

Author
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Houston, TX

Steering Committee
Member
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Speaker & Panellist

World Bank
Columbia
University

Washington, DC
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University MS Program)

A Vision for Prior Knowledge – and How to Manage Knowledge as an Asset. In CASSS CMC
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Contributing book editor: A Lifecycle Approach to Knowledge Excellence in the Biopharmaceutical
Industry. (N. Calnan, P. Kane, M. Lipa, & J. Menezes, Eds.). CRC Press. (2018) (Calnan et al.,

2018)

Yegneswaran, P., Thien, M., & Lipa, M. Why Knowledge Management is Good Business, A
Lifecycle Approach to Knowledge Excellence in the Biopharmaceutical Industry (3-17), CRC Press.
(2018) (Yegneswaran, Thien and Lipa, 2017)
Kane, P. & Lipa, M. The House of Knowledge Excellence - A Framework for Success. In A Lifecycle
Approach to Knowledge Excellence in the Biopharmaceutical Industry (181-224), CRC Press. (2018)
(Kane and Lipa, 2018)
Lipa, M. & Schuttig, J. KM Evolution at Merck & Co., Inc.: Managing Knowledge in Merck
Manufacturing Division. In A Lifecycle Approach to Knowledge Excellence in the
Biopharmaceutical Industry (243-260), CRC Press. (2018) (Lipa and Schuttig, 2018)
Steering Committee Member - 2019 APQC Knowledge Management Conference
Building Learning and Continuous Improvement into Everyday Work: The Quest to Learn Lessons
in Merck Manufacturing. In APQC 2018 KM Conference. (Lipa and Schuttig, 2018)
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Evolution of Merck Strategy for Managing Knowledge. Guest lecture for Information & Knowledge
Strategy MS Program, Columbia University, New York. (2018) (Lipa, 2018b)
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Appendix 2 – Details of Research Study Activities
This appendix provides details of all of the main study outputs including publications,
conference presentations, panel discussions and other interactions to solicit feedback
and disseminate this research to stakeholders across the sector. The figure below from
Chapter 1 (Figure 1-5) provides a mapping of each activity onto the research timeline,
and the table following provides the corresponding details for each activity numbered
1 to 26.
Research Phases
Phase 1: Problem Definition

Phase 2: KM Framework (KTE) & KTE Toolkit
Phase 3: QRM-KM Framework
Phase 4: Verification & Impact

Key Research Activities
1

2H
2018

3

5

1H
2019

7

2H
2019
2

4

9

11

13 15 17 19 21

1H
2020
6

8

10

12 14 16 18 20

Activity
1

2

3

4

Conference /
Presentation

X

Paper /
Publication

22

2H
2021
24

RKI Cycle

26
RKI Cycle
across
product
lifecycle

Primary
Output

Affiliation /
Audience

Research Activity / Output

25

Knowledge Management
Process Model

KTE Framework
and KTE Toolkit

X

23

1H
2021

2H
2020

Location

Description

Lipa, M. J. (2019) Capture and Reuse of Critical
Knowledge in an Evolving Workforce: A Model
for Technology Transfer. In 2019 PDA Annual
Meeting.
Lipa, M. J. & Kane, P. E. (2019) Knowledge
Management Research in the
Biopharmaceutical Sector. In An Audience with
Regulators, Academia and Industry: The Role
of Effective QRM & KM in Product Realisation
for Patients in the 21st Century.
APQC Advanced Benchmarking (invitation only
cohort of 5 companies across industries in KM)

PDA

San Diego,
CA

Speaker &
Panellist

PRST
Conference

Dublin,
Ireland

Speaker,
Lead Author,
Panellist

APQC

Houston,
TX

Lipa, M. J., Kane, P. E. & Greene, A. (2019)
Effective Knowledge Transfer During
Biopharmaceutical Technology Transfer: How
Well Do We Do It? Institute of Validation
Technology (IVT), 25 (4).

IVT Network

n/a

SME,
Philosophical
dialogue w/
other
industries
Lead Author

182

Activity

Affiliation /
Audience

Research Activity / Output

Location

Description

KENX

Cork,
Ireland

Conference
Poster

ISPE

Las Vegas,
NV

Speaker &
Panellist

BioPhorum

n/a

TU Dublin

n/a

Co-Author,
Knowledge
Map SME &
facilitator
Co-Author

PDA

Virtual

Speaker &
Panellist

PDA Journal of
Pharmaceutical
Science and
Technology

n/a

Lead Author

ISPE
Pharmaceutical
Engineering

n/a

Co-Author

Book Chapter
Author

n/a

Lead Author

Columbia
University

New York,
NY

IVT Network

n/a

Guest
Lecturer
(Columbia
University)
Lead Author

*Award recipient, Journal of Validation
Technology 2020 Author of the Year*
5

6

7

8

9

10

11

12

13

14

Lipa, M. J., Kane, P. E., & Greene, A. (2019)
Effective Knowledge Transfer during
Biopharmaceutical Technology Transfer – How
well do we do it? KENX Commissioning,
Qualification & Validation University
Lipa, M. J. (2020) Knowledge Management:
Development of pragmatic industry guidance to
benefit our patients & organizations. In ISPE
2019 Annual Meeting & Expo.
Guenard, R. et al. (2020) A Test Case in CMC
Business Processes from Late-Stage
Development to Commercial Manufacturing.
BioPhorum Operations Group (paper and tool)
Kane, P. E. and Lipa, M. J. (2020) Advancing
Knowledge Management (KM) as an ICH Q10
Enabler in the Biopharmaceutical Industry,
Dublin: TU Dublin Academic Press
Lipa, M. J. (2020) Knowledge Management as a
Pharmaceutical Quality System Enabler: How
Enhanced Knowledge Transfer can help close
the Q10 to Q12 Gap. In 2020 PDA Europe
Lipa, M. J., Greene, A., & Calnan, N. (2020)
Knowledge Management as a Pharmaceutical
Quality System Enabler: How Enhanced
Knowledge Transfer can help close the Q10 to
Q12 Gap. PDA Journal of Pharmaceutical
Science and Technology July 2020 (accepted)
Kane, P. E., Lipa, M. J., Greene, A., & Calnan, N.
(2020) Knowledge Management
Implementation: A Survey of the
Biopharmaceutical Industry. In ISPE
Pharmaceutical Engineering - an Online
Exclusive
Lipa, M. J., Kane, P. E., & Greene, A. (2020)
Knowledge Excellence in the Lab: How
Knowledge Management Can Enhance Lab
Performance, In Quality Control Lab – A Crucial
Contributor to Pharmaceutical Value Creation
and Quality System Performance (ed. T. Friedli
et al)
Lipa, M. J. (2020) Reflections on a KM Journey.
Guest lecture for Information & Knowledge
Strategy MS Program, Columbia University,
New York.
Lipa, M. J., O'Donnell, K., & Greene, A. (2020)
Managing Knowledge and Risk – A Literature
Review on the Interdependency of QRM and
KM as ICH Q10 Enablers. Institute of Validation
technology (IVT), 26 (4).
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15

16

17

18
19
20

21

22

23

24
25
26

Research Activity / Output
Podcast - Voices in Validation - Managing
Knowledge as an Asset in the
Biopharmaceutical Industry (recorded 11-Sep2020)
Lipa, M. J., O'Donnell, K., & Greene, A. (2020)
Knowledge as the Currency of Managing Risk: A
Novel Framework to Unite Quality Risk
Management and Knowledge Management.
Institute of Validation technology (IVT), 26 (5).
Lipa, M. (2020) Knowledge as the Currency of
Managing Risk: A Novel Framework to Unite
Quality Risk Management & Knowledge
Management. In PMTC Guide to Data Analytics
for Pharmaceutical Manufacturing Launch.
“Establishing a “New Normal” for Pharma
Quality Practices” in 2020 Bio/Pharma Virtual
Congress.
Industry SME Reviewer (invited), PDA Technical
Report No. 65, Technology Transfer
Lipa, M, Kane, P., Greene, A. (2020) Simple
Practices to Facilitate the Flow of Valuable
Tacit Knowledge during Biopharmaceutical
Technology Transfer: A Case Study, Level3, vol.
15, no. 2.
Lipa, M, Kane, P., Greene, A. (2021) Mapping
KM Methods and Tools across the
Pharmaceutical Product Lifecycle, Level3, vol.
15, no. 2.
Lipa, M. J. (2021) “Holding On to What You
Know: Improving Knowledge Transfer to
Reduce Risk and Benefit Patients,” in 2021 PDA
Annual Meeting.
Lipa, M., O'Donnell, K., & Greene, A. (2021) A
Survey Report on the Current State of Quality
Risk Management (QRM) and Knowledge
Management (KM) Integration, Level3, vol. 15,
no. 3
Lipa, M. J., (2021) Knowledge Management, on
invitation to the PDA Regulatory Affairs and
Quality Advisory Board (15-Apr-2021)
ISPE (2021b) ISPE Good Practice Guide:
Knowledge Management in the
Pharmaceutical Industry. Tampa, FL: ISPE.
Lipa, M. J. et al. (2021) “Exploring the RiskKnowledge Infinity Cycle (RKI Cycle) Across the
Product Lifecycle,” ISPE Webinar. (Note: This
paper has been accepted by ISPE but not yet
published. It will first be presented at a
webinar scheduled on 20-May-2021.)
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Audience

Location

Description

IVT Network

Online

Speaker

IVT Network

n/a

Lead Author

PMTC

Virtual

Speaker &
Panellist

PharmaTech

Virtual

Panellist

PDA

n/a

TU Dublin

n/a

Invited as
industry SME
Lead Author

TU Dublin

n/a

Lead Author

PDA

Virtual

Speaker &
Panellist

TU Dublin

n/a

Lead Author

PDA

Virtual

Invited
industry SME

ISPE

n/a

ISPE

n/a

SME on
Authoring
Team
Lead Author

